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ABSTRACT 
 
Background 
Age-related macular degeneration (AMD) is the commonest cause of sight impairment in the 
UK. In neovascular AMD (nAMD), vision worsens rapidly (over weeks) due to abnormal blood 
vessels developing that leak fluid and blood at the macula. 
 
Objectives 
To determine the optimal role of optical coherence tomography (OCT) in diagnosing people 
newly presenting with suspected nAMD and monitoring those previously diagnosed with the 
disease. 
 
Data sources 
Databases searched: MEDLINE (1946 to March 2013), MEDLINE In Process (March 2013), 
EMBASE (1988 to March 2013), Biosis (1995 to March 2013), SCI (1995 to March 2013), the 
Cochrane Library (Issue 2 2013), DARE (March 2013), MEDION (March 2013), HTA 
database (March 2013).  
 
Methods 
Types of studies: direct/indirect studies reporting diagnostic outcomes. Index test: time domain 
(TD) or spectral domain (SD) OCT. Comparators: clinical evaluation, visual acuity, Amsler 
chart, colour fundus photographs, infra-red reflectance, red-free images/blue reflectance, 
fundus autofluorescence imaging, indocyanine green angiography, preferential hyperacuity 
perimetry, microperimetry. Reference standard: fundus fluorescein angiography (FFA). Risk of 
bias was assessed using QUADAS-2. Meta-analysis models were fitted using hierarchical 
summary receiver operating characteristic (HSROC) curves.  
 
A Markov model was developed (65 year old cohort, nAMD prevalence 70%), with nine 
strategies for diagnosis and/or monitoring, and cost-utility analysis conducted. NHS and 
Personal Social Services perspective was adopted. Costs (2011/12 prices) and quality-adjusted 
life years (QALYs) were discounted (3.5%). Deterministic and probabilistic sensitivity 
analyses were performed. 
 
Results 
In pooled estimates of diagnostic studies (all TD-OCT), sensitivity and specificity (95% CI) 
was 88% (46% to 98%), and 78% (64% to 885%), respectively. For monitoring, the pooled 
v 
sensitivity and specificity (95% CI) was 85% (72% to 93%) and 48% (30% to 67%), 
respectively. for TD-OCT and SD-OCT combined  
 
The FFA for diagnosis and nurse/technician-led monitoring strategy had the lowest cost 
(£39,769; QALYs 10.473) and dominated all others except FFA for diagnosis and 
ophthalmologist-led monitoring (£44,649; QALYs 10.575; ICER £47,768). The least costly 
strategy had a 46.4%  probability of being cost-effective at £30,000 willingness to pay 
threshold. 
 
Limitations 
Very few studies provided sufficient information for inclusion in meta-analyses. Only a few 
studies reported other tests; for some tests no studies were identified. The modelling was 
hampered by a lack of data on the diagnostic accuracy of strategies involving several tests.   
 
Conclusions 
Based on a small body of evidence of variable quality, OCT had high sensitivity and moderate 
specificity for diagnosis, and relatively high sensitivity but low specificity for monitoring.  
Strategies involving OCT alone for diagnosis and/or monitoring were unlikely to be cost-
effective. Further research is required on (i) the performance of SD-OCT compared with FFA, 
especially for monitoring but also for diagnosis (ii) the performance of strategies involving 
combinations/sequences of tests, for diagnosis and monitoring, (iii) the likelihood of active and 
inactive nAMD becoming inactive or active, respectively, and (iv) assessment of treatment-
associated utility weights (e.g. decrements), through a preference based study.    
 
[Word count: 500 words] 
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PLAIN ENGLISH SUMMARY 
 
In wet age-related macular degeneration (AMD), abnormal blood vessels develop that leak fluid 
and blood in the back of the eye, causing central vision to worsen rapidly (over weeks).  Optical 
coherence tomography (OCT) is a non-invasive imaging test, widely used in the NHS, that can 
detect wet AMD.  The more recent spectral domain OCT (SD-OCT) contains improvements 
over time domain OCT.  OCT is usually used along with other tests, such as visual acuity.  This 
review assessed the evidence for the usefulness of OCT in diagnosing people newly presenting 
with suspected wet AMD, and in determining disease activity during regular monitoring visits 
for those previously diagnosed with the condition.  The date of the last literature searches was 
March 2013.  Twenty-two diagnostic and eight monitoring studies were included. The evidence 
suggested that, for diagnosis, OCT had high sensitivity (very few people with wet AMD would 
be wrongly diagnosed as not having it) and moderate specificity (around one quarter of those 
without wet AMD would be wrongly diagnosed as having it).  For monitoring, OCT also had 
high sensitivity but low specificity (half of those without active disease would be wrongly 
diagnosed as having it).  Therefore, although OCT is a sensitive test and would detect most 
people with wet AMD, if used as the only test to guide treatment then, potentially, a 
considerable number of people with inactive disease would receive treatment.  However, these 
results should be interpreted with caution due to the small number of studies identified, and 
their variable quality. 
 
[Word count: 250 words] 
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1  GLOSSARY AND LIST OF ABBREVIATIONS  
 
Technical terms and abbreviations are used throughout this report.  The meaning is usually clear 
from the context, but a glossary is provided for the non-specialist reader. 
 
GLOSSARY  
Case-control study 
 
This type of study compares a group of people who have the 
disease and a group who do not have it 
Choroidal 
neovascularisation 
New blood vessels originating from the choroid.  The choroid 
is a thin layer of connective tissue that lies between the retina 
and the sclera and supplies blood to the outer layers of the 
retina   
Diagnostic odds ratio 
 
The ratio of the odds of testing positive in those with the 
disease relative to the odds of testing positive in those without 
the disease  
Direct head-to-head 
study 
A study in which people receive both index and comparator 
tests and they are therefore evaluated in the same participants  
False negative/true 
negative/false positive/ 
true positive 
 
In terms of diagnostic accuracy, indicators of index test results 
as compared to the reference standard: negative index test, 
positive reference standard/negative index test, negative 
reference standard/positive index test, negative reference 
standard/positive index test, positive reference standard 
Fundus fluorescein 
angiography 
An invasive imaging test that examines the circulation of the 
retina and choroid.  A fluorescein dye is injected into a vein in 
the arm and a specialised camera photographs the dye as it 
passes through the blood vessels in the eye  
Index test The diagnostic test which is being evaluated 
Likelihood ratio 
 
A description of how many times more likely it is that a person 
with the disease will receive a particular test result than a 
person without the disease 
Macula The central part of the retina containing the xanthophyll 
pigment and two or more layers of ganglion cells.  Damage to 
xvi 
 
the centre of the macula, the so-called fovea, often results in 
loss of central vision 
Meta-analysis The quantitative pooling of data from two or more studies 
Negative predictive 
value 
The proportion of those with negative test results who do not 
have the disease 
Neovascular age-related 
macular degeneration 
In neovascular or ‘wet’ age-related macular degeneration, 
abnormal blood vessels grow into the macula and leak blood or 
fluid, leading to scarring of the macula and rapid loss of central 
vision 
Optical coherence 
tomography 
A non-invasive imaging technology used to obtain high 
resolution cross-sectional images of the retina 
Positive predictive 
value 
The proportion of those with positive test results who actually 
have the disease  
Randomised controlled 
trial (RCT) 
A study in which people are randomly allocated to receive – or 
not receive – a particular treatment or intervention. This is said 
to be the best study type to determine effectiveness of a 
treatment 
Reference standard The best available test for establishing the presence or absence 
of the disease 
Retina The light-sensitive layer of tissue located in the back of the 
eye.  The retina receives images via the eye’s lens, converts 
them to electric signals and transmits them to the brain  
Sensitivity 
 
The proportion of those who actually have the disease and who 
are correctly identified with positive test results 
Specificity 
 
The proportion of those who actually do not have the disease 
and who are correctly identified with negative test results 
Visual acuity Sharpness of vision, which is tested by identifying characters 
on a chart from a set distance.  Normal visual acuity is usually 
referred to as 20/20 vision, meaning the detail that a person 
with normal eyesight would see from 20 feet away   
Visual impairment ≤ 6/60 to > 3/60, severe visual impairment;  
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≤ 3/60, profound visual impairment/blindness 
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LIST OF ABBREVIATIONS 
 
AAO American Academy of Ophthalmology 
AMD Age-related macular degeneration 
anti-VEGF Anti-vascular endothelial growth factor 
ARVO Association for Research in Vision and Ophthalmology 
BIOSIS Bioscience Information Services 
BNF British National Formulary 
CATT Comparison of Age-related Macular Degeneration Treatments Trials 
CDSR Cochrane Database of Systematic Reviews 
CEAC Cost-effectiveness acceptability curve 
CENTRAL Cochrane Central Register of Controlled Trials 
CIs Confidence intervals 
CNV Choroidal neovascularisation 
CNVM Choroidal neovascular membrane 
DARE Database of Abstracts of Reviews of Effects 
DOR Diagnostic odds ratio 
DS-ICGA Digital subtraction indocyanine green angiography 
ETDRS Early Treatment Diabetic Retinopathy Study 
EVER European Association for Vision and Eye Research 
FAF Fundus autofluorescence 
FFA Fundus fluorescein angiography 
FN False negative 
FP False positive 
FPED Fibrovascular pigment epithelial detachment 
GPs General Practitioners 
HCHS Hospital and Community Health Service 
HSROC Hierarchical summary receiver operating characteristic  
ICER Incremental cost-effectiveness ratio 
ICG Indocyanine green 
ICGA Indocyanine green angiography 
ICTRP International Clinical Trials Registry Platform 
IPCV Idiopathic polypoidal choroidal vasculopathy 
IR Infa-red reflectance 
IVAN A randomised controlled trial of alternative treatments to Inhibit VEGF 
in Age-related choroidal Neovascularisation 
LLIO Late leakage of indeterminate origin 
xix 
 
LR Likelihood ratio 
nAMD Neovascular age-related macular degeneration 
NHS National Health Service 
NIA Near-infrared autofluorescence 
NICE National Institute for Health and Care Excellence 
NIR Near infrared fundus reflectance 
OCT Optical coherence tomography 
Oph Ophthalmologist 
PDT Photodynamic therapy 
PED Pigment epithelial detachment 
PHP Preferential hyperacuity perimetry 
QALY Quality-adjusted life year 
QUADAS-2 Quality assessment of diagnostic accuracy studies, version 2 
RAP Retinal angiomatous proliferation 
RCO Royal College of Ophthalmologists 
RCT Randomised controlled trial 
RF Red-free images 
RPE Retinal pigment epithelium 
RR Relative risk 
SCI Science Citation Index 
SD-OCT Spectral domain optical coherence tomography 
SLB Slit-lamp biomicroscopy 
SLO Scanning laser ophthalmoscope 
SROC Summary receiver operating characteristic  
TD-OCT Time domain optical coherence tomography 
Tech Technician 
TN True negative 
TP True positive 
VA Visual acuity 
VEGF Vascular endothelial growth factor 
WMD Weighted mean difference 
xx 
 
2  SCIENTIFIC SUMMARY 
 
Background 
Age-related macular degeneration (AMD) is the commonest cause of sight impairment in the 
UK. In neovascular AMD (nAMD), vision worsens rapidly (over weeks) due to abnormal blood 
vessels developing that leak fluid and blood at the macula.  For patients with nAMD it is 
common practice to initiate treatment with three consecutive (monthly) injections of anti-
vascular endothelial growth factor (anti-VEGF) therapy, and then the patient is reassessed to 
evaluate whether or not the disease is active or inactive.  Many patients require monthly 
monitoring and treatment over a period of several years.  Fundus fluorescein angiography 
(FFA), an invasive test, is considered the reference standard for detecting nAMD at initial 
presentation and it is also used for detecting recurrent activity at some monitoring visits.  
Optical coherence tomography (OCT) is a non-invasive test that can be used for detecting 
nAMD at initial presentation and is often used as the only imaging test for detecting recurrent 
activity during monitoring visits.  The more recently introduced spectral domain OCT (SD-
OCT) incorporates a number of improvements over time domain OCT (TD-OCT).   
 
Objectives 
This review aims to determine the optimal role of OCT in (i) the diagnosis of people newly 
presenting with suspected neovascular AMD and (ii) in monitoring those previously diagnosed 
with the disease.  
 
Methods 
Electronic databases searched included MEDLINE, MEDLINE In-Process, EMBASE, 
Bioscience Information Service (BIOSIS), Science Citation Index (SCI), Cochrane Central 
Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews 
(CDSR), Database of Abstracts of Reviews of Effects (DARE), Medion, Health Technology 
Assessment database, PsycINFO, ASSIA, conference abstracts from the American Academy 
of Ophthalmology (AAO), the Association for Research in Vision and Ophthalmology 
(ARVO), the European Association for Vision and Eye Research (EVER) and current research 
registers.  Searches were carried out from 1995 to March 2013 other than for conference 
abstracts (2009 to November 2012).   
 
Types of studies considered were direct or indirect comparisons reporting diagnostic outcomes.  
The population was people with newly suspected nAMD or those previously diagnosed with 
the disease and under surveillance monitoring.  The index test was TD-OCT or SD-OCT and 
comparator tests considered were clinical evaluation, visual acuity, Amsler chart, colour fundus 
xxi 
 
photographs, infra-red reflectance, red-free images or blue reflectance, fundus autofluorescence 
imaging (FAF), indocyanine green angiography (ICGA), preferential hyperacuity perimetry 
(PHP) and microperimetry.  The reference standard was FFA. 
 
Two reviewers independently screened the titles and abstracts of all reports identified by the 
search strategy and full-text papers were obtained for assessment.  Data extraction was 
undertaken by one reviewer and checked by a second.  Two reviewers independently assessed 
the risk of bias of the studies using the QUADAS-2 instrument. 
 
The results of the individual studies were tabulated and sensitivity, specificity and their 95% 
confidence intervals (CIs) presented for each test or combination of tests. The presence of 
heterogeneity was assessed by visual examination of forest plots of sensitivity and specificity.  
Summary receiver operating characteristic (SROC) curves were derived.  Meta-analysis models 
were fitted using hierarchical SROC (HSROC) curves.  Summary sensitivity, specificity, 
positive and negative likelihood ratios and diagnostic odds ratios were reported as median and 
95% CI.   
 
An economic model was developed to assess the cost-effectiveness of different strategies for 
diagnosis and monitoring of individuals with nAMD.  Three strategies were selected for the 
diagnostic stage and three for the monitoring stage, giving a total of nine diagnosis-monitoring 
combinations.  
 
Diagnostic strategies 
a) Stereoscopic FFA interpreted by an ophthalmologist. If positive (i.e. presence of nAMD), 
treat and monitor; if negative, discharge. 
b) SD-OCT alone interpreted by an ophthalmologist. If positive, treat and monitor; if negative, 
discharge.  
c) Visual Acuity (VA) and SD-OCT and slit-lamp biomicroscopy (SLB) in all patients, 
performed/interpreted by an ophthalmologist. If positive or unclear, arrange for a FFA. If 
negative, discharge. This is the diagnostic strategy that best reflects standard practice. 
 
Monitoring strategies 
a) SD-OCT alone (interpreted by an ophthalmologist). If positive, treat. If negative or unclear, 
review in one month’s time. 
b) VA, SLB and SD-OCT interpreted together by an ophthalmologist. If positive, treat; if 
negative, review in one month’s time. If unclear, then the ophthalmologist will arrange for 
a FFA.  This is the monitoring strategy that best reflects standard practice. 
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c) VA and SD-OCT interpreted by a technician or nurse. If negative, review in one month’s 
time. If positive or unclear, referral to an ophthalmologist for assessment (e.g. SLB and 
ophthalmologist interpretation of VA and SD-OCT test results). If positive, treat; if negative, 
review in one month’s time; if unclear, arrange for a FFA.  
 
The model was run for a cohort of 65 year old men for a lifetime time horizon. A one-month 
cycle length was defined. Costs were expressed in 2011-2012 pounds sterling and effectiveness 
in quality-adjusted life years (QALYs). Costs and QALYs were discounted at 3.5%. Cost-
effectiveness analysis results were reported using incremental cost-effectiveness ratios 
(ICERs).  
 
Uncertainty was explored by conducting one-way sensitivity analyses, scenario analysis and 
probabilistic sensitivity analysis. One-way sensitivity analyses were conducted on test 
sensitivity and specificity for diagnosis, the probability of ophthalmologist diagnosis or 
monitoring having unclear results, test sensitivity and specificity for monitoring, the probability 
of the nurse or technician assessment being unclear, and unit costs for OCT, FFA and 
ranibizumab treatment. 
 
In addition, three scenario analyses were tested. All of these incorporated data favouring OCT 
(e.g. scenario 1 included the 95% CI upper limit for OCT sensitivity and specificity for 
diagnosis and monitoring, with £20.90 and £139 unit costs for OCT and FFA, respectively).  
Scenario 2 assumed a cost per treatment injection of £50 instead of £742, and scenario 3 
explored the effect of monitoring patients with OCT only, within the community, with referral 
to secondary care only for treatment. 
 
Results 
Number and quality of studies 
Twenty-two diagnostic studies (20 full-text, two abstracts) enrolling 2,124 people and eight 
(full-text) monitoring studies enrolling 463 people were included.  Only full-text studies were 
assessed for risk of bias.  For both the diagnostic and monitoring studies, the domains in which 
the greatest number of studies were judged to be at high risk of bias were the patient selection 
domain (55%, 11/20; 25%, 2/8) and flow and timing domain (40%, 8/20; 25%, 2/8).   
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Summary of benefits and risks 
Diagnostic studies 
In a meta-analysis of diagnostic studies (four TD-OCT studies) sensitivity and specificity (95% 
CI) was 88% (46% to 98%) and 78% (64% to 88%) respectively.   
 
In descriptive analyses, across the studies reporting other tests, median sensitivity was high for 
ICGA (93.2%, range 84.6% to 100%; four studies) and FAF (93.3%; one study), followed by 
PHP (81.5%, range 50.0% to 84.8%; three studies), colour fundus photography (70.0%; one 
study) and lowest for Amsler Grid (41.7%; one study). Specificity was highest for colour fundus 
photography (95%; one study), followed by PHP (84.6% and 87.7%; two studies), and was low 
for FAF (37.1%; one study) and ICGA (36.8%; one study).   
 
Monitoring studies 
In a meta-analysis of monitoring studies (three TD-OCT, two SD-OCT studies), sensitivity and 
specificity (95% CI) was 85% (72% to 93%) and 48% (30% to 67%) respectively.  For TD-
OCT, sensitivity and specificity was 70% (56% to 80%) and 65% (48% to 79%) respectively.  
It was not possible to calculate pooled estimates using HSROC methodology for the two SD-
OCT monitoring studies due to insufficient data.  These studies reported high sensitivity of 94% 
and 90% but low specificity of 27% and 47%.   
 
In the one monitoring study reporting ICGA, sensitivity of 75.9% and specificity of 88.0% was 
reported for detecting nAMD activity.  
 
Summary of cost-effectiveness 
The strategy that based its diagnostic decision on the results of FFA only, combined with VA 
and OCT interpreted together by a nurse or technician as a first monitoring step (‘FFA&Nurse’), 
had the lowest total expected cost. This strategy dominated (i.e. lower total cost and higher 
QALYs) all others apart from one. Diagnosis based on FFA only, followed by ophthalmologist-
led monitoring (FFA&Ophthalmologist), had a higher total expected cost and also produced 
higher total expected QALYs but at a cost per additional QALY above £30,000.  Moreover, the 
‘FFA&Nurse’ strategy had a 46.5% probability of being cost-effective at a £30,000 threshold 
value of willingness to pay for an extra QALY. Strategies using OCT alone for diagnosis or 
monitoring were unlikely to be cost-effective. This result seemed to be driven by the SD-OCT 
low specificity that resulted in a high number of false positives.  
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Discussion 
Strengths, limitations of the analyses and uncertainties 
In terms of strengths, a systematic literature search was undertaken and non-English language 
studies were included.  A HSROC model was applied, which takes account of the trade-off 
between true/false positives and models between-study heterogeneity.  The evidence for 
diagnosis and monitoring was considered separately, as was the evidence for TD-OCT and SD-
OCT.  Regarding the economic model, multiple different pathways were developed and 
evaluated.  In terms of limitations, very few studies provided sufficient information for 
inclusion in meta-analyses.  Only a few studies meeting our inclusion criteria reported the 
performance of other diagnostic tests of interest; for some tests no studies were identified.  The 
modelling was hampered by a lack of data on the diagnostic accuracy of strategies involving 
several tests (performed by ophthalmologists or other health professionals).   
 
In terms of uncertainties, there was substantial disagreement between OCT and FFA specificity, 
especially for monitoring.  As FFA was considered the reference standard it was not possible 
to assess whether OCT might have better sensitivity or specificity than FFA.  It was unclear 
why the specificity was lower for SD-OCT compared with TD-OCT.    
 
The model was based on one eye status and outcomes, as this is the approach most commonly 
used in this health area.  The so named ‘one eye models’ can underestimate resources used due 
to a proportion of nAMD individuals having active nAMD in both eyes in one particular visit.  
In the current model, this would increase the cost for those strategies with a higher number of 
false positives (i.e. lower specificity) and therefore would be unlikely to modify the general 
conclusions of this report.  In addition, the model did not consider effects on utility due to 
treatment injections and frequent monitoring. Anxiety in nAMD individuals was believed to 
occur at each monitoring visit mainly due to uncertainty of the underlying condition rather than 
the effects of treatment injections.  Limited evidence was available on the probability of nAMD 
active individuals becoming inactive when under treatment or inactive nAMD individuals 
becoming active. Short time follow-up data were extrapolated to a lifetime time horizon.  
 
Generalisability of the findings 
From the populations evaluated in the primary studies, the results of this report are broadly 
generalisable to the NHS.  One of the UK-based diagnostic studies evaluated a nurse-led, fast 
track screening clinic, which may not be representative of current UK practice.  In addition 
55% of the diagnostic and 25% of the monitoring studies were considered to be at risk of 
selection bias due to either pre-selection of participants and/or inappropriate exclusions. 
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Conclusions 
Implications for service provision 
In terms of OCT test performance, this review found that, based on a relatively small body of 
evidence of variable quality: 
• For diagnosis of newly suspected nAMD, SD-OCT had high sensitivity (98%) and 
moderate specificity (71%) (meta-analysis). 
• For monitoring of those previously diagnosed with nAMD, SD-OCT had high sensitivity 
(94%, 90%) but low specificity (27%, 47%) (two studies). 
• For both diagnosis and monitoring, SD-OCT had higher sensitivity than TD-OCT but lower 
specificity. 
 
The strategy that based its diagnostic decision on the results of FFA only, combined with a 
nurse or technician-led stepwise approach for monitoring, had the lowest expected total cost 
and a 47% probability of being cost-effective at a £30,000 threshold value of willingness to pay 
for an extra QALY.  Strategies using OCT test results alone to make diagnosis and/or 
monitoring treatment decisions were unlikely to be a cost-effective use of resources. 
 
There has already been a shift in the diagnostic and monitoring pathways for nAMD caused by 
the adoption of OCT.  At the diagnostic stage OCT is currently used in addition to FFA 
(reference standard), while for monitoring it has virtually replaced FFA, which is only used in 
selected circumstances.  The evidence suggests that using OCT as the only test for monitoring 
patients with nAMD and detecting activity would, potentially, result in a substantial proportion 
of patients receiving treatment unnecessarily. 
 
The continuing rise in the ageing population, with increasing numbers of people being 
diagnosed with nAMD and moving on to monitoring for renewed disease activity, will continue 
to present challenges for ophthalmology departments to have sufficient capacity to provide 
timely testing, and treatment.     
 
Suggested research priorities 
• Regarding monitoring of nAMD, in current practice OCT is routinely used, while FFA is 
used only in particular scenarios.  There is a substantial disagreement between OCT and 
FFA.  There is a need to research that OCT (without FFA) is an acceptable way of detecting 
active nAMD and guiding treatment.  As there is the theoretical possibility of OCT being 
better in some cases than the current reference standard, such studies might be designed to 
include a ‘fair umpire’ test, if available, to examine differences between OCT and FFA, or 
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be designed to incorporate sufficient follow-up to assess the consequences of the tests in 
terms of clinical effectiveness outcomes (e.g. visual acuity). 
• Regarding diagnosis of nAMD, current practice consists of FFA (as reference standard) 
associated with OCT.  Further research should be considered to establish the added value 
of OCT, and whether OCT (associated with slit-lamp biomicroscopy and visual acuity) can 
fully replace FFA.  As above, such studies might be designed to include a ‘fair umpire’ test, 
or the evaluation of the consequences of the diagnostic intervention.   
• Regarding the different phenotypes of nAMD, further evidence on the diagnostic 
performance of OCT according to phenotype of nAMD is required. 
• For both diagnosis and monitoring of nAMD, prospective studies are required to assess the 
diagnostic accuracy and clinical effectiveness of strategies involving possible different 
combinations and sequences of tests (e.g. visual acuity, slit-lamp biomicroscopy, fundus 
autofluorescence imaging, OCT), including a comparison of their interpretation by 
ophthalmologists compared with other health professionals.  
• To strengthen the evidence base used to develop the economic model, it would be important 
to explore the likelihood of active and inactive nAMD individuals becoming inactive or 
active, respectively.  In addition, a preference based study to assess utility weights (e.g. 
decrements) associated with treatment and frequent monitoring is needed.  
• Further research is needed to evaluate health status (utilities) in patients with nAMD, taking 
into consideration the visual function and spectrum of disease in both eyes and exploring 
the value added by inclusion of fellow eye information. 
 
Prospero registration number: CRD42012001930 
 
[Word count: 2400 words]  
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3  BACKGROUND 
 
3.1 Description of health problem 
3.1.1 Brief statement describing the health problem 
Neovascular age-related macular degeneration (nAMD) causes severe visual loss and is the 
commonest cause of blindness in persons > 50 years old in the western world.  In recent years, 
there have been significant advances in the clinical management of patients with nAMD.  For 
example, there are now effective treatments, specifically anti-vascular endothelial growth factor 
(anti-VEGF), and novel diagnostic technologies, including both imaging and functional tests.   
Patients who are being treated for nAMD with anti-VEGF require frequent and long-term 
follow-up for treatment to be most effective. 
 
The current reference standard for diagnosis of nAMD is fundus fluorescein angiography 
(FFA)1 which may also be used to monitor the activity of the disease after treatment.  However, 
FFA is time-consuming, invasive and requires expert interpretation.  Optical coherence 
tomography (OCT) is now widely used for diagnosis and management of nAMD.   OCT is non-
invasive, safer and more straightforward to do and interpret than FFA.  OCT may help clinicians 
to provide a more cost-effective service for people with nAMD by potentially replacing the 
current reference standard of FFA and helping to distinguish between those patients with active 
disease requiring treatment and those whose disease is not active at a particular point in time 
and who do not require treatment.  OCT might also lead to efficiencies by allowing other 
categories of health professionals to become involved in the diagnosis and monitoring of 
patients. 
 
3.1.2 Aetiology, pathology and prognosis 
Neovascular AMD is a pathological process in which new blood vessels arising from the 
choroid breach the normal tissue barriers and come to lie within the subretinal pigment 
epithelium (RPE) and/or subretinal spaces.  These new vessels, commonly referred to as 
choroidal neovascularisation (CNV) or choroidal neovascular membrane (CNVM), leak fluid, 
lipids and blood, elicit an inflammatory response and, as part of their natural history, undergo 
a scarring process, all of which has a deleterious effect on the visual cells of the retina 
(photoreceptors), leading to central loss of vision.  Besides CNV, there are two other recognised 
phenotypes of nAMD (a) retinal angiomatous proliferation (RAP) in which vascular complex 
seems to arise de novo from the retinal circulation, or results from CNV anastomosing with the 
retinal circulation; and (b) intra-choroidal/subretinal pigment epithelium (RPE) aneurysmal 
dilatation(s) of the choroidal vasculature, known as idiopathic polypoidal choroidal 
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vasculopathy (IPCV).2 These phenotypes may occur in isolation or be mixed with other 
phenotypes.3 
 
The onset of nAMD results in progressive and unremitting loss of central vision in the affected 
eye, with rare exceptions in cases of IPCV in which spontaneous improvement may be 
observed. A number of studies have shown that extrafoveal CNV will grow towards the fovea. 
Once foveal involvement has occurred CNV will expand and involve ever-increasing areas of 
the macula. Thus the majority of eyes will experience acute visual loss, either moderate (defined 
as a doubling of the visual angle which equates to a three line worsening on the Early Treatment 
Diabetic Retinopathy Study [ETDRS] visual acuity chart) or severe (defined as a quadrupling 
of the visual angle and which equates to a six line worsening on the ETDRS visual acuity chart).  
However, some patients with a fellow eye with good vision will not notice any such changes 
despite the onset of neovascularisation.   
 
Neovascular AMD is now treated with repeated intraocular injections of drugs designed to 
antagonise vascular endothelial growth factor (anti-VEGF). This will stabilise sight in most 
patients (~90%), and improves vision in a smaller group (~30%) during the first two years of 
treatment.1 Long-term (beyond 3-4 years) outcomes from randomised clinical trials (RCTs) 
using anti-VEGF are, however, not available.  These drugs are administered monthly (often 
with a mandated minimum of three injections for the first three months, and thereafter 
depending on whether active nAMD is present) as intraocular injections until the macula is 
rendered fluid free. When the disease becomes quiescent, treatment is stopped and patients are 
monitored for relapse, with treatment being restarted if needed, by monthly intraocular 
injections based on findings of visual acuity checks, clinical examination and OCT.  FFA is 
typically used to confirm the diagnosis of nAMD prior to initiating anti-VEGF therapy, but it 
is used only in selected circumstances for monitoring activity of nAMD after treatment.  
Relapse of nAMD is unpredictable and can occur within weeks, months or even years after 
stopping treatment. 
 
3.1.3 Epidemiology, incidence and prevalence 
The prevalence of all forms of AMD (including neovascular and atrophic AMD), which affects 
more than 600,000 people in the UK, is expected to rise by a quarter to nearly 756,000 by 2020.  
The estimated number of individuals with nAMD in the UK for 2011 is 368,000 and will 
increase substantially due to the ageing population.4-6 Estimates of incidence of nAMD in the 
UK suggest that there are between 13,000 and 37,000 new cases annually.5  The NICE guidance 
on ranibizumab and pegaptanib for the treatment of age-related macular degeneration (issued 
2008 and modified 2012) estimated that there were about 26,000 new cases of nAMD in the 
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UK each year.7 Many of these individuals will require monthly monitoring and treatment for 
several years.  Relevant risk factors include age, cigarette smoking, nutritional factors, 
cardiovascular diseases, and genetic markers, including genes regulating complement, lipid, 
angiogenic, and extracellular matrix pathways. 
 
3.1.4 Impact of health problem 
Significance for patients in terms of ill-health (burden of disease); significance for the NHS 
AMD is the most common cause of blindness and partial sighted registration in the UK.1 As the 
incidence of AMD increases with age, the burden of disease to the NHS and society is expected 
to increase with an ageing population.  Furthermore, loss of vision contributes to a 
psychological ill-health (depression, emotional distress) and reduced quality of life. 
  
Ophthalmology accounts for 10% (five million per year) of all outpatient attendances to the 
NHS, and age-related macular degeneration accounts for 15% of all ophthalmology outpatient 
attendances.1 Loss of visual acuity is associated with a profound impairment of quality of life.  
Visual loss increases the risk of frequent falls. Depression and visual hallucinations (Charles 
Bonnet syndrome) are frequent accompaniments of severe central vision loss. Patients with 
Charles Bonnet syndrome (associated with visual loss) and their family members should be 
informed that visual symptoms are not unusual and are not a sign of psychosis or mental 
deterioration.  
 
3.1.5 Measurement of disease 
The spectrum of disease may be classified according to the reduction of visual acuity, e.g., mild, 
moderate, or severe.   In addition to this spectrum of disease, during monitoring of patients 
undergoing treatment with anti-VEGF drugs, it is important to determine whether the disease 
is active or not.   Disease activity is typically determined with imaging technologies, mainly 
FFA and OCT.    
 
3.2 Current service provision 
3.2.1 Management of disease 
Diagnosis of nAMD and care pathway 
Typically patients with possible AMD present to primary care (optometrists or GPs) with non-
specific symptoms (such as reduced, blurred and distorted vision).   Some patients do not report 
symptoms and are detected at routine eye examination.  Clinical examination of the retina 
reveals typical changes associated with AMD such as drusen and irregularities in the 
appearance of the RPE, most commonly in both eyes.   However the presence of a neovascular 
component may be difficult to detect clinically, especially early on in the course of its 
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development.  The diagnostic pathway for nAMD and the management of patients with known 
disease include imaging technologies (Figure 1).    
 
Figure 1 Current diagnostic pathway of nAMD 
 
According to current guidelines from the Royal College of Ophthalmologists (RCO),1 FFA 
interpreted by an ophthalmologist is the method of choice and reference standard test to 
diagnose nAMD. Occasionally, indocyanine green angiography is associated with FFA as part 
of the reference standard when particular phenotypes of nAMD are suspected, including RAP 
and IPCV (see above).   FFA is an invasive and time-consuming procedure, entailing the 
injection of a dye into a peripheral vein by a nurse and a trained photographer to undertake the 
test (obtain the images of the CNV, RAP, IPCV lesions). In addition to FFA, current guidelines 
recommend using OCT at diagnosis.   Due to recent developments in technology, it is possible 
that in some cases OCT might be superior to FFA in detecting nAMD (see below and Table 1).  
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Table 1 Apparent features of optical coherence tomography (OCT) and fluorescein 
angiography (FFA) for neovascular age-related macular degeneration (nAMD)  
Features OCT (index test) FFA (reference standard) 
Accuracy High? Reference standard 
Invasiveness Non-invasive Invasive 
Knowledge and skills 
needed to interpret 
Moderate High 
Interpretable Most tests  Nearly all tests  
Cost Low to moderate Moderate 
Side effects None Allergy (rarely anaphylactic 
shock) 
 
Treatment and monitoring of nAMD 
When active nAMD is confirmed, treatment with anti-VEGF therapy is initiated.8,9 For all 
patients with nAMD it is common practice to use three consecutive (monthly) intravitreal 
injections of anti-VEGF therapy, and then the patient is reassessed to evaluate whether or not 
the disease is active (i.e., neovascularisation leaking fluid/blood at the macula) or inactive 
(Figure 2).  For this purpose, both FFA and OCT may be used, although the latter more often 
than the former, according to the guidelines of the Royal College of Ophthalmologists.1  Studies 
that have a large influence in current practice used visual acuity and OCT at monthly intervals 
and FFA at quarterly intervals to decide on the need for re-treatment. In some units OCT is the 
only test performed to determine activity of the neovascular process in clinical practice; in some 
centres FFA is performed in selected cases during the monitoring phase.  Other technologies 
such as fundus autofluorescence may also be used at baseline and at variable intervals during 
the follow-up of these patients as areas of atrophy in the RPE (difficult to detect clinically but 
easily observed on autofluorescence images) could be associated with fluid in the retina in the 
absence of active nAMD.   
 
If fluid is not seen intraretinally or subretinally, further treatment is not given and the patient is 
followed thereafter regularly.  The timing of follow-up visits is variable, typically every four 
weeks for the first year, extending the intervals after the second year.   Varying intervals have 
been proposed, such as “treat and extend” strategy, where if there is no active disease no 
treatment is given and the monitoring intervals are progressively extended.  If the disease is 
judged to be active, further injections of anti-VEGF are given.   Either a single or three 
injections are administered if activity is detected on follow-up and then the patient returns to 
the monthly monitoring scheme.  The possibility of using visual acuity (without imaging tests) 
as the only test to guide treatment during monitoring (i.e., treatment would be given if there is 
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a loss of >5 letters from best previously observed visual acuity) has been modelled using data 
from published trials for nAMD.10 The authors concluded that an individualised visual acuity-
guided regimen could sustain visual outcomes and improve cost-effectiveness compared with 
current regimes.   
 
Figure 2 Current monitoring pathway of nAMD 
 
3.2.2 Current service cost 
Table 2 shows an estimation of unit costs associated with current diagnosis and monitoring care 
pathways. A first referral visit to a hospital eye service will involve an eye examination and is 
costed at £106. In addition, OCT and FFA tests can be indicated, with the overall cost for the 
first visits ascending to £274.71.  A follow-up monitoring visit can involve a face-to-face 
attendance with an ophthalmologist and an OCT test only (£131). However, if an FFA is 
indicated, the monitoring visit will cost £248.27.  Without doubt the major cost category is 
given by the treatment cost. There are two possible anti-VEGF treatments: ranibizumab and 
bevacizumab at £742.17 and £50 per injection, respectively.  NICE guidelines advocate for the 
use of ranibizumab unless individual sight is heavily deteriorated. It should be noted that special 
cost arrangements are in place and a reduced cost for ranibizumab is agreed under a patient 
access scheme negotiated between the manufacturer and the Department of Health.  Under this 
agreement the cost of ranibizumab to the UK NHS (confidential) is significantly lower than the 
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list price given above.  The cost of bevacizumab is based on that of a compounded product as 
supplied by different compounding pharmacies in the UK. 
 
Table 2 Diagnosis and monitoring costs associated with nAMD health care  
 
Unit costs 
(£ 2011-12)   
 Diagnosis Monitoring Source 
Ophthalmologist 
visit £106.18 £79.74 
National Schedule of Reference Costs - 
Year 2011-12 -  Ophthalmology - 
Consultant Led: First Attendance or 
follow-up Non-Admitted Face-to-face - 
FFA £117.26 £117.26 
NHS Reference Costs 2011-12. (HRG 
BZ23Z Minor Vitreous Retinal 
Procedures) 
OCT £51.27 £51.27 
NHS Reference Costs 2011-12. (HRG 
RA23Z Ultrasound Scan, less than 20 
minutes) 
Medication 
ranibizumab 
(Lucentis®)  £742.17 
Ranibizumab (Lucentis®). Source: BNF 
(accessed 9/5/2013) Lucentis® 
(Novartis) Solution for intravitreal 
injection, ranibizumab 10 mg/mL, net 
price 0.23-mL vial = £742.17 
Medication 
bevacizumab 
(Avastin®)  £50.00 
As supplied by compounding 
pharmacies. Manufacturer’s list price 
not applicable 
 
3.2.3 Variation in service and/or uncertainty about best practice 
Once nAMD has been diagnosed, monotherapy with an anti-VEGF drug (administered into the 
vitreous) is the current standard of care.  Ranibizumab is highly effective and recommended by 
current guidelines.   Bevacizumab remains unlicensed in the UK although its use worldwide 
reflects the fact that it is much cheaper than ranibizumab (as currently supplied for intravitreal 
administration) with similar efficacy.8,9 
 
Retinal imaging with OCT before and after intravitreal administration of anti-VEGF therapy is 
regularly used.11   Following anti-VEGF therapy a reduction of intraretinal and subretinal fluid 
is typically observed, often with rapid unification of the retinal layers and improvement / 
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restoration of the anatomical contours. This anatomical improvement is often accompanied by 
improvements in visual acuity.  
 
The ultimate treatment goal when nAMD has already developed is to achieve restoration of 
central vision and prevent visual loss with normal or near normal foveal and macular anatomy. 
Complete cessation of exudation can result in good unification of the tissue layers, but most 
patients report difficulty with reading small print and other visually demanding tasks, even 
when tissue contours have been apparently restored. High resolution OCT scans obtained after 
anti-VEGF treatment show persistent abnormalities of the outer retina even though the tissues 
appear to be fluid free.  In cases where localised atrophy and fibrosis have already occurred, 
considerable impairment of central visual function can remain despite the achievement of a 
fluid free macula.   
 
Patients who have been treated with anti-VEGF therapy should be examined at regular 
intervals.  Although most clinicians will use OCT for monitoring patients with nAMD, there is 
probably large variability on the tests used, e.g., biomicroscopy of the fundus, FFA, and fundus 
photography. 
 
As explained above, patients treated with anti-VEGF injection should receive injections 
monthly for the first three months and, thereafter, should be monitored monthly. If active 
nAMD is present treatment should be continued, and if there is no active exudative AMD, 
observation at monthly intervals is recommended.  The use of technologies, including OCT, 
FFA and fundus autofluorescence (FAF) during the follow-up of these patients is variable as it 
depends on clinical findings, the judgment of the treating ophthalmologist, and the clinical 
pathways established at different centres. The workload associated with such contemporary 
AMD services is significant and is expected to increase, as the best outcomes are achieved with 
monthly follow-up visits. It is expected that these follow-up visits may continue for as long as 
four years or longer. The pressure on resources and service delivery in the AMD clinics is 
expected to become even more intense as many patients cannot be discharged, and there is a 
need to accommodate new incident cases. The regular monthly follow-up for AMD patients 
under treatment, in order to maintain efficacy, is demanding. This situation is likely to be further 
aggravated by the impending treatments with intravitreal therapies of macular oedema 
secondary to diabetic retinopathy and retinal vein occlusion.  As such the problem seems more 
acute than was originally envisaged, and is expected to get worse.  It has been suggested 
engaging non-medical staff (optometrists, nurses, technicians) to undertake some of the duties 
in the AMD clinic in order to increase capacity. Such roles include clinical assessments, 
especially re-treatment decision making.  
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3.2.4 Relevant national guidelines, including National Service Frameworks 
Subsequent to the technology appraisal and issuing of guidance by the National Institute for 
Health and Care Excellence (NICE), ranibizumab has been widely adopted as the treatment of 
choice for subfoveal nAMD in the UK.7 However, the high cost of ranibizumab, along with the 
positive clinical experience with bevacizumab, has stimulated a debate on whether 
bevacizumab could be used in practice.     
 
In the UK, guidelines for the management and treatment of nAMD were published by the RCO 
in 2009, and in 2013 were undergoing revision.1  According to the RCO guidelines, FFA 
interpreted by an ophthalmologist is the method of choice and reference standard test to 
diagnose nAMD. Occasionally, indocyanine green angiography is associated with FFA as part 
of the reference standard when particular phenotypes of nAMD are suspected, including RAP 
and IPCV.   In addition to FFA, current guidelines recommend using OCT at diagnosis.   During 
follow-up and monitoring of disease activity after treatment the current guidelines recommend 
the use of OCT mainly, and FFA at the discretion of the clinician.  
 
3.3 Description of technologies under assessment 
3.3.1 Reference standard - fundus fluorescein angiography (FFA)  
FFA is currently the reference standard for diagnosing CNV in AMD. A fluorescein angiogram 
is a sequence of images captured of the fundus over a ten minute period after injection of the 
non-toxic dye fluorescein isothiocyanate into a suitable peripheral vein. 
 
Neovascular lesions are classified by their location with reference to the foveal avascular zone 
– extra-foveal, juxtafoveal or subfoveal.  Lesions lying more than 200μm from fixation are 
defined as extrafoveal, and may also be described as juxtafoveal or subfoveal when 
immediately adjacent to or involving the geometric centre of the fovea, respectively.  
Neovascular lesions located away from the macula are termed peripheral and those around the 
optic nerve juxtapapillary. A more refined classification of the neovascular lesion is obtained 
by describing the composition of the exudative lesion after stereoscopic review of the entire 
sequence of the angiogram. The exudative lesion is defined as the area occupied by the 
neovascular complex, any associated blood, thick exudate and pigment epithelial detachments 
that are contiguous to the neovascular complex and obscure its margins.  The neovascular 
complex can, therefore, consist of retinal angiomatous proliferation (RAP), choroidal 
neovascularisation (CNV) and idiopathic polypoidal choroidal vasculopathy (IPCV).   
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The classification of neovascular AMD lesions is based on the temporal and spatial features of 
the patterns of fluorescence as observed on the FFA.  CNV lesions are classified according to 
their location relative to the fovea (see above), and pattern of fluorescein angiographic leakage. 
The majority of CNVs occur subfoveally.   
 
Classic CNV is said to be present when an area of well delineated hyperfluorescence appears 
in the early phases of the FFA, usually before seconds have elapsed following injection of the 
fluorescent dye into a peripheral vein. Most commonly, classic CNV represents new vessels 
that have breached the RPE and lie in the subretinal space. Sometimes a typical lacy pattern of 
hyperfluorescence is observed in the very early phase of the angiogram which corresponds to 
the vascular profiles before the fluorescein has leaked out of these vessels and obscured the 
margins. Classic CNV also leak aggressively and hence there is considerable pooling of 
fluorescein dye in the subretinal space in late frames of the angiogram. 
 
Occult CNV as its name suggests, refers to the presence of leakage without clear evidence of 
neovascular profiles in the early angiographic images. Two types of occult leakage are 
recognised. The first is a characteristic stippled hyperfluorescence which occurs early and is 
located at the level of the RPE. The RPE layer is elevated and in the later phases of the 
angiogram there is increasing hyperfluorescence and pooling of dye in the subretinal pigment 
epithelial space. The pattern of leakage suggests new vessels between Bruch’s membrane and 
the RPE and it is therefore considered to be a fibrovascular pigment epithelial detachment 
(FPED). The second pattern of occult leakage is a more diffuse hyperfluorescence with poorly 
demarcated boundaries which occurs late in the angiographic phase, generally after two minutes 
have elapsed since injection of dye. There is no corresponding hyperfluorescence in the early 
frames and there is shallow elevation of the RPE. This type of leakage is referred to as late 
leakage of indeterminate origin (LLIO). Many lesions are mixed showing combinations of 
classic and occult features. It is now common practice to classify lesions by presence or absence 
of classic and or occult CNV. In the absence of any occult CNV, lesions are termed classic with 
no occult (100% classic) and conversely occult with no classic (0% classic). 
 
When CNV is mixed the lesion is classified by the proportion of classic. When the lesion is 
composed primarily of classic CNV (i.e. classic greater than 50%) it is termed predominantly 
classic. When there is 1 to 49% classic the lesions are termed minimally classic.  
 
Retinal angiomatous proliferation (RAP) One type of neovascularisation that has been well 
recognised by the use of high speed video angiography using the scanning laser 
ophthalmoscope is the RAP lesion.  RAP is seen commonly as a round area of intraretinal 
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telangiectatic, dilated blood vessels located juxta- or extrafoveally.  On viewing stereo pairs of 
images, the vessels are often seen to turn sharply from the inner retina towards the choroidal 
interface.  Except in early stages, RAPs are associated with PEDs. They leak and hence the 
adjacent retina is usually disrupted with cystoid spaces.  ICGA is a helpful test to determine the 
presence of RAP. 
 
Idiopathic polypoidal choroidal vasculopathy (IPCV) Polyps are seen as focal, round areas 
of abnormal dilated choroidal vessels, often associated with large areas of lipid deposition and 
haemorrhage.  The presence of haemorrhagic PED is highly suggestive of the presence of this 
phenotype.   These are best visualised by ICGA. 
 
3.3.2 Optical coherence tomography (OCT) 
OCT was developed at the Michigan Institute of Technology, USA in 1991.  It is a light-wave 
based technology producing cross-sectional images of the retina with scan rates and resolution 
parameters that have greatly improved over the last ten years.  OCT is a non-invasive, non-
contact visual test that requires around 5-10 minutes to assess both eyes.12 From the 
investigator’s point of view it is user friendly (e.g., OCT is easier to do than FFA), typically 
undertaken by trained medical photographers or ophthalmic imaging technicians, and 
interpreted by ophthalmologists.  Automated analysis can also be used.  
 
There are two main types of OCT system.  The earlier time domain (TD) system, available from 
1995, had an image rate of 100 to 400 scans per second and provided information for a limited 
view of the retina by taking six scans radially-oriented 30 degrees from each other with a 
resolution in the range of 10 to 20 µm.12 The newer system, spectral domain (SD) OCT, has 
been available since 2006.  Improvements with this system include (i) a faster scan speed of 
approximately 27,000 scans per second, (ii) the ability to scan larger areas of the retina by 
taking several horizontal line scans such that there are no ‘missed areas’, (iii) increased 
resolution at 5 µm, and (iv) ‘real time registration’, which was not previously available with 
TD-OCT.12 The real-time registration feature enables the identification of specific anatomical 
locations on the retina, against which subsequent tests may be evaluated, which is of particular 
importance in the monitoring of patients.12 Compared with TD-OCT, the faster scan speed of 
SD-OCT enables the collection of additional information on larger regions of the retina and 
eliminates image distortion arising from patient movement, while the improved resolution 
allows for a clearer and more distinguishable view of retinal layers, with the possibility of 
detecting earlier signs of disease.12  
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3.3.3 Identification of important sub-groups 
There are different sub-groups of patients with nAMD.  They are diagnosed according to FFA 
findings, and are described above.   Subgroup classification depends on the location (extra-, 
juxta-, and subfoveal) and type of neovascularisation (classic and occult choroidal 
neovascularisation, retinal angiomatous proliferation (RAP), and idiopathic polypoidal 
choroidal vasculopathy (IPCV)), which could be mixed in different combinations.   Although 
the initial treatment is similar for all sub-groups (with anti-VEGF therapy), the natural history 
and progression after treatment are different.  It is also possible that the performance of 
diagnostic technologies may be different among sub-types of nAMD.  OCT is not currently 
used in isolation to identify sub-groups.   
 
3.3.4 Current usage in the NHS 
Both FFA and OCT are currently used in the NHS to diagnose and monitor patients with 
nAMD.  They are recommended technologies to provide standard care.  FFA is essential for 
diagnosis of the condition.  Regarding monitoring, FFA is less commonly used than OCT. 
 
3.3.5 Anticipated costs associated with intervention 
Table 3 presents an estimation of the number of visits in a lifetime of the population. Based on 
Census, nAMD prevalence and Interim Life Table data it is possible to estimate the number of 
visits for the population lifetime. Calculations in Table 3 are for England and Wales, based on 
2011 data and assumed that every individual with nAMD would contact NHS services. This 
estimation resulted in 33.7 million visits. If OCT was conducted at every monitoring visit this 
would result in an undiscounted lifetime cost of above £1.7 billion (e.g. £51.27 (see Table 2) 
times 33.7 million).  
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Table 3 nAMD prevalence and lifetime total number of monitoring visits for 
England and Wales 
 
Population for 
England & 
Wales, 2011 
Census-based 
estimates13 
nAMD 
prevalence 
rates6  
Number 
nAMD 
cases 
Life 
expectancy14  
Total 
number of 
monthly 
monitoring 
visits 
(lifetime) 
Men      
Age      
65 to 69 1,096,335  0.38% 4,166  16.64  833,215  
70 to 74 1,027,959  1.40% 14,391  13.06  2,259,454  
75 to 79 810,590  2.63% 21,319  9.87  2,515,585  
80to 84 557,203  5.56% 30,980  7.16  2,664,322  
85 to 89 295,680  5.56% 16,440  5.07  1,002,828  
90 to 99 333,448  5.56% 18,540  3.00  667,430  
Total males      9,942,833  
      
Women 
Age     
 
65 to 69 1,154,292  0.92% 10,619  19.15  2,442,482  
70 to 74 1,140,959  1.42% 16,202  15.20  2,948,694  
75 to 79 976,657  2.17% 21,193  11.59  2,945,891  
80to 84 788,087  10.50% 82,749  8.46  8,440,412  
85 to 89 532,677  10.50% 55,931  5.95  3,971,107  
90 to 99 717,989  10.50% 75,389  3.36  3,015,554  
Total 
females     
 23,764,139  
Total 
overall 
population 
    33,706,973 
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3.4 Alternative tests 
3.4.1 Clinical evaluation (with slit-lamp biomicroscopy with or without use of diagnostic 
contact lens and evaluation of patients’ symptoms) 
The onset of exudative AMD is heralded by the appearance of central visual blurring and 
distortion. Most patients will complain that straight lines appear crooked or wavy.  Sometimes 
patients do not notice visual symptoms when the first eye is affected. When nAMD occurs in 
the second eye, patients suddenly become limited in their daily activities, e.g., reading, driving, 
and seeing fine detail such as facial expressions.  
 
Examination of the macula usually reveals fluid and or lipid (yellow deposition) and/or blood.  
Other features of AMD such as drusen and pigmentary irregularities are most often present. 
Sometimes these latter features are not observed once exudative AMD has supervened or in 
certain phenotypes such as IPCV. However, the fellow eye would usually exhibit some or all 
of these AMD early clinical signs (drusen and RPE changes) and their presence is helpful in 
confirming that the neovascular lesion is due to AMD (again with the exception of IPCV where 
the fellow eye may also be normal). Following slit-lamp biomicroscopy the presence or absence 
of the following signs should be noted:  
• Subretinal or sub-RPE neovascularisation which may be visible as a dark grey lesion. 
Occasionally the lesion will have a dark pigmented edge which is thought to be due to 
proliferation of the RPE at the edge of the membrane. 
• Serous detachment of the neurosensory retina. 
• RPE detachment. 
• Haemorrhages - subretinal pigment epithelial, subretinal, intraretinal or preretinal. 
Breakthrough bleeding into the vitreous may also occur, indicating most often the presence 
of IPCV. 
• Hard exudates (lipids) within the macular area related to any of the above, and not related 
to other retinal vascular disease. 
• Epiretinal, intraretinal, subretinal or sub-pigment epithelial scar/glial tissue or fibrin-like 
deposits. 
• Retinal angiomatous proliferations: red, round, extra- or juxtafoveal lesions located within 
the retina 
• Polyps: red, round lesions located underneath the RPE or protruding through the RPE 
layer. 
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3.4.2 Visual acuity (for monitoring) 
Visual acuity (VA) is a measure of the spatial resolution of the visual processing system. VA 
is tested by requiring the person whose vision is being tested to identify characters (like letters 
and numbers) on a chart from a set distance. Chart characters are typically represented as black 
symbols against a white background (for maximum contrast). The distance between the person's 
eyes and the testing chart is set at a sufficient distance to approximate infinity in the way the 
lens attempts to focus.   
 
3.4.3 Amsler chart 
The Amsler chart is a grid of horizontal and vertical lines used to monitor a person's central 
visual field. It is a diagnostic tool that aids in the detection of visual disturbances caused by 
changes in the retina, particularly the macula (e.g. macular degeneration).  In the test, the person 
looks with each eye separately at the small dot in the center of the grid. Patients with macular 
disease may see wavy lines or some lines may be missing.  Amsler grids are supplied by 
ophthalmologists, optometrists or from web sites, and may be used to test one's vision at home. 
 
3.4.4 Colour fundus photographs 
Colour fundus photography provides a record of the appearance of the macular retina. 
Stereoscopic images of the macula viewed appropriately can help localise pathology to the 
different tissue layers. For the purposes of recording macular pathology stereoscopic pairs of 
images taken at 35 degrees centred on the macula are recommended.   Red-free images (RF) 
can help detect some features of the fundus associated with nAMD, such as haemorrhages.   
 
3.4.5 Infra-red reflectance (IR) 
Confocal near-infrared fundus reflectance (NIR) is a non-invasive en face imaging technique 
using an 830 nm diode laser capable of visualising subretinal pathology.  In contrast to visible 
wavelength illumination, fundus reflectance may be up to ten times higher in the near infrared 
wave-length, and is then largely independent of melanin content, which advances the visibility 
of deep fundus structures. 
 
3.4.6 Red-free images (RF) or blue reflectance 
Mentioned in section above on colour fundus photographs. 
 
3.4.7 Fundus autofluorescence imaging (FAF) or blue reflectance 
This test can give an indication of the health of the RPE. The conventional fundus 
autofluorescence (FAF) signal (obtained with 488nm) originates, predominantly, from 
lipofuscin in RPE cells.  The near-infrared autofluorescence (NIA) signal originates, 
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predominantly, from melanin in the RPE, with some contribution from choroidal melanin.  
Increased FAF represents accumulation of lipofuscin and suggests that the RPE cells are 
beginning to fail.  Absence of FAF and NIA signal, which appears as black areas in FAF and 
NIA images, is due to loss of RPE cells. The finding of patches of absent autofluorescence may 
explain central scotoma patterns. While different patterns have been described in early and late 
AMD the exact diagnostic performance of autofluorescence is yet to be determined.   The role 
of FAF may be more important in monitoring patients undergoing anti-VEGF therapy to 
evaluate atrophy, e.g., for potential discontinuation of treatment. 
 
3.4.8 Indocyanine green angiography (ICGA), dynamic high speed or digital subtraction 
ICGA (DS-ICGA) 
Indocyanine green (ICG) is an alternative dye to fluorescein which is used to visualise the 
choroidal circulation. This dye binds to plasma protein and hence does not egress easily through 
the fenestrae of the choroidal vessels, remaining within the vascular compartment. ICGA is 
obtained using longer wavelengths than FFA and, thus, can penetrate through areas of 
fluid/blood, permitting visualisation of pathology in circumstances where fluorescein may not. 
ICG also has some limitations and very thick blood or pigment can reduce or block transmission 
of the ICG infrared wavelength and the emitted light is of lower intensity compared with that 
of fluorescein. The use of the scanning laser ophthalmoscope (SLO) with video capture can 
however yield images of high resolution. Video ICGA also allows better imaging of RAP. As 
ICG dye does not leak into the subretinal and subpigment epithelial spaces to the same extent 
as fluorescein the enhanced definition of the vascularised tissue as a hotspot is possible and a 
combination of FFA and ICGA can produce complementary information. A dose of 25mg of 
ICG in aqueous solution is usually injected intravenously and images acquired for up to 30 
minutes. 
 
3.4.9 Preferential hyperacuity perimetry (PHP) 
Preferential hyperacuity perimetry is a psychophysical test of macular function that exploits the 
ability of the human visual system to perceive even minute differences in the relative 
localisation of two objects in space; a phenomenon termed hyperacuity.  When there is 
separation of the retinal layers through breakdown of the blood retinal or blood retinal pigment 
epithelial barriers, distorted vision is the consequence.  Through presentation of lines with 
artificial distortions of different intensities on the PHP, the presence of a real distortion in the 
patient’s central visual field can be detected as the brain ignores the smaller deviation when a 
larger one is introduced. 
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In a PHP test, the macula is scanned with a succession of stimuli, each stimulus consisting of a 
series of dots arranged along a vertical or horizontal axis. In each stimulus, a small number of 
dots are misaligned, thereby creating an artificial distortion (bump or wave). The examinee's 
task is to perceive these artificial distortions and mark their locations on the visual field. When 
a stimulus is projected on a healthy portion of the retina, the examinee identifies the artificial 
distortion and is likely to mark a correct location. If the stimulus is projected on a damaged 
region of the retina, a pathological distortion may be perceived instead of the artificial 
distortion, especially if the pathological distortion is more prominent than the artificial 
distortion. The examinee may then mark a location that is distant from the artificial distortion, 
indicating that a pathological distortion may have been perceived.  By manipulating the 
amplitude of artificial distortions, the amplitude of the pathology in the area of interest can be 
quantified. At the end of the test, comparison of the set of erroneous responses against a 
normative data base is used to determine if test results are within normal limits. 
 
3.4.10 Microperimetry 
One conventional measure of vision is subjective visibility thresholds of small, short-duration 
stimuli as performed by conventional automated static perimetry.  In conventional perimetry, 
retinal localisation of a stimulus is implied indirectly from the assumed retinal location of 
fixation. This approach can work well when fixation is stable and foveal.  However, loss of 
fixation stability or foveal vision, such as occurs commonly in nAMD, complicates the 
measurement of macular function with conventional perimetry. Accurate correspondence 
between retinal structures and visual function requires simultaneous imaging of the fundus.  
Microperimetry includes real-time automated tracking of the fundus and appropriate 
compensation of the location of stimulus presentation at predefined retinal loci. 
 
3.5 Care pathway 
See above Section 3.2.1, Management of disease: Diagnosis of nAMD.  Currently, patients with 
suspected nAMD seen by optometrists or other health professionals will be referred to 
secondary care where ophthalmologists with expertise on AMD will perform the following 
tests: visual acuity measurement, slit-lamp biomicroscopy and, if the diagnosis of nAMD 
remains a possibility, FFA and OCT.  The FFA and OCT imaging tests are used to confirm the 
diagnosis, and they also provide a baseline reference for future comparisons during the follow-
up of the patient.  Alternative technologies are used at presentation in some units, e.g., fundus 
autofluorescence imaging, to evaluate the status of the retinal pigment epithelium (RPE) which 
may have prognostic implications.  
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4  DEFINITION OF THE DECISION PROBLEM 
 
4.1 Decision problem 
New treatments for neovascular age-related macular degeneration (nAMD) have been approved 
by NICE for use in the NHS.  These treatments often require repeated injections of anti-vascular 
endothelial growth factor (anti-VEGF) over a period of years, with frequent monitoring greatly 
increasing the demand on secondary care AMD services. 
 
Fundus fluorescein angiography (FFA), an invasive test, is the reference standard recommended 
for detecting nAMD at initial presentation and also for detecting recurrent activity at some 
monitoring visits (e.g. quarterly, or according to clinician criteria).  Optical coherence 
tomography (OCT) is a non-invasive test now widely used for detecting nAMD both at initial 
presentation and for detecting recurrent activity during monitoring visits.  Two OCT systems 
are in use.  The more recently introduced spectral domain OCT (SD-OCT) incorporates a 
number of improvements over the earlier time domain OCT (TD-OCT).  Depending on the 
performance of OCT, in some situations its use could possibly replace that of FFA.  Also, as 
the interpretation of OCT images is more straightforward than that of FFA, it could potentially 
be interpreted by other health professionals (e.g. medical photographers, nurses).   
 
However, the value of OCT has not been well-defined and given the burden of monthly lifelong 
monitoring by ophthalmologists, involving multiple tests, an assessment of the role of OCT in 
the diagnosis, monitoring and guiding of treatment for nAMD is needed.  
 
4.1.1 Index test(s) 
The index test considered was OCT, either alone or in combination with alternative tests as 
described below.  Both time-domain OCT (TD-OCT) and spectral-domain OCT (SD-OCT) 
were considered. 
 
4.1.2 Population  
The population considered was people with newly suspected nAMD or those previously 
diagnosed with the disease and under surveillance monitoring.  
 
The setting considered was secondary care. 
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4.1.3 Relevant comparators 
The alternative tests considered included the following examinations: 
• Clinical evaluation (with slit-lamp biomicroscopy (SLB) with or without use of diagnostic 
contact lens and evaluation of patients’ symptoms); 
• Visual acuity (VA) (for monitoring); 
• Amsler chart; 
• Colour fundus photographs; 
• Infra-red reflectance (IR);  
• Red-free images (RF) or blue reflectance; 
• Fundus autofluorescence imaging (FAF);  
• Indocyanine green angiography (ICGA), dynamic high-speed or digital subtraction ICGA 
Angiography (DS-ICGA); 
• Preferential Hyperacuity Perimetry (PHP); and 
• Microperimetry. 
 
4.1.4 Reference standard 
The reference standard considered was ophthalmologist interpreted FFA.  FFA is generally 
acknowledged as being the recognised reference standard for detecting nAMD.  The Royal 
College of Ophthalmologists states in its guidelines for management of AMD that FFA is 
currently the reference standard for diagnosing exudative disease.1   However as few studies 
reported individual ophthalmologist-interpreted FFA (rather than reading centre interpreted 
FFA), studies using FFA as the reference standard but with unclear information about which 
type of healthcare professionals interpreted the images were also considered.  
 
4.1.5 Outcomes 
The following outcomes were considered for the use of OCT at presentation and during follow-
up of patients with nAMD: 
• Diagnostic accuracy (e.g. sensitivity, specificity, likelihood ratios, diagnostic odds ratio); 
• Clinical effectiveness (e.g. visual acuity, anatomical control of the disease, patient reported 
outcomes); 
• Interpretability of the test – to be defined as in included studies, considering the ability to 
acquire a quality image that can be interpreted or analysed; 
• Acceptability of the test – to be defined as in included studies, considering users and 
healthcare providers’ perspective;  
• Proportion of participants not able to receive the diagnostic test (due to an eye condition 
e.g. lens or other media opacity, or personal circumstances e.g. wheelchair bound). 
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The evidence for the use of OCT was considered separately for the purposes of diagnosis and 
monitoring.  
 
4.1.6 Key issues 
The key issues to be addressed are: 
• How good a test is OCT, when used either alone or in combination with alternative tests, in 
the diagnosis of people newly presenting with a suspicion of nAMD? 
• How good a test is OCT, when used either alone or in combination with alternative tests, in 
detecting recurrent nAMD activity during surveillance monitoring of people previously 
diagnosed with the disease? 
• Is SD-OCT a better test than TD-OCT? 
• Could OCT images be interpreted by other health professionals in addition to 
ophthalmologists? 
• Could OCT replace FFA in some situations in the diagnostic and/or monitoring pathways? 
• How cost-effective are strategies involving OCT, both in the diagnostic and monitoring 
pathways? 
 
4.2 Overall aims and objectives of assessment 
The overall aim of the review was to determine the optimal role of OCT in (i) the diagnosis of 
people newly presenting with suspected nAMD and (ii) in monitoring those previously 
diagnosed with the disease.  
 
Specific research objectives were:  
• To determine the diagnostic performance of OCT, alone or in combination with alternative 
tests, in detecting nAMD, including accuracy, interpretability, and acceptability;  
• To determine the performance of OCT and/or other alternative tests in the monitoring of 
the disease post-diagnosis, specifically in detecting activity of the disease and the need for 
further treatment;   
• To determine the performance of other health professionals (e.g. medical photographers, 
nurses) compared with ophthalmologists in interpreting OCT findings;    
• To model the effects of using OCT and/or other alternative tests in the diagnosis and 
management of the disease and estimate the relative cost-effectiveness of alternative 
diagnostic and monitoring strategies, including  determination of an optimal cut-off point 
for sensitivity and specificity for use in practice, and the alternative timing between tests 
during monitoring; and 
• To identify future research needs. 
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5  METHODS FOR REVIEWING TEST PERFORMANCE 
 
Methods were in accordance with the protocol, which is presented in Appendix 1. 
 
5.1 Identification of studies 
Published, unpublished and ongoing studies were identified from literature searches of 
electronic databases (from 1995 onwards) and appropriate websites.  The search strategies were 
designed to be highly sensitive, including appropriate subject headings and text word terms that 
reflected both the clinical condition and diagnostic tests under review.  There were no language 
restrictions.  Databases searched included MEDLINE, MEDLINE In-Process, EMBASE, 
Biosis and Science Citation Index (SCI) for all reviews. The Cochrane Central Register of 
Controlled Trials (CENTRAL) was searched for additional reports of RCTs for the 
effectiveness review and PsycINFO and ASSIA for patient acceptability data. The Cochrane 
Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects 
(DARE), MEDION and HTA database were searched for relevant systematic reviews and HTA 
reports. Abstracts and presentations from recent conferences (2009 onwards) of the American 
Academy of Ophthalmology (AAO), the Association for Research in Vision and 
Ophthalmology (ARVO), and the European Association for Vision and Eye Research (EVER) 
were also searched. The WHO International Clinical Trials Registry Platform (ICTRP), Clinical 
Trials.gov and EU Clinical Trials Register were searched for ongoing studies. Websites of 
professional organisations and manufacturers of optical coherence tomography (OCT) 
equipment were also consulted.  Reference lists of all included studies were scanned and experts 
contacted for details of additional potentially relevant reports.  The date of the final searches 
was March 2013. Full details of the search strategies used are provided in Appendix 2. 
 
5.2 Inclusion and exclusion criteria 
5.2.1 Types of studies 
The following types of studies were considered: 
(i) Diagnostic studies: 
• Direct (head-to head) comparisons in which the index test and comparator test(s) are 
evaluated in the same study population.  These could be fully paired (all study 
participants receive the index test, comparator test(s) and the reference standard) or not 
fully paired (participants receive only a subset of the tests, e.g. a randomised direct 
comparison in which study participants are randomly allocated to receive the index test 
or the comparator and all receive the reference standard.   
• Indirect comparisons in which estimates of the accuracy of the respective tests are 
obtained in different study groups, e.g. two-gate or ‘case-control’ type studies where 
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different sets of criteria are used for those with and without the target condition.  
Indirect comparisons were to be considered if there was insufficient evidence from 
direct comparisons. 
(ii) Studies reporting clinical effectiveness: 
• RCTs evaluating outcomes when treatment was based on OCT compared with fundus 
fluorescein angiography (FFA) findings. 
(iii) Qualitative studies evaluating patients’ and/or clinicians’/healthcare professionals’       
acceptability and/or interpretability of the OCT tests.  
 
5.2.2 Types of participants 
The types of participants considered were people with newly suspected nAMD or those 
previously diagnosed with the disease and under surveillance monitoring.  
 
The setting considered was secondary care. 
 
5.2.3 Index tests 
The index test considered was OCT, either alone or in combination with alternative tests as 
described below.  Both time-domain optical coherence tomography (TD-OCT) and spectral-
domain optical coherence tomography (SD-OCT) were considered. 
 
5.2.4 Comparator tests 
The alternative tests considered included the following examinations: 
• Clinical evaluation (with slit-lamp biomicroscopy (SLB) with or without use of 
diagnostic contact lens and evaluation of patients’ symptoms); 
• Visual acuity (VA) (for monitoring); 
• Amsler chart; 
• Colour fundus photographs; 
• Infra-red reflectance (IR);  
• Red-free images (RF) or blue reflectance; 
• Fundus autofluorescence imaging (FAF);  
• Indocyanine green angiography (ICGA), dynamic high-speed or digital subtraction 
ICGA Angiography (DS-ICGA); 
• Preferential Hyperacuity Perimetry (PHP); and 
• Microperimetry. 
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5.2.5 Reference standard 
The reference standard considered was ophthalmologist interpreted FFA.  FFA is generally 
acknowledged as being the recognised reference standard for detecting nAMD.  The Royal 
College of Ophthalmologists states in its guidelines for management of AMD that FFA is 
currently the reference standard for diagnosing exudative (neovascular) AMD.1,15   However as 
few studies reported individual ophthalmologist-interpreted FFA (rather than reading centre 
interpreted FFA), studies using FFA as the reference standard but with unclear information 
about which type of healthcare professionals interpreted the images were also considered.  
 
5.2.6 Types of outcomes 
The following outcomes were considered for the use of OCT at presentation and during follow-
up of patients with nAMD: 
• Diagnostic accuracy (e.g. sensitivity, specificity, likelihood ratios, diagnostic odds ratio); 
• Clinical effectiveness (e.g. visual acuity, anatomical control of the disease, patient reported 
outcomes); 
• Interpretability of the test – defined as in the included studies, considering the ability to 
acquire a quality image that can be interpreted or analysed; 
• Acceptability of the test – defined as in the included studies, considering users and 
healthcare providers’ perspective;  
• Proportion of participants not able to receive the diagnostic test (due to an eye condition 
e.g. lens or other media opacity, or personal circumstances e.g. wheelchair bound). 
 
The evidence for the use of OCT was considered separately for the purposes of diagnosis and 
monitoring.  
 
5.3 Data extraction strategy 
Two reviewers (MC plus GM or AAB) screened the titles (and abstracts if available) of all 
reports identified by the search strategy.  Full-text copies of all studies deemed to be potentially 
relevant were obtained and two reviewers (MC plus AAB or GM) independently assessed them 
for inclusion.  Disagreements were resolved by consensus or arbitration by a third reviewer. 
 
A data extraction form was developed and piloted.  One reviewer (MC) extracted details of 
study design, participants, index, comparator and reference standard tests and outcome data, 
and a second reviewer (AAB or GM) checked the data extraction.  Disagreements were resolved 
by consensus or arbitration by a third reviewer.  
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5.4 Critical appraisal strategy 
Two reviewers (MC plus AAB or GM) independently assessed the risk of bias and applicability 
concerns of all included full-text diagnostic and monitoring studies using the updated quality 
assessment of diagnostic accuracy studies (QUADAS-2) checklist.16 Any disagreements were 
resolved by consensus or arbitration by a third party.  The original QUADAS checklist was 
developed for use in systematic reviews of diagnostic studies through a formal consensus 
method and was based on empirical evidence.  Following anecdotal reports and feedback which 
suggested problems with QUADAS, the QUADAS-2 tool was developed.  QUADAS-2 consists 
of four key domains covering (1) patient selection, (2) index test, (3) reference standard, and 
(4) flow of patients through the study and timing of the index test(s) and reference standard.  
Each domain is assessed in terms of the risk of bias.  The first three domains are also assessed 
for concerns regarding their applicability in terms of whether (i) the participants and setting, 
(ii) index test, its conduct or interpretation and (iii) target condition as defined by the reference 
standard match the question being addressed by the review.  Within each domain signalling 
questions are included to assist in making a judgment about the risk of bias, with the standard 
tool containing 11 such questions across the four domains.  
 
Both the original and updated checklists were designed to be adapted to be more applicable to 
a specific review topic.  For this review, QUADAS-2 was modified by adding an additional 
signalling question to domain 1 (patient selection) to assess whether participant pre-selection 
had been avoided.  Domains 2 (index test), 3 (reference standard) and 4 (flow and timing) were 
retained in their entirety.  Therefore the modified tool contained 12 signalling questions, with 
each worded so that a rating of ‘Yes’ was always optimal in terms of methodological quality.  
If any signalling questions within a domain were rated ‘No’ then that domain was judged to be 
at high risk of bias.  With regard to question 9 in the modified tool (appropriateness of the time 
interval between the index test and the reference standard), it was agreed that to be considered 
appropriate, the time interval between the index test and reference standard should be no longer 
than one week.  An example of the QUADAS-2 checklist used in this review is shown at the 
end of the protocol (Appendix 1).  
 
We planned to assess the methodological quality of any RCTs reporting effectiveness outcomes 
that met our inclusion criteria using the Cochrane risk of bias tool.17 This tool addresses six 
specific domains relating to methodological quality (sequence generation, allocation 
concealment, blinding, incomplete outcome data, selective outcome reporting and ‘other 
issues’).  However no RCTs reporting effectiveness outcomes were identified that met our 
inclusion criteria.   
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5.5 Methods of data synthesis 
The results of the individual diagnostic studies were tabulated and, where data allowed, 
sensitivity, specificity, predictive values, likelihood ratios and diagnostic odds ratios were 
calculated.   
 
Summary receiver operating characteristic (SROC) curves were produced for each test where 
two or more diagnostic studies reported sufficient data.  In the event of studies reporting 2x2 
data (true positives, false positives, false negatives, true negatives) for a number of different cut 
off values we planned to select the most frequently used cut off value across studies.  However 
this situation did not arise.  Meta-analysis models were fitted using the hierarchical summary 
receiver operating characteristic (HSROC) model18  in SAS version 9.1.  A symmetric SROC 
model was used, which takes proper account of the diseased and non-diseased sample sizes in 
each study, and allows estimation of random effects for the threshold and accuracy effects.  The 
SROC curves from the HSROC models were produced on the corresponding SROC plots.  
Summary sensitivity, specificity, positive and negative likelihood ratios and diagnostic odds 
ratios (DORs) for each model were reported as point estimate and 95% confidence interval (CI).   
 
If numerical difficulties were encountered with the HSROC model and there was no evidence 
of a threshold effect then we planned to pool sensitivity and specificity using the weighted 
average method19 Pooled likelihood ratios and DOR were to be calculated using the 
DerSimonian and Laird random effects method.20 These analyses were to be carried out using 
Metadisc software,21 with heterogeneity assessed using the I2 statistic, which describes the 
percentage of the variability in effect estimates that is due to heterogeneity rather than sampling 
error.22 
 
For relevant clinical outcomes reported based on use of the tests, where appropriate, we planned 
to use meta-analysis to estimate a summary measure of effect.  Dichotomous outcome data were 
to be combined using the Mantel-Haenszel relative risk (RR) method and continuous outcomes 
were to be combined using the inverse-variance weighted mean difference (WMD) method.  
For the estimates of RR and WMD 95% confidence intervals (CIs) and p-values were to be 
calculated.  Chi-squared tests and I-squared statistics were to be used to explore statistical 
heterogeneity across studies, with possible reasons for heterogeneity being investigated using 
sensitivity analysis.  Heterogeneity is to be expected in diagnostic test accuracy studies, and 
random effects models were to be used to describe the variability across studies.  However no 
studies reporting clinical outcomes based on use of the tests were identified that met our 
inclusion criteria.   
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Where a quantitative synthesis was considered inappropriate (e.g. studies reporting 
acceptability of tests), or not feasible, a narrative synthesis of results was provided. 
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6  ASSESSMENT OF DIAGNOSTIC AND MONITORING STUDIES 
 
This chapter is structured as follows.  Section 6.1 describes the quantity of research available 
for both diagnostic and monitoring studies together, sections 6.2 and 6.3 report the results for 
the diagnostic and monitoring studies respectively, while section 6.4 provides a summary of the 
chapter.  Within each of the sections on diagnostic and monitoring studies there are subsections 
on the characteristics of the included studies, their risk of bias, diagnostic accuracy results 
(single tests; studies directly comparing tests; studies reporting combinations of tests) and other 
outcomes of interest. 
 
6.1 Quantity of research available 
6.1.1 Number and type of studies included 
Appendix 3 lists the 29 studies, published in 31 reports, that met the inclusion criteria for the 
review of diagnostic and monitoring studies.15,23-52 There were two reports of the studies by 
Cachulo et al.24,46 and Torron et al.49,50 Figure 3 shows a flow diagram outlining the screening 
process, with reasons for exclusion of full-text papers.   
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Figure 3 Flow diagram outlining the screening process 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Twenty-seven studies (29 reports in total as two studies each had two associated reports) were 
full-text papers and two studies were only available as abstracts.33,41 Four studies (five reports) 
were non-English language, with one each in Japanese,28 Chinese,25 German36 and Spanish.49,50  
Of the 29 included studies, 22 (24 reports)23-26,28,30,32-41,43-50 were diagnostic studies involving 
people with suspected nAMD and eight15,27,29,31,42,44,51,52 were monitoring studies involving 
people previously diagnosed with nAMD and under follow-up surveillance.  One study, by 
Salinas-Alaman et al.,44 reported results for both diagnosis and monitoring. 
  
Number of records screened  
4682 
 
 
 
 
 
Excluded: 4503 
Number of full text articles assessed for eligibility 
179  
148 reports excluded: 
Invalid study design:                      32 
No nAMD participants:                   6 
Invalid reference standard:            14 
Required outcomes not reported:  65 
Retained for background:              31 
Number of studies included in qualitative synthesis 
31 reports of 29 studies 
Number of studies included in meta-analyses 
8 reports of 8 studies 
Number of records after duplicates removed 
4682 
 
 
 
 
 
 
Number of records identified 
through database searching 
6774 
  
 
 
 
 
 
 
 
Number of additional records 
identified through other sources 
323  
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6.1.2 Number and type of studies excluded 
A list of full-text papers that were excluded along with the reasons for their exclusion is given 
in Appendix 4.  These reports were excluded because they failed to meet one or more of the 
inclusion criteria in terms of the type of study, participants, test, reference standard or outcomes 
reported. 
 
6.2 Assessment of diagnostic studies 
6.2.1 Characteristics of the included diagnostic studies 
Appendix 5 (Table a) provides details of the individual study characteristics for the 22 
diagnostic studies.  Table 4 provides summary information for these studies.  Of the 22 studies, 
nine were prospective23,24,26,32,38-40,44,45 and seven were retrospective.33-35,37,38,48,50  Seven studies 
did not provide this information.25,28,30,36,41,43,47  (The study by Loewenstein and colleagues38 
reported both a prospective and retrospective component.)  In ten studies participant recruitment 
was consecutive.32,33,37,38,41,43-45,47,48  The studies enrolled more than 2,000 participants.  Twenty-
one studies reported eye as the unit of analysis (1754 eyes), while one41 reported patient as the 
unit of analysis (155 patients).   
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Table 4 Summary of the characteristics of the included diagnostic studies 
Characteristic Number Number of 
studies 
Participants enrolled 2124 22 
  Analysed (eyes) 1754 21 
  Analysed (patients) 155 1 
Age: Median (range) of 
means/medians 
76 (51.4 to 84.6) 15 
Gender: male: female n (%) 742 (45.4%): 891 (54.6%) 14 
Median (range) prevalence of nAMD 80.0% (17.2% to 100%) 13 
Tests reported (number enrolled)   
  OCT 1335  13 
    TD-OCT 1316 12 
    SD-OCT 19 1 
  ICGA 458 8 
  PHP 491 3 
  Colour fundus photography 185 1 
  Amsler Grid 98 1 
  FAF 62 1 
Notes: 
1. FAF, fundus autofluorescence; ICGA, indocyanine green angiography; OCT, optical 
coherence tomography; PHP, preferential hyperacuity perimetry; TD-OCT, time domain 
optical coherence tomography; SD, spectral domain optical coherence tomography. 
2. The study by Kozak et al.35 enrolled 654 participants (1,272 eyes analysed) with a diagnosis 
of suspected or confirmed macular oedema of various aetiologies but did not specify how 
many were nAMD.  Of these, 541 eyes with a diagnosis of suspected or confirmed nAMD 
were included in the analysis and this number has been included in the above table as an 
approximation of the number of nAMD participants enrolled by this study.  
3. The median (range) prevalence of nAMD was derived from 13 studies where this information 
was available at participant level.  Studies reporting eye as the unit of analysis where it was 
not possible to ascertain the number of participants with nAMD or studies reporting results 
only at phenotype level were not included in these calculations.  
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Seven studies were undertaken in the USA,26,33,35,37,39,40,43 three in the UK,32,45,48 two each in 
Japan,28,30  Austria36,47 and Spain44,50 and one each in Portugal,24 Italy (involving eight centres),41 
South Korea34 and China.25 The remaining two studies were international, taking place in (a) 
seven centres in the USA, Germany, Israel, Austria and Portugal23 and (b) 15 centres in Israel 
and the USA.38 Of the three UK-based studies, two took place at the Royal Victoria Infirmary, 
Newcastle upon Tyne45,48 while the third took place at King’s College Hospital, London.32 One 
of the UK-based studies, by Talks et al., involved a nurse-led, fast track screening clinic.48 
 
The largest study was by Kozak et al.,35 which reported time-domain optical coherence 
tomography  (TD-OCT), was set in the USA and analysed 541 eyes, while the smallest was by 
Sulzbacher et al.,47 reporting indocyanine green angiography (ICGA) and including only 13 
eyes.     
 
Across 15 studies reporting the mean or median age of the participants,23-26,28,30,34-36,38,39,44,45,48,50  
the median (range) of these values was 76 years (51.4 to 84.6 years).  Fourteen studies involving 
1633 participants provided information on gender, in which 742 (45.4%) participants were men 
and 891 (54.6%) were women.23,24,26,28,30,34,35,38-40,44,45,48,50  The median (range) prevalence of 
nAMD across 13 studies where this information was available at participant level was 80.0% 
(17.2% to 100%).23,24,26,32,34,37-40,43,44,48,50 
 
In three studies, by Cachulo et al.,24 Do et al.,26 and Padnick-Silver et al.39 the inclusion criteria 
specified that participants were required to have previously diagnosed nAMD in the non-study 
eye.  
 
Thirteen studies reported OCT (twelve TD-OCT;24,26,32-37,39,44,45,48 one SD-OCT).40 The study by 
Kozak et al., reporting TD-OCT, included a subset of patients who underwent additional 
examination with SD-OCT.35  
 
Of the other tests reported, three studies reported preferential hyperacuity perimetry 
(PHP),23,26,38 one reported colour fundus photography,23 one Amsler grid,26 one fundus 
autofluorescence imaging (FAF)24 and eight ICGA.24,25,28,30,41,43,47,50  Of the studies reporting 
more than one test, Cachulo et al.24 reported TD-OCT, ICGA and FAF, Do et al.26 TD-OCT, 
Amsler Grid and PHP, and Alster et al.23 reported PHP and colour fundus photography.  Two 
studies reported combinations of tests; Alster et al.23 reported colour fundus photography plus 
visual acuity, while Sandhu et al.45 reported TD-OCT plus colour fundus photography.      
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The 13 studies reporting OCT analysed 1262 eyes; in eight studies one eye per patient was 
analysed (n = 479 eyes) (all TD-OCT).24,26,32-34,37,39,48  Eight studies reported detection of nAMD 
phenotypes (predominantly classic, minimally classic, occult CNV).24,32,33,36,37,40,45,48  Four of 
these studies also reported detection of RAP.24,33,36,37  
 
Of the eight studies reporting ICGA, seven used the eye as the unit of analysis (number of eyes 
analysed = 291).24,25,28,30,43,47,50 In three of these studies one eye per patient was analysed (n = 
109 eyes).24,30,43  Three studies only reported detection of nAMD phenotypes: idiopathic 
polypoidal choroidal vasculopathy (IPCV);30 occult CNV;25 and type 2 CNV without an occult 
component.47  The study by Parravano et al.,41 with patient as the unit of analysis (n=155 
patients), also only reported detection of an nAMD phenotype – retinal angiomatous 
proliferation (RAP).   
 
The three studies reporting PHP analysed one eye per patient (n = 302 eyes),23,26,38 as did the 
studies reporting colour fundus photography (n = 120 eyes),23 Amsler grid (n = 46 eyes)26 and 
FAF (n = 50 eyes).24 
 
6.2.2 Risk of bias of the included diagnostic studies 
All 20 full-text papers were assessed using a modified version of the QUADAS-2 tool 
containing 12 items.  QUADAS-2 consists of four key domains covering (1) patient selection, 
(2) index test, (3) reference standard, and (4) flow of patients through the study and timing of 
the index test(s) and reference standard.  Each domain is assessed in terms of the risk of bias 
and the first three domains are also assessed for concerns regarding their applicability in terms 
of whether they match the question being addressed by the review.  Figure 4 presents a summary 
of the results for the QUADAS-2 risk of bias and applicability domains across the full-text 
diagnostic papers.  Appendix 6 (Table a) presents the results of the risk of bias and applicability 
concerns for the individual studies. 
 
No study was judged to have a low risk of bias across all domains; in three studies the risk of 
bias was judged to be unclear across all domains.28,34,47 The domains in which the greatest 
number of studies were judged to be at high risk of bias were the patient selection domain (n = 
11, 55%) and flow and timing domain (n = 8, 40%). 
 
In the patient selection domain only one study35 was judged to be at low risk of bias, while the 
majority were considered to have either a high (n = 11, 55%)23,26,30,36-40,43,44,48 or unclear (n = 8, 
40%)24,25,28,32,34,45,47,50  risk of bias.  Reasons for studies being judged to be at high risk of bias 
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included not enrolling a consecutive sample of participants,26,36 not avoiding inappropriate 
exclusions23,30,37-40,43 and not avoiding pre-selection of participants.23,26,30,38,39,43,44,48 
 
In the index/comparator test domain eight studies (40%) were judged to be at low risk of 
bias,23,26,32,36,37,40,45,48 two (10%) were considered high risk of bias43,50  while in half (n = 10, 
50%) the risk of bias was considered to be unclear.24,25,28,30,34,35,38,39,44,47 The reasons for the two 
studies being judged to be at high risk of bias was that the test (ICGA in both cases) was 
interpreted with knowledge of the results of the reference standard.   
 
In the reference standard domain five studies (25%) were judged to be at low risk of 
bias,23,26,32,36,45  three (15%) were considered high risk of bias43,48,50 while in the majority (n = 
12, 60%) the risk of bias was considered to be unclear.24,25,28,30,34,35,37-40,44,47 The reasons for the 
three studies being judged to be at high risk of bias was that the reference standard test was 
interpreted with knowledge of the results of the index test (TD-OCT)48 or comparator test 
(ICGA).43,50 
 
In the flow and timing domain six studies (30%) were judged to be at low risk of 
bias,25,30,36,37,40,43 while the majority were considered to have either a high (n = 8, 
40%)23,24,26,35,38,39,45,48 or unclear (n = 6, 30%)28,32,34,44,47,50 risk of bias.  Reasons for studies being 
judged to be at high risk of bias included an interval of more than one week between the 
index/comparator test and reference standard,23,38 not all patients receiving the reference 
standard test38 or not all patients being included in the analysis.23,24,26,35,38,39,45,48  
 
All 20 diagnostic studies were judged to have low concerns for applicability regarding the 
patient selection, index/comparator test, and reference standard domains, in that the participants 
and setting, index/comparator test and target condition as defined by the reference standard 
were considered to match the question being addressed by the review.   
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Figure 4 Summary of risk of bias and applicability domains (diagnostic studies) 
 
 
 
6.2.3 Results – diagnostic accuracy  
Individual study results are presented in Appendix 7 (Table a). 
 
Single tests 
• OCT 
Thirteen studies, analysing 1262 eyes, reported the diagnostic accuracy of OCT in detecting 
nAMD (twelve TD-OCT;24,26,32-37,39,44,45,48 one SD-OCT).40    In eight studies one eye per patient 
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was analysed (n = 479 eyes) (all TD-OCT).24,26,32-34,37,39,48   Eight studies reported detection of 
nAMD phenotypes.24,32,33,36,37,40,45,48 
  
The median (range) prevalence of nAMD across nine OCT studies where this information was 
available at participant level was 100% (17.2% to 100%).24,26,32,34,37,39,40,44,48  
 
Figure 5 shows a forest plot of the sensitivity and specificity of the individual studies (excluding 
three where information was only available at phenotype level).33,36,37  Across these ten studies, 
the median (range) sensitivity and specificity values reported were 94.5% (36% to 100%) and 
73.5% (66% to 94%) respectively.  Only four studies (all TD-OCT) reported specificity.  For 
TD-OCT, across the studies, the median (range) sensitivity and specificity values reported was 
92.3% (36% to 100%) and 73.4% (66% to 94%), while the only SD-OCT study reported 
sensitivity of 100% and did not report specificity. 
 
 
Figure 5 Individual study results for all OCT diagnostic studies reporting 
sensitivity and/or specificity 
 
 
 
The studies shown in Figure 5 demonstrate heterogeneity across the sensitivities reported.  The 
lowest sensitivity reported was by Hughes et al. (36%) and Do et al. (40%).26,32  In the study by 
Hughes et al.,32 set in the UK, 22 individuals were classed as nAMD by fluorescein angiography 
(FFA), seven with classic and 15 with occult CNV.  TD-OCT detected six of the seven classic 
CNVs but only two of the 15 occult CNVs, hence the low overall sensitivity.  The overall 
prevalence of nAMD in this study was 100%.  Do et al.,26 using TD-OCT in a study set in the 
USA, reported two separate sets of results, one for when the reference standard was fluorescein 
angiogram graded as positive by the reading centre irrespective of treatment decision 
(sensitivity 40.0%, specificity 70.8%), and one for when the reference standard was fluorescein 
angiogram graded as positive by the reading centre and the clinician recommended treatment 
(sensitivity 69.2%, specificity 66.2%) (see also Appendix 7, Table a).  The former reference 
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standard was considered closer to the one used in this review and therefore it was these results 
that were taken to represent the study.  Of 87 eyes analysed by Do et al.,26 15 were classed as 
nAMD by FFA, with 13 of the 15 CNVs described as occult with no classic.  The overall 
prevalence of nAMD in this study was low at 17.2%.  In theory prevalence should not affect 
sensitivity, but if the low prevalence contained more people with phenotypes that were difficult 
to diagnose compared with studies with a higher prevalence of disease, then this might reduce 
the sensitivity of the test.   
 
By far the largest study was that by Kozak et al.35 This retrospective study was set in the USA 
and involved the analysis of 1,272 eyes of 654 participants with a diagnosis of confirmed or 
suspected macular oedema of various aetiologies; in 541 eyes (number of participants not 
reported) the aetiology was nAMD.  In this study, no data were presented for true negatives for 
the nAMD group and the total number of suspected nAMD classed by FFA as without disease 
was not reported; as such it was not possible to calculate specificity.  The study stated that TD-
OCT had detected nAMD in 13 eyes that had not been detected by FFA.  As the reference 
standard of FFA, for the purposes of this review, was considered to have perfect sensitivity and 
specificity, these 13 cases were classed as TD-OCT false positive (although not shown in Figure 
5 in order to prevent a spurious specificity value of 0% being calculated based on 13 false 
positives and zero true negatives).      
 
Pigment epithelial detachments (PEDs) can be classified as serous (non-specific) or 
vascularised.  The latter are characteristic of nAMD.  A serous PED can occur as a result of 
retinal conditions other than nAMD, such as central serous chorioretinopathy, angioid streaks 
or others.  The study by Sandhu et al.,45 considered a serous PED to constitute presence of 
nAMD and on this basis reported sensitivity of 96.4% and specificity of 66.0%.  However as a 
serous PED did not fall within our definition of nAMD for diagnostic studies, cases with serous 
PED were classed as non-nAMD and the data from the study were recalculated accordingly, 
resulting in alternative values for sensitivity of 77.8% and specificity of 76.0% and it was these 
values that were taken to represent this study. 
 
Four studies, all TD-OCT,26,39,45,48 reported both sensitivity and specificity, providing sufficient 
data for inclusion in a meta-analysis.  One of the studies, by Talks et al.48 was a retrospective 
audit on new patients referred with nAMD to a nurse-led, fast track screening clinic.  Figure 6 
shows a forest plot of the sensitivity and specificity of the individual studies and SROC curves 
for the four OCT studies.  Table 5 shows the pooled estimates for the OCT studies.  For all 
OCT studies, the pooled sensitivity and specificity (95% CI) was 88% (46% to 98%) and 78% 
(64% to 88%) respectively.   
36 
 
A likelihood ratio (LR) describes how many times a person with disease is more likely to 
receive a positive (LR+) or negative (LR-) test result than a person without disease.  It has been 
suggested that positive likelihood ratios greater than 10 or negative likelihood ratios less than 
0.1 can provide convincing diagnostic evidence, whilst those above 5 and less than 0.2 
demonstrate strong diagnostic evidence.53  The LR+ did not exceed 5 for OCT.  
 
The diagnostic odds ratio (DOR) is a single summary of diagnostic performance and describes 
the ratio of the odds of a positive test result in an individual with disease compared to someone 
without disease.  It has been suggested that a DOR of 25 could provide strong diagnostic 
evidence and that a DOR of 100 could provide convincing diagnostic evidence.19  
 
Figure 6 All OCT diagnostic studies reporting sensitivity and specificity – 
individual study results, pooled estimates and SROC curve 
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Table 5 Pooled estimates for the OCT diagnostic studies 
Test Number of 
studies 
Number of 
eyes analysed 
Pooled estimates (95% CI) 
Sensitivity % Specificity % LR+ LR- DOR 
All OCT 4 406 88 (46 to 98) 78 (64 to 88) 4.08 (2.37 to 7.04) 0.15 (0.02 to 0.98) 26.86 (3.36 to 214.81) 
Notes: 
1. LR+, positive likelihood ratio; LR-, negative likelihood ratio; DOR, diagnostic odds ratio. 
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The risk of bias assessment of the four OCT studies included in the meta-analysis is shown in 
Table 6.  The domains in which most studies were judged to be at high risk of bias were the 
patient selection domain, for reasons such as not enrolling a consecutive sample of 
participants,26  not avoiding inappropriate exclusions39 and not avoiding pre-selection of 
participants,26,39,48 and the flow and timing domain, due to all patients not being included in the 
analysis (all four studies).  
 
Table 6 Risk of bias of the four OCT studies included in the meta-analysis  
 Risk of bias domain 
 Patient 
selection 
Index/ 
comparator test 
Reference 
standard 
Flow and 
timing 
Do 201226 High  Low Low High 
Padnick-Silver 
201139 
High  Unclear Unclear High 
Sandhu 200545 Unclear Low Low High 
Talks 200748 High  Low High High 
 
 
Eight studies24,32,33,36,37,40,45,48 reported the sensitivity of OCT in the detection of nAMD 
phenotypes (see Table 7).  The studies by Cachulo et al.24 and Khondkaryan et al.,33 using TD-
OCT, and Park et al.40 and Talks et al.,48 using TD-OCT, showed equally high sensitivity for 
the detection of each phenotype.  On the other hand, the studies by Hughes et al.32 (TD-OCT), 
Krebs et al.36 (TD-OCT), Liakopoulos et al.37 (TD-OCT) and Sandhu et al.45 (TD-OCT) 
reported higher sensitivity for OCT in the detection of classic CNV compared with occult CNV.      
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Table 7 Sensitivity of OCT in detecting nAMD phenotypes 
Study id Test Unit of 
analysis 
nAMD phenotype  Number 
by FFA 
OCT 
sensitivity 
% 
Cachulo 
201124 
TD-OCT Eye Predominantly classic 2 100 
Minimally classic 4 100 
Occult 6 100 
RAP 5 100 
Hughes 
200532 
TD-OCT Eye Classic 7 85.7 
Occult 15 13.3 
Khondkaryan 
200933 
TD-OCT Eye Classic 
Not 
reported 
80.9 
Occult 81.1 
RAP 57.1 
Krebs 200736 TD-OCT Eye Primarily classic  5 100 
RAP 11 72.7 
Liakopoulos 
200837 
TD-OCT Eye Subretinal fluid:   
     Predominantly 
classic 
11 100 
     Minimally classic 23 91.3 
     Occult with no 
classic 
24 79.2 
     RAP stage III 8 50.0 
Cystoid oedema:   
     Predominantly 
classic 
11 81.8 
     Minimally classic 23 73.9 
     Occult with no 
classic 
24 58.3 
     RAP stage III 8 100 
Park 201040 SD-OCT Eye Classic  7 100 
Minimally classic 3 100 
Occult 11 100 
Sandhu 
200545 
TD-OCT Eye Classic 56 78.6 
Occult 25 20.0 
Classic 56 82.1 
40 
 
TD-OCT 
+ fundus 
photo 
Occult 25 12.0 
Talks 200748 TD-OCT Eye Predominantly classic 22 100 
Minimally classic 6 100 
Occult 45 100 
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• Amsler Grid 
One study, by Do et al.,26  in an analysis of 46 eyes of 46 patients, reported sensitivity of 41.7% 
for the Amsler Grid in detecting nAMD (specificity not reported and insufficient information 
to calculate prevalence of nAMD in this group).  As this study also reported OCT, information 
on risk of bias is presented in that section. 
 
• Fundus autofluorescence imaging (FAF) 
One study, by Cachulo et al.,24 in an analysis of 50 eyes of 50 patients, reported sensitivity of 
93.3% and specificity of 37.1% for FAF in detecting nAMD.  The prevalence of nAMD in this 
group was 30.0%.  As this study also reported ICGA, information on risk of bias is presented 
in that section. 
 
• Colour fundus photography 
One study, by Alster et al.,23 in an analysis of 120 eyes of 120 patients, reported sensitivity of 
70.0% and specificity of 95.0% for colour fundus photography in detecting nAMD.  The 
prevalence of nAMD in this study was 53.3%.  As this study also reported PHP, information 
on risk of bias is presented in that section. 
 
• Preferential hyperacuity perimetry (PHP) 
Three studies analysing 302 eyes of 302 patients reported the diagnostic accuracy of the PHP 
test in detecting nAMD.23,26,38  Figure 7 shows a forest plot with the individual study results for 
sensitivity and specificity.  The studies by Alster et al.23 and Loewenstein et al.38 reported 
similarly high sensitivity and specificity.  However it was not possible to calculate pooled 
estimates using HSROC methodology due to insufficient data.  The study by Do et al.26 reported 
lower sensitivity and did not report specificity.  Across the studies the median (range) of 
sensitivity values reported was 82% (50% to 85%).  The specificity values reported by Alster 
et al.23 and Loewenstein et al.38 were 88% and 85% respectively.   
 
Across the three studies, the median (range) prevalence of nAMD was 50.4% (17.2% to 53.3%). 
 
The risk of bias assessment of the three PHP studies is shown in Table 8.  The domains in which 
most studies were judged to be at high risk of bias were the patient selection domain, for reasons 
such as inappropriate exclusions23,38 and pre-selection of participants,23,26,38 and the flow and 
timing domain, for reasons such as an interval of more than one week between the index test 
and reference standard,23,38 not all patients receiving the reference standard test38 and not all 
patients included in the analysis.23,38  
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 Figure 7 PHP studies – individual study results for sensitivity and specificity 
 
 
 
Table 8 Risk of bias of the PHP studies 
 Risk of bias domain 
 Patient 
selection 
Index/ 
comparator 
test 
Reference 
standard 
Flow and 
timing 
Alster 200523 High Low Low High 
Do 201226 High Low Low High 
Loewenstein 201038 High Unclear Unclear High 
 
Loewenstein et al.38 also reported the ability of PHP in detecting nAMD phenotypes, with 90% 
(18/20) sensitivity for minimally or predominantly classic CNV and 82.6% (38/46) sensitivity 
for occult CNV. 
 
• Indocyanine green angiography (ICGA) 
Eight studies reported the diagnostic accuracy of ICGA in detecting nAMD, of which 
seven24,25,28,30,43,47,50 reported the eye as the unit of analysis and one41 reported the patient as the 
unit of analysis.  Four of these studies only reported detection of nAMD phenotypes: IPCV;30 
occult CNV;25 type 2 CNV without an occult component;47 and RAP.41 
 
The median (range) prevalence of nAMD across three studies where this information was 
available at participant level (and excluding studies reporting results only at phenotype level) 
was 80.0% (32.7% to 100%).24,43,50 
 
Figure 8 shows a forest plot of the sensitivity and specificity of the individual studies (excluding 
the four that only reported detection of phenotypes).  Across the studies the median (range) 
sensitivity reported was high at 93% (85% to 100%).  Only the study by Fujii et al.28 reported 
specificity, which was low at 37%. 
 
43 
 
Figure 8 ICGA sensitivity and specificity – individual study results 
 
 
In the study by Reichel et al.43 all participants were deemed to have nAMD (therefore there 
could be no true negatives and it was not possible to calculate specificity).  Only participants 
who were suspected to have a CNV obscured by haemorrhage were included in this study.  The 
authors stated that ICGA had detected nAMD in four eyes that had not been detected by FFA.  
As the reference standard of FFA, for the purposes of this review, was considered to have 
perfect sensitivity and specificity, these four cases were classed as ICGA false positives 
(although not shown in Figure 8 in order to prevent a spurious specificity value of 0% being 
calculated based on four false positives and zero true negatives ).      
 
The risk of bias assessment of the four ICGA studies is shown in Table 9.  The domains in 
which most studies were judged to be at high risk of bias were the index/comparator test 
domain, due to the ICGA test being interpreted with knowledge of the FFA results, and the 
reference standard domain, due to FFA being interpreted with knowledge of the ICGA 
results.43,50   
 
Table 9 Risk of bias of the four ICGA studies included in the forest plot  
 Risk of bias domain 
 Patient 
selection 
Index/ 
comparator 
test 
Reference 
standard 
Flow and 
timing 
Cachulo 201124 Unclear Unclear Unclear High 
Fujii 199628 Unclear Unclear Unclear Unclear 
Reichel 199543 High High High Low 
Torron 200250 Unclear High High Unclear 
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Four studies25,30,41,47 reported the sensitivity of ICGA in the detection of nAMD phenotypes, 
with each study reporting detection of a different phenotype (see Table 10).  Sensitivity was 
100% for detection of IPCV30 and type 2 CNV without an occult component,47 high (85.1%) 
for detection of RAP41 but lower (62.9%) for detection of occult CNV.25  
 
Table 10 Sensitivity of ICGA in detecting nAMD phenotypes 
Study id Test Unit of 
analysis 
nAMD 
phenotype  
Number 
by FFA 
ICGA 
sensitivity % 
Chen 200325 ICGA Eye Occult CNV 35 62.9 
Gomi 200730 ICGA Eye IPCV 37 100 
Sulzbacher 201147 ICGA Eye Type 2 CNV without 
an occult component 
13 100 
Parravano 201241 ICGA Patient RAP 155 85.1 
 
Studies directly comparing tests 
• PHP versus colour fundus photography versus colour fundus photography plus visual 
acuity 
One study, by Alster et al.,23  analysing one eye per patient, reported PHP (n=122 eyes) 
compared with colour fundus photography (n=120 eyes) and colour fundus photography plus 
visual acuity (n=66 eyes).  Sensitivity was highest for PHP (81.5%), followed by colour fundus 
photography (70.0%) and lowest for colour fundus photography plus visual acuity (53.0%).  
Specificity was similarly high for colour fundus photography (95.0%) and colour fundus 
photography plus visual acuity (94.0%), followed by PHP (87.7%).  
 
• TD-OCT versus ICGA versus fundus autofluorescence imaging (FAF) 
One study, by Cachulo et al.,24 analysing one eye per patient, reported TD-OCT (n=52 eyes) 
compared with ICGA (n=52 eyes) and FAF (n=50 eyes).  Sensitivity was high for all three tests 
(TD-OCT 100%, ICGA 94.1%, FAF 93.3%).  Specificity was only reported for FAF, which 
was low at 37.1%.    
 
• TD-OCT versus Amsler grid versus PHP 
One study, by Do et al.,26 analysing one eye per patient, reported TD-OCT (n=87 eyes) 
compared with Amsler grid (n=46 eyes) and PHP (n=49 eyes).  Based on the set of results for 
CNV defined as positive by FFA irrespective of the treatment decision, the sensitivity for all 
three tests was fairly low (PHP 50.0%, Amsler grid 41.7%, TD-OCT 40.0%).  Specificity was 
only reported for TD-OCT, which was moderate at 70.8%.  As previously stated, the overall 
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prevalence of nAMD in this study was low at 17.2%, the majority of which were occult CNV, 
which might at least partly explain the low sensitivity reported by this study for TD-OCT.   
 
• TD-OCT versus TD-OCT plus stereo colour fundus photography 
One study, by Sandhu et al.,45 reported TD-OCT compared with TD-OCT plus stereo colour 
fundus photography (both n=131 eyes of 118 participants).  As previously stated, serous PED 
did not fall within this review’s definition of nAMD for diagnostic studies and the study data 
were recalculated accordingly.  Based on the recalculated data, sensitivity was similar and 
moderately high for both tests (TD-OCT 77.8%, TD OCT plus stereo colour fundus 
photography 74.1%) while specificity was higher for the combination (92.0%) than for TD-
OCT alone (76.0%).  
 
Studies reporting combinations of tests 
Two studies reported combinations of tests.  Sandhu et al.45 reported TD-OCT combined with 
stereo colour fundus photography.  Alster et al.23 reported colour fundus photography combined 
with visual acuity.  As both studies also reported other tests, the results for the test combinations 
are included in the preceding section on studies directly comparing tests. 
 
Assessment of other outcomes of interest 
• Clinical effectiveness 
No studies were identified that met our inclusion criteria of providing information on clinical 
effectiveness outcomes (e.g. visual acuity) when treatment was based on OCT compared with 
FFA findings.   
 
• Interpretability of the tests 
Six diagnostic studies23,24,26,35,38,45 provided information relating to the interpretability of the 
tests, inasmuch as they reported on the numbers excluded from analysis due to poor image 
quality (see Table 11).  In the TD-OCT study by Do et al.,26 166 individuals were screened and 
98 were enrolled; in six of the 68 individuals screened but not enrolled the reason given was 
poor image quality.  However it was unclear whether the excluded images related to OCT, 
colour fundus photography or FFA.  In the TD-OCT study by Sandhu et al.,45 10/128 individuals 
(7.8%) were excluded from the analysis due to poor image quality.  It was also unclear in this 
study whether the excluded images related to OCT or FFA.      
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Table 11 Studies reporting numbers excluded from analysis due to poor image quality 
Study id Test Excluded from analysis, n (%) Reason  
Alster 200523 
PHP 11/185 (5.9%) individuals/eyes Results judged to be unreliable 
Colour fundus photography 17/185 (9.2%) individuals/eyes Inadequate or poor quality photographs 
Cachulo 201124 FAF 2/52 (3.8%) individuals/eyes Pattern of autofluorescence could not be determined 
Do 201226 TD-OCT, PHP, Amsler 
Grid, colour fundus 
photography 
6/104 (5.8%) individuals/eyes Poor image quality that was insufficient to permit 
successful participation 
Kozak 200835 TD-OCT 35/1307 (2.7%) eyes Poor quality or image decentration 
Loewenstein 
201038 
PHP, colour fundus 
photography 
40/208 (19.2%) individuals/eyes Geographic atrophy, early AMD, pattern dystrophy, no or 
poor-quality photographs 
Sandhu 200545 TD-OCT 10/128 (7.8%) individuals Poor quality of the images 
Notes: 
1.  In the study by Do et al.,26 166 individuals were screened for study participation, of whom 98 were enrolled.  Of the 68 individuals screened but not 
enrolled, the reason for this in 6 was poor image quality. Our calculation of 5.8% excluded from the analysis was based on 6 as a percentage of 104 (98 
+ 6), on the assumption that these 6 individuals would have been enrolled had their images been of sufficient quality.  
2.  In the study by Kozak et al.,35 of 1272 eyes analysed, 541 were nAMD with the remainder macular oedema due to other aetiologies.  35 eyes were 
excluded prior to analysis due to poor quality or image decentration, but it was not reported how many of these specifically related to nAMD.  
3.  In the study by Loewenstein et al.,38 the specific number of individuals excluded solely due to poor quality photographs was not reported.     
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• Acceptability of the tests 
No studies were identified meeting our inclusion criteria that reported the acceptability of the 
tests, either to those providing the tests or to those receiving them. 
 
• Proportion of participants unable to receive the diagnostic test 
Ten studies reported exclusion criteria relating to eye conditions (see Appendix 8, Table 
a).23,24,26,30,38-40,43,47,48  The studies detailed various eye-related exclusion criteria, for example 
evidence of macular disease other than AMD, previous surgical or laser treatment within the 
macular area, presence of any significant media opacity that precluded a clear view of the 
fundus, subretinal or subpigment epithelial haemorrhages that obscured lesions, and recent 
ocular surgery in the study eye. 
 
A few non-ophthalmic exclusion criteria were reported including current or past history of a 
medical condition that would preclude scheduled study visits or completion of the study,24 
allergy to fluorescein dye26 and allergy to iodine-based dye.43 In the PHP study by Loewenstein 
et al.,38 individuals with no experience of using a computer mouse were taught how to use the 
mouse and participation in the study was conditional on passing an in-house computer mouse 
tutorial.  The authors reported that 15 people did not pass the tutorial and were excluded from 
the study.     
 
• Other health professionals compared with ophthalmologists interpreting OCT 
findings 
No studies were identified meeting our inclusion criteria that reported the performance of other 
health professionals compared with ophthalmologists in interpreting OCT findings.  The setting 
for the TD-OCT study by Talks et al.48 was a nurse-led, fast-track screening clinic in the UK 
for new nAMD referrals but did not involve a comparison with other health professionals in 
interpreting OCT findings.  Trained nurses and an ophthalmic photographer, who consulted an 
ophthalmologist when in doubt, conducted the screening visit.  If the visual acuity was ≥ 6/60 
an OCT was performed.  If dry AMD or other retinal pathology was seen, the patient was 
referred for management appropriate to their condition but no further imaging was performed.  
The remaining patients underwent simultaneous FFA and ICGA.  The images were taken, using 
standard protocols, by an ophthalmic photographer.  The ophthalmologist reviewed the images 
the following day.48       
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6.3 Assessment of monitoring studies 
6.3.1 Characteristics of the included monitoring studies 
Appendix 5 (Table b) provides details of the individual study characteristics for the eight 
monitoring studies.  Table 12 provides summary information for the studies.  Of the eight 
monitoring studies, four were prospective,31,42,44,52 three were retrospective15,27,29 while in the 
study by van de Moere et al.51 this information was not reported.  In five studies the participants 
were a consecutive sample.27,29,42,44,52 The eight studies enrolled 463 participants.   
 
Five studies used the eye as the unit of analysis (363 eyes),15,27,29,51,52  while three used test 
examination as the unit of analysis (61 pairs of OCT and FFA examinations,31 176 pairs of OCT 
and FFA examinations44 and 54 pairs of ICGA and FFA examinations).42  
 
Table 12 Summary of the characteristics of the included monitoring studies 
Characteristic Number Number of 
studies 
Participants enrolled 463 8 
  Analysed (eyes) 363 5 
  Analysed (examinations, pairs) 291 3 
Age: Median (range) of 
means/medians 
76.5 (73.9 to 78.1) 7 
Gender: male: female n (%) 177 (46.8%): 201 (53.2%) 6 
Median (range) prevalence of nAMD  57.9% (49.2% to 83.3%) 5 
Tests reported (number enrolled)   
  OCT 442 7 
    TD-OCT 349 6 
    SD-OCT 152 2 
  ICGA 21 1 
Type of treatment received   
  Anti-VEGF 149 2 
  PDT 293 5 
  Laser photocoagulation  21 1 
Notes: 
1. Anti-VEGF, anti-vascular endothelial growth factor; ICGA, indocyanine green 
angiography; nAMD, neovascular age-related macular degeneration; OCT, optical 
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coherence tomography; PDT, photodynamic therapy; TD-OCT, time domain optical 
coherence tomography; SD-OCT, spectral domain optical coherence tomography. 
2. The median (range) prevalence of active nAMD was derived from five studies where this 
information was available at participant level.  Three studies reporting examination as the 
unit of analysis, where it was not possible to ascertain the number of participants with 
nAMD, were not included in these calculations.31,42,44  
3. One study reported both TD-OCT and SD-OCT.15 
 
Two studies were undertaken in the USA15,42 and one each in Italy,29 Germany,31 the 
Netherlands,52  Spain44 and the UK (Royal Victoria Infirmary, Newcastle upon Tyne).51  One 
study was international, taking place in two centres in the USA and Germany.27 
 
The largest study was by van de Moere et al.,51 which reported TD-OCT, was set in the UK and 
analysed 121 eyes, while the smallest was by van Velthoven et al.,52 reporting TD-OCT and 
analysing 30 eyes.    
 
Across seven studies15,27,29,42,44,51,52 reporting the mean or median age of the participants  the 
median (range) of these values was 76.5 years (73.9 to 78.1 years).  Six studies involving 378 
participants provided information on gender,27,29,42,44,51,52  in which 177 (46.8%) participants 
were men and 201 (53.2%) women.  The median (range) prevalence of active nAMD across 
five studies where this information was available at participant level was 57.9% (49.2% to 
83.3%).15,27,29,51,52 
 
Seven studies reported OCT (six TD-OCT;15,27,31,44,51,52 and two SD-OCT).15,29,44,51  (The study 
by Khurana et al.15 reported both TD-OCT and SD-OCT.)  One study, by Regillo et al.,42 
reported ICGA. 
 
Of the seven studies reporting OCT, five used the eye as the unit of analysis (number of eyes 
analysed = 363).15,27,29,51,52  In four of these studies one eye per patient was analysed (n = 304 
eyes).27,29,51,52 Two studies reported examination as the unit of analysis (both TD-OCT). 31,44  
Two studies reported detection of nAMD phenotype activity: classic and occult CNV;29 and 
pigment epithelial detachment (PED) and cystoid macular oedema.51 The studies by Henschel 
et al.31 and van de Moere et al.51 also reported the performance of OCT in detecting intraretinal 
and subretinal fluid.  
 
In two OCT monitoring studies15,29 the participants had received anti-vascular endothelial 
growth factor (anti-VEGF) therapy while in five27,31,44,51,52 the treatment was photodynamic 
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therapy (PDT).  In the study reporting ICGA42 the participants had received laser 
photocoagulation treatment.   
 
6.3.2 Risk of bias of the included monitoring studies 
Figure 9 presents a summary of the results for the QUADAS-2 risk of bias and applicability 
domains across the eight full-text monitoring papers.  Appendix 6 (Table b) presents the results 
of the risk of bias and applicability concerns for the individual studies. 
 
No study was judged to have a low risk of bias across all domains.  More studies in the patient 
selection domain (n = 2, 25%) and the flow and timing domain (n = 2, 25%) were judged to be 
at high risk of bias than in the index/comparator test domain (n = 1, 12.5%) and reference 
standard domain (n = 1, 12.5%). 
 
In the patient selection domain three studies42,51,52 (37.5%) were judged to be at low risk of bias, 
while two29,44 (25%) were considered to have a high risk of bias and in three15,27,31 (37.5%) the 
risk of bias was unclear.  The study by Giani et al.29 was judged to be at high risk of bias due to 
not avoiding inappropriate exclusions and pre-selection of participants, while the study by 
Salinas-Alaman et al.44 was judged to be at high risk of bias due to not avoiding pre-selection 
of participants. 
 
In the index/comparator test domain three studies (37.5%) were judged to be at low risk of 
bias,27,29,31 one (12.5%) was considered high risk of bias42 while in the remaining four (50%) 
the risk of bias was considered to be unclear.15,44,51,52 The reasons for the study by Regillo et 
al.42 being judged to be at high risk of bias was that the test (ICGA) was interpreted with 
knowledge of the results of the reference standard.   
 
In the reference standard domain four studies (50%) were judged to be at low risk of 
bias,27,29,31,52 one (12.5%) was considered high risk of bias42 while in the remaining three 
(37.5%) the risk of bias was considered to be unclear.15,44,51 The Regillo et al.42 study was judged 
to be at high risk of bias as the reference standard test was interpreted with knowledge of the 
results of the comparator test (ICGA).   
 
In the flow and timing domain two studies (25%) were judged to be at low risk of bias,15,42 
two44,51 (25%) were considered to have a high risk of bias while in the remaining four27,29,31,52 
(50%) the risk of bias was considered to be unclear.  The studies by Khurana et al.15 and Regillo 
et al.42 were judged to be at high risk of bias as not all patients were included in the analysis.   
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All eight studies were judged to have low concerns for applicability on the patient selection, 
index/comparator test, and reference standard domains.   
 
Figure 9 Summary of risk of bias and applicability domains (monitoring studies) 
 
 
 
 
 
6.3.3 Results – detection of active nAMD  
Individual study results are presented in Appendix 7 (Table b). 
 
Single tests 
• OCT 
Seven studies reported the accuracy of OCT in detecting active nAMD, of which five reported 
TD-OCT,27,27,31,31,44,51,52,52 one reported SD-OCT29,44,51 and one reported both TD-OCT and SD-
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OCT.15 In five studies the unit of analysis was the eye15,27,29,51,52 while in two the unit of analysis 
was pairs of OCT and FFA examinations.31,44 
 
The median (range) prevalence of active nAMD across five studies where this information was 
available at participant level was 57.9% (49.2% to 83.3%).15,27,29,51,52  
 
Three TD-OCT studies15,27,52 and two SD-OCT studies,15,29 with eye as the unit of analysis, 
reported both sensitivity and specificity, providing sufficient data for inclusion in a meta-
analysis.  Figure 10 shows forest plots of the sensitivity and specificity of the individual studies 
and SROC curves for (a) all of the OCT studies, (b) the three TD-OCT studies and (c) the two 
SD-OCT studies respectively.  Table 13 shows the pooled estimates for these studies.  As the 
study by Khurana et al.15 reported both TD-OCT and SD-OCT for the same 59 eyes, we chose 
to display only the data for SD-OCT from this study in the forest plot of all OCT studies and to 
include only the SD-OCT data from this study in the pooled estimates for all OCT studies, in 
order to avoid double counting and on the basis that the SD-OCT data were the more appropriate 
to include in the pooled estimates for all OCT.  The TD-OCT data from Khurana et al.15 are 
included in the forest plot and SROC curve for TD-OCT in Figure 10 and were included in the 
pooled estimates for TD-OCT shown in Table 13.  For all OCT studies, the pooled sensitivity 
and specificity (95% CI) was 85% (72% to 93%) and 48% (30% to 67%) respectively.  For TD-
OCT, the pooled sensitivity and specificity (95% CI) was 70% (56% to 80%) and 65% (48% to 
79%).  For both TD-OCT and the group of all four OCT studies the likelihood ratio and DOR 
values reported were below the level suggestive of strong diagnostic evidence.   
 
It was not possible to calculate pooled estimates using HSROC methodology for the two SD-
OCT studies due to insufficient data.  These studies reported sensitivities of 94%29  and 90%15 
and specificities of 27%29 and 47%,15 which suggests that SD-OCT has higher sensitivity than 
TD-OCT but lower specificity.  In order to provide a pooled estimate using HSROC 
methodology for SD-OCT monitoring for the economic model a third study, by Salinas-Alaman 
et al.,44 using examination as the unit of analysis (n=176), was included along with those of 
Giani et al29 and Khurana et al.15  This resulted in pooled sensitivity and specificity (95% CI) 
of 94% (90% to 97%) and 44% (29% to 61%) respectively.   
  
53 
 
Figure 10 OCT monitoring studies reporting sensitivity and specificity for detection 
of nAMD activity – individual study results and SROC curves 
Sensitivity and specificity – individual study results – all OCT 
 
Sensitivity and specificity – individual study results – TD-OCT 
 
Sensitivity and specificity – individual study results – SD-OCT 
 
SROC curve – all OCT 
 
SROC curve – TD-OCT 
 
SROC curve – SD-OCT 
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Table 13 Pooled estimates for the OCT monitoring studies 
Test Number of 
studies 
Number of eyes 
analysed 
Pooled estimates (95% CI) 
Sensitivity % Specificity % LR+ LR- DOR 
All OCT 4 242 85 (72 to 93) 48 (30 to 67) 1.64 (1.19 to 
2.26) 
0.31 (0.18 to 
0.54) 
5.33 (2.57 to 11.06) 
TD-OCT 3 149 70 (56 to 80) 65 (48 to 79) 2.00 (1.19 to 
3.36) 
0.47 (0.28 to 
0.78) 
4.27 (1.58 to 11.53) 
SD-OCT 2 152 Not calculable using HSROC methodology 
Notes: 
1.  Khurana et al.15 reported both TD-OCT and SD-OCT for the same 59 eyes of 56 patients analysed; only the SD-OCT data were included in the 
pooled estimates for ‘All OCT’ in order to avoid double counting.   
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The risk of bias assessment of the four OCT studies included in the meta-analysis is shown in 
Table 14.  The only judgement of high risk of bias was for the study by Giani et al.29 for the 
patient selection domain (inappropriate exclusions and pre-selection of participants).   
 
Table 14 Risk of bias of the four OCT studies included in the meta-analysis  
 Risk of bias domain 
 Patient 
selection 
Index/ 
comparator test 
Reference 
standard 
Flow and 
timing 
Eter 200527 Unclear Low Low Unclear 
Giani 201129 High Low Low Unclear 
Khurana 201015 Unclear Unclear Unclear Low 
Van Velthoven 
200652 
Low Unclear Low Unclear 
 
Two studies used examination as the unit of analysis.  Henschel et al.,31 in an analysis of 61 
pairs of TD-OCT and FFA examinations from 14 patients, reported sensitivity of 96.8% and 
specificity of 36.7% for CNV based on detection of intraretinal and/or subretinal fluid.  Salinas-
Alaman et al.,44 in an analysis of 176 pairs of TD-OCT and FFA examinations (number of 
patients not stated), reported sensitivity of 95.7% and specificity of 59.0% based on detection 
of intraretinal or subretinal fluid. 
 
Four studies15,29,31,51 reported the sensitivity of OCT in detecting active nAMD phenotypes or 
active nAMD based on detection of intraretinal/subretinal fluid (see Table 15).  The study by 
Giani et al.29 reported high sensitivity for the detection by SD-OCT of both classic and occult 
CNV activity (90.9% and 100% respectively).  In the studies by Henschel et al.31 (unit of 
analysis: examination) and van de Moere et al.51 (unit of analysis: eye) sensitivity was higher 
for nAMD activity based on detection of intraretinal fluid (90.3% and 82.9% respectively) 
compared with subretinal fluid (71.0% and 47.1% respectively).  Van de Moere et al.51 also 
reported sensitivity of TD-OCT for detection of cystoid macular oedema and pigment epithelial 
detachment, both low at 22.9% and 5.7% respectively.  In the study by Khurana et al15 the 
sensitivity of SD-OCT was higher than that of TD-OCT for nAMD activity based on the 
detection of intraretinal fluid, retinal cystoid abnormalities or subretinal fluid.     
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Table 15 Sensitivity of OCT in detecting nAMD phenotype activity 
 Unit of 
analysis 
Detection of Number by 
FFA 
OCT 
sensitivity % 
Giani 201129  
(SD-OCT) 
Eye Classic CNV 57 90.9 
Occult CNV 36 100 
Khurana 201015 
(TD-OCT) 
Eye Intraretinal 
fluid 
29 
37.9 
Retinal cystoid 
abnormalities 
29 
34.5 
Subretinal fluid 29 48.3 
Khurana 201015 
(SD-OCT)  
Eye Intraretinal 
fluid 
29 
65.5 
Retinal cystoid 
abnormalities 
29 
58.6 
Subretinal fluid 29 69.0 
Van de Moere 
2006 51 
(TD-OCT) 
Eye Intraretinal 
fluid 
Not reported 
82.9 
Subretinal fluid 47.1 
CMO 22.9 
PED 5.7 
Henschel 2009 31 
(TD-OCT) 
Exam Intraretinal 
fluid 
31 90.3 
Subretinal fluid 31 71.0 
Notes: 
1.  CMO, cystoid macular oedema; PED, pigment epithelial detachment. 
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• ICGA 
One study, by Regillo et al.,42 in an analysis of 54 pairs of indocyanine green angiograms 
compared with fluorescein angiograms, obtained from 24 eyes of 21 patients, reported 
sensitivity of 75.9% and specificity of 88.0% in detecting nAMD activity.  It was not possible 
to ascertain (at participant-level) the prevalence of nAMD.  This study was judged as high risk 
of bias for the index/comparator test, and reference standard, domains, due to the ICGA-FFA 
pairs being analysed directly from the computer monitor (ICGA test results interpreted with 
knowledge of the FFA results, and vice versa) and low risk of bias for the other domains.   
 
Studies directly comparing tests 
• TD-OCT versus SD-OCT 
One study, by Khurana et al.,15 compared TD-OCT with SD-OCT in an analysis of 59 eyes of 
56 participants.  Although sensitivity was considerably higher for SD-OCT than for TD-OCT 
(89.7% versus 58.6%), specificity was lower (46.7% versus 63.3%). 
 
6.3.4 Assessment of other outcomes of interest 
• Clinical effectiveness 
No studies were identified that met our inclusion criteria providing information on clinical 
effectiveness outcomes (e.g. visual acuity) when treatment was based on OCT compared with 
FFA findings.   
 
• Interpretability of the tests 
Only one monitoring study, by van de Moere et al.,51  reported information relating to the 
interpretability of the tests.  This TD-OCT study reported that, of 136 participants enrolled, 17 
(12.5%) were excluded from the analysis due to the poor quality of the OCT or FFA images.  
The study did not specify how many of these poor quality images were OCT images and how 
many were FFA. 
 
• Acceptability of the tests 
No studies were identified that met our inclusion criteria reporting the acceptability of the tests, 
either to those providing the tests or to those receiving them. 
 
• Proportion of participants unable to receive the monitoring test 
Two studies reported exclusion criteria relating to eye conditions (see Appendix 8, Table b).15,29  
The study by Giani et al.29 contained the following exclusion criteria: any previous laser 
treatment, photodynamic therapy, or vitreoretinal surgery on the study eye; significant macular 
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haemorrhage that obscured the lesion; and a spherical refractive error > 6 diopters.  The study 
by Khurana et al.15 excluded patients with CNV resulting from causes other than AMD. 
 
• Other health professionals compared with ophthalmologists interpreting OCT 
findings 
No studies were identified meeting our inclusion criteria that reported the performance of other 
health professionals compared with ophthalmologists in interpreting OCT findings. 
 
6.4 Summary of the reviews of diagnostic and monitoring studies 
6.4.1 Diagnostic studies 
Twenty-two diagnostic studies were included (20 full-text papers, two abstracts).  The full-text 
papers were assessed for risk of bias using the QUADAS-2 checklist.  The domains in which 
the greatest number were judged to be at high risk of bias were the patient selection domain 
(55%, 11/20), for reasons such as inappropriate exclusions and pre-selection of participants, 
and flow and timing domain (40%, 8/20), for reasons such as the length of time between the 
index test and the reference standard, and not all participants being included in the analysis.  
The risk of bias in the index/comparator test and reference standard domains was judged to be 
unclear in 50% (10/20) and 60% (12/20) of studies respectively.  All of the studies were judged 
to have low concerns in terms of their applicability to the question being addressed by the 
review. 
 
A descriptive summary of the results of the diagnostic studies with eye as the unit of analysis 
is shown in Table 16 (excluding studies that only reported detection at phenotype level).  Across 
the studies the median (range) sensitivity was high for OCT (94.5%, range 36.0% to 100%; ten 
studies.  Sensitivity was also high for ICGA (93.2%, range 84.6% to 100%; four studies) and 
FAF (93.3%; one study), followed by PHP (81.5%, range 50.0% to 84.8%; three studies), colour 
fundus photography 70.0%; one study) and lowest for Amsler Grid (41.7%; one study).  The 
median (range) specificity for OCT was moderate (73.5%, range 65.8% to 93.5%; four studies).  
Specificity was highest for colour fundus photography (95%; one study), followed by PHP 
(84.6% and 87.7%; two studies), and was low for FAF (37.1%; one study) and ICGA (36.8%; 
one study).   
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Two studies reported the diagnostic accuracy of combinations of tests.  Sensitivity and 
specificity for TD-OCT plus colour fundus photography was 74.1% and 92.0% respectively, 
while for colour fundus photography plus visual acuity sensitivity was lower at 53.0% but with 
similarly high specificity at 94.0%. 
 
Table 16 Descriptive summary of sensitivity and specificity of diagnostic studies  
Test No. of 
studies 
No. of eyes 
analysed 
Median (range) 
sensitivity % 
Median (range) 
specificity % 
All OCT  10 1117 94.5 (36 to 100) 73.4 (66 to 94) 
TD-OCT 9 1096 92.3 (36 to 100) 73.4 (66 to 94) 
SD-OCT 1 21 100.0 Not reported 
Amsler Grid 1 46 41.7 Not reported 
PHP 3 302 81.5 (50.0 to 84.8) (84.6, 87.7) 
Colour fundus 
photography 
1 120 70.0 95.0 
FAF 1 50 93.3 37.1 
ICGA 4 167 93.2 (84.6 to 100) 36.8 
TD-OCT + colour 
fundus photography 
1 131 74.1 92.0 
Colour fundus 
photography + visual 
acuity 
1 66 53.0 94.0 
 
Four OCT diagnostic studies (all TD-OCT) provided sufficient data for inclusion in a meta-
analysis (see Table 17).  The pooled sensitivity and specificity (95% CI) for all four OCT 
studies was 88% (46% to 98%) and 78% (64% to 88%) respectively.   
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Table 17 Pooled estimates for the OCT diagnostic studies 
Test No. of studies 
No. of eyes 
analysed 
Pooled estimates (95% CI) 
Sensitivity % Specificity % 
All OCT  4 406 88 (46 to 98) 78 (64 to 88) 
 
Eight diagnostic studies reported the sensitivity of OCT in the detection of specific nAMD 
phenotypes.  Four showed equally high sensitivity for the detection of each phenotype.  In four 
others sensitivity for OCT was higher in the detection of classic CNV (range 79% to 100%) 
compared with occult CNV (range 13% to 79%).  Four studies reported the sensitivity of ICGA 
in the detection of specific nAMD phenotypes.  Each study reported detection of a different 
phenotype, with 100% sensitivity for detection of IPCV and type 2 CNV without an occult 
component, high sensitivity (85.1%) for detection of RAP but lower sensitivity (62.9%) for 
detection of occult CNV.       
 
6.4.2 Monitoring studies 
Eight monitoring studies were included (all full-text papers).  Seven reported OCT, six with 
eye as the unit of analysis (one of which only reported detection at phenotype level) and two 
with test examination as the unit of analysis.  One study reported ICGA.  As with the diagnostic 
studies, the QUADAS-2 domains in which the greatest number of monitoring studies were 
judged to be at high risk of bias were the patient selection domain (25%, 2/8), for reasons such 
as inappropriate exclusions and pre-selection of participants, and flow and timing domain (25%, 
2/8), for reasons such as the length of time between the index test and the reference standard, 
and not all participants being included in the analysis.  The risk of bias in the index/comparator 
test and reference standard domains was judged to be unclear in 50% (4/8) and 37.5% (3/8) of 
studies respectively.  All of the monitoring studies were judged to have low concerns in terms 
of their applicability to the question being addressed by the review.     
 
Four OCT monitoring studies, with eye as the unit of analysis, provided sufficient data for 
inclusion in a meta-analysis (see Table 18).  The pooled sensitivity and specificity (95% CI) for 
all four OCT studies was 85% (72% to 93%) and 48% (30% to 67%) respectively.  For TD-
OCT, the pooled sensitivity and specificity was 70% (56% to 80%) and 65% (48% to 79%).  It 
was not possible to calculate pooled estimates using HSROC methodology for the two SD-OCT 
studies due to insufficient data.  These two studies reported sensitivities of 94% and 90% and 
specificities of 27% and 47%, which, similar to the diagnostic studies, suggests that SD-OCT 
has higher sensitivity than TD-OCT but lower specificity.   
Table 18 Pooled estimates for the OCT monitoring studies 
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Test No. of studies 
No. of eyes 
analysed 
Pooled estimates (95% CI) 
Sensitivity % Specificity % 
All OCT  4 242 85 (72 to 93) 48 (30 to 67) 
TD-OCT 3 149 70 (56 to 80) 65 (48 to 79) 
SD-OCT 2 152 Not calculable using HSROC 
methods 
Notes: 
1. Three studies reported TD-OCT and two studies reported SD-OCT, with one study reporting 
both TD-OCT and SD-OCT.  Only the data for SD-OCT from this study were included in the 
pooled estimates for all OCT to avoid double counting.  
 
Two OCT monitoring studies used test examination as the unit of analysis.  The first, in an 
analysis of 61 pairs of TD-OCT and FFA examinations from 14 patients, reported high 
sensitivity of 96.8% but low specificity of 36.7%, for CNV based on detection of intraretinal 
and/or subretinal fluid.  The second, in an analysis of 176 pairs of SD-OCT and FFA 
examinations (number of patients not stated), reported similarly high sensitivity of 95.7% and 
moderate specificity of 59.0% based on detection of intraretinal or subretinal fluid. 
 
One ICGA monitoring study used test examination as the unit of analysis.  In an analysis of 54 
pairs of indocyanine green angiograms compared with fluorescein angiograms, obtained from 
24 eyes of 21 patients, sensitivity of 75.9% and specificity of 88.0% was reported for detecting 
nAMD activity.  
  
Three studies reported OCT sensitivity in detecting activity of specific nAMD phenotypes or 
nAMD activity based on detection of intraretinal/subretinal fluid.  SD-OCT sensitivity was high 
for the detection of both classic and occult CNV activity (90.9% and 100% respectively) (one 
study).29 Sensitivity of TD-OCT for detection of cystoid macular oedema and pigment epithelial 
detachment was low (22.9% and 5.7% respectively) (one study).51  In two studies sensitivity 
was higher for detection of nAMD activity based on intraretinal fluid (90.3% and 82.9% 
respectively) compared with subretinal fluid (71.0% and 47.1% respectively).31,51  
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7  ASSESSMENT OF COST-EFFECTIVENESS  
 
The health economic component of this study explored the evidence in cost-effectiveness of 
using OCT for diagnosis and/or monitoring of individuals with neovascular age-related macular 
degeneration (nAMD). For this, a two-step approach was used, with (1) a systematic review of 
economic evaluations to retrieve any readily available evidence on cost-effectiveness, followed 
by (2) a de-novo decision analytic model to synthesise the available evidence on effectiveness, 
health care resources used and costs. Section 7.1 reports the systematic review of cost-
effectiveness studies and section 7.2 focuses on the economic model exercise. 
 
7.1 Systematic review of economic evaluations 
The aim of this review was to retrieve evidence, from the perspective of the UK NHS, on the 
cost-effectiveness of the use of OCT in the diagnosis and/or monitoring of individuals with 
nAMD. This was attempted by systematically identifying and quality assessing all economic 
evaluations comparing strategies that included OCT for diagnosing and/or monitoring of 
individuals with nAMD.  
 
7.1.1 Inclusion and exclusion criteria 
Inclusion criteria required the studies to be full economic evaluations,54 that is, to consider cost 
and effects for more than one strategy, in order to be included in the review. No restrictions 
were imposed in the way cost and/or effects were calculated. In addition, at least one of the 
compared strategies for diagnosis or monitoring of nAMD had to include OCT.  Finally, the 
studies were required to be performed in adults with nAMD.  
 
7.1.2 Search strategy 
Studies that reported both costs and outcomes in diagnosing AMD using OCT were sought 
from a systematic review of the literature.  No language restrictions or limitations to searches 
were imposed. 
 
Databases searched were Medline (1996 – November Week 2 2012), Embase (1980 - Week 45 
2012), Medline In-Process (14th November 2012), NHS EED (October 2012), HTA Database 
(October 2012), Health Management Information Consortium (1979 – September 2012), 
Research Papers in Economics (RePeC) (September 2012) and ARVO Meeting Abstracts from 
April, 2009. In addition, reference lists of all included studies were scanned to identify 
additional potentially relevant studies. Full details of the search strategies used are documented 
in Appendix 2. 
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7.1.3 Results 
From the database searches 473 hits (titles & abstracts) were retrieved; from these 44 studies 
were selected for full-text assessment. No studies fulfilled the inclusion criteria as none of these 
were diagnosis or monitoring interventions for individuals with nAMD.  
 
7.2 Economic evaluation modelling exercise 
The aim of the economic model was to determine the relative efficiency of strategies for 
diagnosis and monitoring of individuals with nAMD.  Care pathways were developed within 
the Project Management Group and the Project Advisory Group meetings. The groups initially 
considered all possible tests (see Background chapter) and several combinations of these. After 
subsequent discussions a number of these options were excluded. For instance, FFA only was 
originally considered as one of the (monthly) monitoring pathways. However, this option was 
deemed unfeasible (i.e. FFA is an invasive test) and consequently dropped.  Three different 
strategies were finally selected for the nAMD diagnosis and monitoring stages, respectively, 
giving a total of 9 diagnosis-monitoring combinations:  
 
Diagnosis strategies 
a) (Stereoscopic) fundus fluorescein angiography (FFA) interpreted by an 
ophthalmologist. If positive, treat and monitor; if negative, discharge. 
b) Optical coherence tomography (OCT) alone interpreted by an ophthalmologist. If 
positive, treat and monitor; if negative, discharge.  
c) Visual acuity (VA) and OCT and slit-lamp biomicroscopy (SLB) in all. If positive or 
unclear, then arrange for stereoscopic FFA. If negative, discharge. This is the strategy 
for diagnosis that best reflects standard practice. 
 
Monitoring strategies 
a) OCT alone (interpreted by an ophthalmologist). If positive, treat. If negative or unclear 
review in one month’s time. 
b) VA and SLB and OCT interpreted together by an ophthalmologist. If positive, treat; if 
negative, review in one month’s time. If unclear, then the ophthalmologist will arrange for 
a stereoscopic FFA. This is the monitoring strategy that best reflects standard practice. 
c) VA and OCT interpreted by a technician or nurse. If negative, review in one month’s time. 
If positive or unclear, refer for ophthalmologist assessment (e.g. SLB and ophthalmologist’s 
own interpretation of VA and OCT test results). The ophthalmologist will make a decision:  
if positive, treat; if negative, review in one month’s time; if unclear, arrange for stereoscopic 
FFA.  
  
64 
 
Monitoring strategy d) has been included in the monitoring stage in order to explore the cost-
effectiveness of the option, for example, of virtual clinics involving other healthcare 
professionals (e.g. nurses, technicians, etc).  Virtual clinics are increasingly used in NHS 
services for monitoring patients with nAMD.55 
 
Table 19 shows the final nine combined strategies incorporated into the decision model. All 
strategies considered monitoring on a monthly basis with a decision to treat when the disease 
was deemed active (i.e. retinal fluid on OCT). All monitoring strategies that relied on 
stereoscopic FFA as a final assessment step (e.g. monitoring strategies b and c) would treat if 
FFA positive, or review in a month’s time if FFA negative. Treatment consisted of one injection 
only (i.e. 0.5mg ranibizumab) with review in one month’s time.   
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Table 19 Strategies for the economic evaluation model 
Strategy Strategy Label Diagnostic  pathway Monitoring pathway Treatment 
1 FFA & OCT FFA interpreted by an ophthalmologist. If 
positive, treat and monitor; if negative, 
discharge 
OCT alone (interpreted by an ophthalmologist). If 
positive, treat. If negative or unclear review in 1 
month 
1 monthly injection if 
disease deemed 
active 
2 FFA & 
Ophthalmologist 
FFA interpreted by an ophthalmologist. If 
positive, treat and monitor; if negative, 
discharge 
VA and SLB and OCT interpreted together by an 
ophthalmologist. If positive, treat; if negative, review 
in a month’s time. If unclear, then the 
ophthalmologist will arrange for stereoscopic FFA 
1 monthly injection if 
disease deemed 
active 
3 FFA & Nurse FFA interpreted by an ophthalmologist. If 
positive, treat and monitor; if negative, 
discharge 
VA and OCT interpreted by a technician or nurse. If 
negative, review in a month. If positive or unclear, 
referral for an ophthalmologist assessment (e.g. SLB 
and own interpretation of VA and OCT test results). 
If assessment positive, treat; if negative, review in a 
month time; if unclear, arrange for stereoscopic FFA 
1 monthly injection if 
disease deemed 
active 
4 OCT & OCT OCT alone interpreted by an 
ophthalmologist. If positive, treat and 
monitor; if negative, discharge 
OCT alone (interpreted by an ophthalmologists). If 
positive, treat. If negative or unclear review in 1 
month 
1 monthly injection if 
disease deemed 
active 
5 OCT & 
Ophthalmologist 
OCT alone interpreted by an 
ophthalmologist. If positive, treat and 
monitor; if negative, discharge 
VA and SLB and OCT interpreted together by an 
ophthalmologist. If positive, treat; if negative, review 
in a month’s time. If unclear, then the 
ophthalmologist will arrange for stereoscopic FFA 
1 monthly injection if 
disease deemed 
active 
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Strategy Strategy Label Diagnostic  pathway Monitoring pathway Treatment 
6 OCT & Nurse OCT alone interpreted by an 
ophthalmologist. If positive, treat and 
monitor; if negative, discharge 
VA and OCT interpreted by a technician or nurse. If 
negative, review in a month. If positive or unclear, 
referral for an ophthalmologist assessment (e.g. SLB 
and own interpretation of VA and OCT test results). 
If assessment positive, treat; if negative, review in a 
month time; if unclear, arrange for stereoscopic FFA 
1 monthly injection if 
disease deemed 
active 
7 Ophthalmologist 
& OCT 
VA, OCT and SLB in all interpreted by an 
ophthalmologist. If negative, discharge. If 
positive or unclear, then arrange for 
stereoscopic FFA. If FFA positive, treat and 
monitor; if negative, discharge  
OCT alone (interpreted by an ophthalmologist). If 
positive, treat. If negative or unclear review in 1 
month 
1 monthly injection if 
disease deemed 
active 
8 Ophthalmologist 
& 
Ophthalmologist 
VA, OCT and SLB in all interpreted by an 
ophthalmologist. If negative, discharge. If 
positive or unclear, then arrange for 
stereoscopic FFA. If FFA positive, treat and 
monitor; if negative, discharge 
VA and SLB and OCT interpreted together by an 
ophthalmologist. If positive, treat; if negative, review 
in a month time. If unclear, then the ophthalmologist 
will arrange for stereoscopic FFA 
1 monthly injection if 
disease deemed 
active 
9 Ophthalmologist 
& Nurse 
VA, OCT and SLB in all interpreted by an 
ophthalmologist. If negative, discharge. If 
positive or unclear, then arrange for 
stereoscopic FFA. If FFA positive, treat and 
monitor; if negative, discharge 
VA and OCT interpreted by a technician or nurse. If 
negative, review in a month. If positive or unclear, 
referral for an ophthalmologist assessment (e.g. SLB 
and own interpretation of VA and OCT test results). 
If assessment positive, treat; if negative, review in 1 
month; if unclear, arrange for stereoscopic FFA 
1 monthly injection if 
disease deemed 
active 
Note: FFA (stereoscopic fundus fluorescein angiography); OCT (optical coherence tomography); VA (visual acuity); SLB (slit-lamp biomicroscopy). 
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7.2.1 The economic model 
A Markov model approach was selected for the decision analytic model exercise.56-59 Markov 
models have Markov states where individuals spend a period of time, named a ‘cycle’. At the 
end of each cycle the individuals can remain in their current Markov state or move to another 
state. The probabilities of moving to other Markov states or remaining in the current state are 
named ‘transition probabilities’.  Individuals in the model would accrue costs and benefits (e.g. 
‘life years’) depending on the time spent in each Markov state and the interventions and/or 
events modelled within each Markov state. Markov models are particularly suitable to model 
recurrent issues and chronic diseases. They allow incorporating health states to reflect the 
movement of the patients during diagnosis-monitoring.  In the current study, model states 
reflect the underlying condition (e.g. nAMD active or inactive) together with the decision on 
treatment (e.g. treated or untreated nAMD) and visual acuity states of the individuals (Table 
20).  In all these models, an absorbing state is included where all individuals would end up if 
the model was run for a sufficiently long period of time (e.g. death state).  
 
The present model incorporates a first diagnosis stage combined with a recurrent (monthly) 
monitoring phase.  
 
The Markov models 
This section presents a stepwise introduction to the Markov models used to compare the 
alternative strategies.  Individuals’ visual acuity status is set aside for the moment to focus on 
the other two issues and assumptions underpinning the movement of individuals throughout the 
model: (1) the underlying disease condition (e.g. if the disease is present or not and, if present, 
its active or inactive status) as well as (2) the diagnosis or monitoring test results on which the 
treatment decision will depend (i.e. a positive result will trigger a decision to treat and a negative 
results will trigger a decision not to treat). Figure 13 shows the schematic diagram of the final 
model used for the economic evaluation for this study. 
 
This section presents three schematic diagrams for this model. The figures differ in the 
assumptions made with respect to the information retrieved from the diagnosis and/or 
monitoring test or assessments. Namely, if perfect information from the tests or assessments is 
assumed, then there would be no false positive or false negative results (i.e. equivalent to 
assuming sensitivity and specificity are equal to 1).  That is, the underlying condition is detected 
with certainty.  When this assumption is relaxed, then the possibility of incorrect assessments 
appears. 
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Perfect information from diagnosis and monitoring tests 
Figure 11 assumes perfect information at diagnosis and monitoring stages in the model. The 
whole modelled cohort starts at the black arrow on the left hand side of the figure 
(corresponding to an initial Markov model stage). The assumption of perfect information means 
that, at diagnosis stage, all individuals with the disease will have a positive result while all those 
without the disease will obtain a negative result.  Individuals with a positive result will go to a 
monitoring scheme while those with a negative result will be discharged.  Those individuals 
with the disease and positive results will start within a Markov model state with an “Active 
disease and under Treatment” (e.g. ‘Active/Treated’ state). Note that ‘Active’ refers to the 
underlying condition while ‘Treated’ or not depends on the test or assessment result.  
 
Figure 11 Markov model schematic diagram assuming perfect information at 
diagnosis and monitoring stages  
 
Assuming monthly monitoring visits and assessments, a positive result at a monitoring visit 
means the individual’s disease is active (assuming, again, perfect information and no possibility 
of false positive or false negative results) and will therefore mean that the person remains in the 
‘Active/Treated’ Markov state.  If a negative result from the monitoring assessment is obtained, 
then it would mean that the individual’s disease has become inactive and the decision not to 
administer treatment will follow.  In this case, the individual will move to the 
‘Inactive/Untreated’ Markov state.  At each Markov cycle (monthly) individuals can become 
active or inactive; this status would be detected at the next monitoring visit with a positive or 
negative result, and the individual will either move or stay in the corresponding Markov model 
state with a consistent treatment decision. 
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 Individuals without the disease at the moment of first diagnosis could develop the disease in 
the future (i.e. incident cases among the population).  In the model (Figures 11 to 13), it was 
assumed that these individuals would be correctly diagnosed within a second visit and 
eventually moved to be monitored within the ‘Active/Treated’ state. Finally, the “Dead” state 
is the absorbing state in this model (i.e. a state that individuals cannot move out of); individuals 
can move from any other Markov state into the ‘Dead’ absorbing state. 
 
Imperfect information from diagnosis test combined with perfect information from monitoring 
tests 
Figure 12 shows a similar schematic diagram but in this case there is imperfect information at 
the moment of first diagnosis. After this initial diagnostic intervention, further diagnosis and/or 
monitoring assessments will be done with certainty (e.g. assuming perfect information).  This 
opens the possibility of obtaining true as well as false positive and negative results from the 
initial diagnosis test/s.  Individuals with positive results, therefore, might not have nAMD while 
individuals with negative diagnostic test results might actually have the disease.  This situation 
will have an effect on the Markov states the individuals will start at after diagnosis. Those with 
a true positive result will start with their active disease being treated and eventually move to an 
inactive state (e.g. ‘Inactive/Untreated’) depending on the treatment effect.  Individuals with a 
false positive result will not have nAMD but will be treated and monitored. However, this 
treatment cannot be effective as these people did not have the disease.  As this schematic 
diagram assumes perfect information at the monitoring phase, these individuals would be 
correctly assessed in their subsequent monitoring visits, moving to the ‘“Inactive”/Untreated’ 
state.  
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Figure 12 Markov model schematic diagram assuming imperfect information at 
diagnosis and perfect information at monitoring stage 
 
 
Note: “Inactive”= underlying condition regarded as inactive nAMD when the disease was 
actually not present. 
 
In addition, if the person has a negative result at diagnosis, this could be a true negative or a 
false negative result.  In either case the individual would be discharged under the belief that 
nAMD was not present.  If true negative, meaning that the disease was not present, the 
individual will start at the ‘No Disease’ state and will remain at that stage unless they develop 
nAMD.  If false negative (patients with the disease and negative test) the person will start within 
the ‘Disease (active)’ state.  
 
Finally, an identical assumption of using FFA for diagnosis for those presenting for a second 
time (re-diagnosis) is followed for those with false negative results at first diagnosis. These 
people will start to be monitored and moved to the ‘Active/Treated’ state after second 
presentation for diagnosis.  A further assumption is used for this sub-group: based on expert 
opinion, these nAMD individuals that have been missed at first diagnosis will present for re-
diagnosis within three months. The rationale behind this was the natural history of the disease 
and the belief that nAMD would advance with visual acuity deterioration making the individual 
return for a further eye check.   
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Imperfect information from diagnosis and monitoring tests 
Figure 13 shows the schematic diagram for the actual Markov model used. In this case, 
imperfect information at diagnosis as well as monitoring phases was assumed.  The cases for 
those with first diagnosis negative results are identical to those in Figure 12 (lower part of 
Figure 13).  However, the diagram for those with positive results at first diagnosis will differ. 
 
Individuals with true positive results at first diagnosis will start as before within the 
‘Active/Treated’ state.  After this, depending on the underlying condition (e.g. active or 
inactive) and the monitoring assessment result (e.g. positive or negative, with a positive result 
reflecting the presence of disease activity), individuals will move to alternative Markov states 
(e.g. ‘Inactive/Untreated’; ‘Inactive/Treated’; ‘Active/Untreated’). The arrows in the figure 
show the direction in which individuals can move due to their underlying condition and 
assessment while the arrow labels refer to the result of the assessment (e.g. TN: true negative, 
TP: true positive, FN: false negative, FP: false positive).  
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Figure 13 Markov model schematic diagram assuming imperfect information at 
diagnosis and monitoring stages 
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A further assumption in the model is that those individuals under monitoring who do not have 
nAMD (i.e. “Inactive” states) that subsequently become nAMD would be detected by the 
monitoring strategy test/s. This monitoring strategy could include FFA (perfect information 
test) or other non-perfect information test (e.g. OCT alone). Therefore, these individuals that 
now have nAMD could move to ‘Active/Treated’ or ‘Active/Untreated’ depending on positive 
or negative monitoring assessment, respectively. 
 
7.2.2 Markov model states and health status valuation link 
The former diagrams show how individuals can move in the model according to their 
underlying condition and the result of the test/s or assessments. However, it is not possible to 
attach utility weights to these Markov states. In essence, individuals can experience alternative 
active or inactive disease but no difference in their reported health status. The economic model 
attaches utility weights according to, mainly, visual acuity. Therefore, the effect on health status 
will come through the deterioration in visual acuity, while visual acuity deterioration will result 
from the fact of individuals being misdiagnosed (e.g. no nAMD when actually the disease was 
present) or misclassified as inactive when their true condition was active nAMD.  
 
In terms of the presented diagrams, the number of Markov states is multiplied by the number 
of visual acuity ranges considered by the model. Therefore, there is a trade-off between the 
number of visual acuity ranges in order to reflect differences in visual acuity - and patient 
reported health status - and the model complexity. Utility differences between the alternative 
model strategies result from the different periods of time individuals are misclassified within 
each strategy. It was considered that five visual acuity states (Table 20) would give sufficient 
refinement for utility differences to be reflected.  This approach has been used in other models 
in this area of healthcare.60 Therefore, each strategy (i.e. each Markov model) has 32 Markov 
model states (e.g. four visual acuity states times six monitoring states, plus four visual acuity 
states times one nAMD undiagnosed state, plus profound visual loss/blindness, a ‘No disease’ 
state –normal visual acuity only–, the absorbing state ‘Dead’, and an initial state for first 
diagnosis). 
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Table 20 Visual acuity states  
 
Visual health states  
(Snellen fractions) 
Visual health status 
1 >6/12 Normal visual acuity  
2 ≤6/12 to > 6/24 Mild visual acuity loss  
3 ≤6/24 to > 6/60 Moderate visual acuity loss 
4 ≤6/60 to > 3/60 Severe visual acuity loss 
5 ≤3/60 Profound visual loss/blindness 
 
Figure 14 shows a Markov model schematic diagram for the visual acuity states considered in 
the model. Arrows in the figure show the possible movements in the model in one cycle (e.g. 
one month).  Individuals’ visual acuity can remain the same, improve or deteriorate in one 
particular cycle.  Individuals can have their visual acuity improved and move one level up at 
the end of a cycle; however, their visual acuity can deteriorate and move one or two levels down 
from their current visual acuity state. Finally, the model considered that a visual acuity 
deterioration of ≤3/60 (i.e. profound visual loss/ blindness) was not reversible and the individual 
was referred to supportive care.  
 
Figure 14 Markov model schematic diagram for visual acuity states 
 
 
Parameter estimates used in the economic model 
The parameter estimates required to populate the economic model were obtained from the 
systematic review of diagnostic and monitoring studies (see chapter 6) as well as structured and 
focused literature searches. When no suitable data resulted from these searches, expert opinion 
was sought. The next section gives details of the probabilities, unit costs and utility weights 
used in the model.  The section also provides details of the probability distributions used for 
the probabilistic sensitivity analysis.61 Probabilistic sensitivity analysis involves attaching 
probability distributions to model parameters and conducting a number of Monte Carlo 
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simulations (e.g. 1000). In each of these simulations a set of parameter values will be drawn 
from the attached distributions, the model is run and results calculated. It is possible then to 
obtain a distribution of the model cost-effectiveness results that reflects the overall parameter 
uncertainty in the economic evaluation model.62,63 
 
7.2.3 Probabilities 
Table 21 shows data on nAMD prevalence, incidence and visual acuity at the start of the model 
run.  Recently, Colquitt et al.60  reviewed studies assessing the prevalence and incidence of 
AMD and nAMD. The setting for this economic evaluation was secondary care; therefore the 
prevalence rate to inform the model should be that corresponding to the group of individuals 
referred to Hospital Eye services with a suspected nAMD diagnosis. The prevalence rate used 
was obtained from the literature retrieved by the systematic review of test accuracy and agreed 
within the project management and advisory groups.  An overall incidence of 1% per year was 
used based on Mitchell et al.64 Incidence figures presented by Mitchell et al. for Australia were 
similar to the results by Van Leeuwen et al. for the Rotterdam study but were reported in a form 
that could be readily incorporated into the economic model.65  Mortality data were obtained 
from Interim Life Tables for England and Wales (2009-2011). No difference in mortality rates 
were found when comparing age specific mortality rates form the Interim Life Tables and those 
from the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)8 and 
the Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)9 studies. Therefore, no 
excess mortality was included due to nAMD.66,67  However, excess mortality risk was 
incorporated for the last disease visual acuity stage (profound visual loss/blindness – visual 
acuity ≤ 3/60). 
 
Table 21 also shows probability distributions defined for the probabilistic sensitivity analysis. 
Uninformative uniform distributions were used for nAMD prevalence and profound visual 
loss/blindness excess mortality. Ranges for defining these were assumptions based on data from 
the literature if available (e.g. from the review of test accuracy). A gamma distribution was 
defined for nAMD incidence based on mean and standard deviation (e.g. 1/10 of the mean) 
using the tool provided by Treeage (TreeAge Software, Inc., Williamstown, MA, 2013).  
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Table 21 Prevalence, incidence, and visual acuity at start 
Variable Value 
Probability 
Distribution Source 
Epidemiological data    
Prevalence for nAMD 70% Uniform(0.6; 0.8) 
Expert opinion and articles 
from SR test accuracy  
Incidence rate of nAMD 
(monthly) 0.084% Gamma(1; 1190) Mitchell et al64 
Mortality various  
Interim Life Tables, 
England & Wales (2009-
2011)14 
Profound visual 
loss/blindness excess 
mortality 17% Uniform(0.1; 0.5) Assumption 
Cohort details at Start     
Age (years) 65 n/a 
Assumption based on 
expert opinion 
Mean Visual Acuity    
Individuals with 
nAMD:    
≤6/12 to > 6/24 
state 100% n/a 
Assumption based on 
expert opinion and CATT 
and IVAN RCTs mean VA 
at start 
Individuals without 
nAMD:    
>6/12 100% n/a 
Assumption based on 
expert opinion 
 
The cohort start age was set at 65 years as this is the age where particular changes are observed 
in the retina and macula (personal communication – Dr. Noemi Lois and Project Advisory 
Group).  In addition, mean visual acuity at start was set at between ≤ 6/12 to > 6/24 for those 
individuals with nAMD. This was agreed to be the most common visual acuity at presentation 
by experts and also the mean visual acuity at baseline in the CATT and IVAN studies.8,9  
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Table 22 presents diagnostic test performance data.  As mentioned above, three strategies were 
defined for diagnosis within the economic model. For each of these strategies, sensitivity and 
specificity data were needed, specifically for FFA, OCT, and Ophthalmologist assessment (i.e. 
with visual acuity test, SLB, and the results from the OCT).  FFA interpreted by an 
ophthalmologist was stated as the reference standard for the diagnosis of nAMD; therefore, 
perfect information was assumed from this test, with sensitivity and specificity equal to 1. OCT 
sensitivity and specificity were obtained from the systematic review of diagnostic studies. 
These data correspond to OCT pooled estimates (four studies, number of eyes 406.26,39,45,48 No 
studies were identified on the ophthalmologist assessment diagnostic performance.  Hence, 
sensitivity and specificity estimates were derived from expert opinion.  
 
Table 22 Test performance parameters - diagnosis of nAMD 
Variable Value Range 
Probability 
Distribution Source 
FFA     
Sensitivity 1 n/a n/a Assumption 
Specificity 1 n/a n/a Assumption 
OCT     
Sensitivity 0.88 
(0.46, 
0.98) Beta(36.3; 4.9) 
Systematic review of diagnostic 
studies 
Specificity 0.78 
(0.64, 
0.88) 
Beta(82.9; 
23.4) 
Systematic review of diagnostic 
studies 
Ophthalmologist 
assessment 
(with VA, OCT 
and SLB)     
Sensitivity 0.99  
Beta(0.22; 
0.002) 
Assumption based on expert 
opinion, using the systematic 
review results as a starting point 
Specificity 0.9  Beta(9.1; 1) 
Assumption based on expert 
opinion, using the systematic 
review results as a starting point 
Unclear 0.1 (0  to 0.5) 
Beta(89.9; 
809.1) 
Assumption based on expert 
opinion 
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Sensitivity and specificity data are bounded between zero and 1. Therefore, beta distributions 
were defined for probabilistic sensitivity analysis. For OCT, these were obtained using mean 
values and standard deviation in order to obtain values within the 95% CI provided by the 
systematic review of diagnostic studies (see chapter 6, Table 17). Probability distributions for 
ophthalmologist diagnosis assessment were obtained using the approximation tool provided by 
Treeage based on mean and standard deviation (e.g. 1/10 of mean).  
 
Table 23 shows similar data to Table 22 but for monitoring of individuals with nAMD.  FFA 
was also stated as the reference standard to detect disease activity; therefore, perfect information 
was assumed, with sensitivity and specificity defined as equal to 1.  OCT monitoring sensitivity 
and specificity data were obtained from the systematic review of test performance (chapter 6). 
Pooled estimates, (e.g. four studies,   N=242), were used.15,27,29,52 No studies were identified 
reporting the diagnostic performance of nurse or technician assessment, or for ophthalmologist 
assessment.  Therefore, estimates for the sensitivity and specificity of these strategies were 
derived from expert opinion.  
 
Table 23 Test performance data - monitoring of nAMD 
Variable Value Range 
Probability 
Distribution Source 
FFA     
Sensitivity 1 n/a n/a Assumption 
Specificity 1 n/a n/a Assumption 
OCT     
Sensitivity 0.85 (0.72, 0.93) Beta(105; 18.5) 
Systematic review of 
monitoring studies 
Specificity 0.48 (0.30, 0.67) Beta(32.8; 35.5) 
Systematic review of 
monitoring studies 
Technician/nurse 
assessment (VA and 
OCT)     
Sensitivity 0.9  Beta(108.9; 12.1) 
Assumption based on 
expert opinion, using 
the systematic review 
results as a starting 
point  
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Variable Value Range 
Probability 
Distribution Source 
Specificity 0.6  Beta(72.6; 48.4) 
Assumption based on 
expert opinion, using 
the systematic review 
results as a starting 
point 
Unclear 0.1  Beta(89.9; 809.1) 
Assumption based on 
expert opinion 
     
     
Ophthalmologist 
assessment (VA, 
OCT & SLB)     
Sensitivity 0.97  Beta(2.51; 0.08) 
Assumption based on 
expert opinion, using 
the systematic review 
results as a starting 
point 
Specificity 0.8  Beta(19.2; 4.8) 
Assumption based on 
expert opinion, using 
the systematic review 
results as a starting 
point 
Unclear 0.1  Beta(89.9; 809.1) 
Assumption based on 
expert opinion 
 
A similar approach to the one used for the sensitivity and specificity of diagnostic tests was 
used for this information for monitoring tests. Beta probability distributions were approximated 
and defined using mean and standard deviation (e.g. 1/10 of the mean) values. The range of 
values of OCT used in the model did not exceed the 95% CI values obtained from the systematic 
review of monitoring studies (i.e. OCT range data in Table 23). 
 
Disease progression in the model was defined in terms of visual acuity changes. Gaining or 
losing three lines in the Snellen chart (approximately 15 letters in the Early Treatment Diabetic 
Retinopathy Study (ETDRS) chart) was assumed to make individuals move from their current 
Markov model state to the next level (see Table 20 and Figure 14).  Data for this were obtained 
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from Rosenfeld et al. (i.e. MARINA study).68 This study was based in the USA, involved 716 
participants and compared monthly treatment with ranibizumab (0.3mg, N = 238 or 0.5mg, 
N=240) against sham injection (N = 238). Data from treatment (0.5 mg) and control groups 
were used to calculate monthly progression probabilities for active treated and non-treated 
individuals, respectively.  No visual acuity progression was assumed for nAMD inactive 
individuals as well as non-AMD individuals.  
 
Table 24 Disease progression data – visual acuity 
  
Year 1 
  
Year 2 onwards 
  
  Value 
Probability 
distribution Value 
Probability 
distribution 
Treatment     
Gain at least 3 lines 0.0338 Beta(96.6; 2761.9) 0.0167 Beta(98.3; 5777) 
Gain or lose less than 3 
lines Default  Default  
Lose between 3 and 6 
lines 0.0036 Beta(99.6; 27817) 0.0032 Beta(99.7; 30634) 
Lose 6 lines or more 0.0010 Beta(99.9; 99252) 0.0011 Beta(99.9; 94640) 
     
No treatment     
Gain at least 3 lines 0.0043 Beta(99.6; 23244) 0.0016 Beta(99.8; 61799) 
Gain or lose less than 3 
lines Default  Default  
Lose between 3 and 6 
lines 0.0221 Beta(97.8; 4331) 0.0116 Beta(98.8; 8431) 
Lose 6 lines or more 0.0128 Beta(98.7; 7627) 0.0107 Beta(98.9; 9171) 
 
Beta distributions were attached to visual acuity progression data for probabilistic sensitivity 
analysis (Table 24). Unfortunately there were no data available to construct confidence intervals 
around mean values used in the model. As such, probability distributions parameter values were 
developed using mean values and assuming 1/10 of mean values for standard errors. 
 
Additional data were required on disease status, namely, the probability of becoming active 
when the individual’s disease was inactive and under no treatment, as well as the probability of 
becoming inactive when the individual’s disease was active and under treatment. First year data 
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for these were developed using data from the IVAN study (personal communication – Dr. Chris 
Rogers, 12th June 2013). The IVAN study was a 2x2 factorial design and adult individuals with 
untreated nAMD were randomised into four groups: ranibizumab or bevacizumab, given either 
every month (continuous) or as needed (discontinuous). All individuals were reviewed on a 
monthly basis. Survival data for participants’ first treatment failure (e.g. subretinal fluid, 
increasing intraretinal fluid, or fresh blood) for the discontinuous arm (N=302) were used to 
develop mean probability values. All individuals were active at baseline and 95% of these did 
not fail the retreatment criteria (e.g. did not need to be treated) at 3 months. This rate was used 
to obtain the monthly probability of becoming inactive when active and under treatment.61 At 
month six, 54% of individuals were still inactive. The difference between the proportion of 
inactive individuals at months three and six was used to develop the probability of becoming 
active when inactive and under no treatment (Table 25).  Probability distributions were 
developed using the 95% CI from the IVAN study survivor function using Crystal Ball software 
(Table 25). 
 
Table 25 Disease progression data - active and inactive nAMD 
Variable Value 
Probability 
Distribution Source 
Probability of becoming:    
Inactive when active and under 
treatment    
Year 1 0.616 Beta(176.6; 110) 
based on data from 
IVAN study9 
Year 2 onwards 0.365 Beta(63.1; 110) 
based on data from 
CATT study8 
    
Active when inactive and 
under no treatment    
Year 1 0.306 Beta(148; 335) 
based on data from 
IVAN study9 
Year 2 onwards 0.097 Gamma(100; 1029) based on Hörster et al69 
Active when inactive and 
under treatment 0.5 x Active when inactive and under no treatment 
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Second year data for the probability of becoming inactive were developed using data from the 
CATT study. The inclusion criteria and the treatment group for the CATT study were similar 
to that of the IVAN study. However, within the IVAN study three monthly injections were 
administered when participants failed the disease inactive criteria. The CATT study 
administered one injection only and reviewed participants in one month’s time before making 
a further treatment decision. A monthly probability was sought in order to obtain the CATT 
study mean number of injections within the as needed arm at two years. A beta distribution was 
attached based on mean value and 1/10 of the mean value as standard error (Treeage software). 
 
Second year data for the probability of becoming active when participants were inactive and 
under no treatment was developed using data reported by Hörster et al.69  The authors reviewed 
data on all patients receiving intravitreal ranibizumab injections for nAMD at the University of 
Cologne. Eyes with at least two recurrences (i.e. re-appearance of intraretinal or subretinal fluid 
on OCT, and/or leakage on angiography) were selected. The mean follow-up time (months) and 
number of recurrences were 28.8 and 2.8 respectively.   
 
A number of individuals that were inactive at three months within the monthly treatment group 
in the IVAN study9 failed the no re-treatment criteria (e.g. subretinal fluid, increasing 
intraretinal fluid, or fresh blood) in subsequent months. This means that, even under monthly 
treatment, inactive individuals could become active again. Based on this, half the probability of 
becoming active when inactive and under no treatment was assumed for the probability of 
becoming active when inactive and under treatment. 
 
Diagnosis or monitoring strategies could result in over- or under-treatment; therefore, it was 
believed important to include adverse events as a result of treatment. Two recent studies8,9 
report systemic and ocular adverse event rates. It was not clear from inspection of these data 
that systemic adverse events could be due to treatment of nAMD. Therefore, only ocular 
adverse events were included in the model. Table 26 shows monthly estimates for the 
proportion of individuals that were under treatment that experienced cataract, endophthalmitis, 
glaucoma, retinal detachment and uveitis. 
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Table 26 Adverse events 
Variable 
Value 
(monthly %) Source 
Cataract 0.34% The CATT Research Group8 
Endophthalmitis 0.40% The CATT Research Group8 
Glaucoma 0.05% The CATT Research Group8 
Retinal detachment 0.03% The CATT Research Group8 
Uveitis 0.03% The CATT Research Group8 
 
7.2.4 Costs 
Table 27 shows cost estimates used in the model. Prices are expressed in 2011-2012 pounds 
sterling (£). Strategy assessment costs were a combination of the cost of a visit (e.g. 
ophthalmologist, nurse or technician) and the cost of a particular test used for the assessment 
(e.g. FFA or OCT). For instance, the diagnosis cost for strategies where diagnosis was 
conducted using FFA only was calculated adding up the cost of an ophthalmologist visit and 
the cost for an FFA (e.g. £79.74 + £117.26 = £197.00). NHS Reference Costs were used for all 
but the ranibizumab unit costs in Table 27, for which BNF data were used (£742.17).70  The 
unit cost for face-to-face consultant-led follow-up attendance that resulted in non-admission for 
the Ophthalmology service was used for the cost of a diagnosis or monitoring visit to the 
ophthalmologist (£79.74). Likewise, non-consultant led was used for the cost of a nurse or 
technician monitoring visit (£58.53).  Minor Vitreous Retinal Procedures cost category (HRG 
BZ23Z code) was used to cost FFA (£117.26).  Finally, after consultation with clinical experts, 
an ultrasound scan (HRG RA23Z Ultrasound Scan, less than 20 minutes) was deemed more 
likely to reflect the cost of an OCT test (£51.27). 
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Table 27 Unit costs 
Variable 
£ (2011-
2012) Range 
Probability 
Distribution Source 
Ophthalmologist 
visit 79.74 (68; 86) 
Gamma 
(309.9; 3.9) 
NHS Reference Costs 
(Consultant Led: Follow-up 
Attendance Non-Admitted 
Face-to-face. 130: 
Ophthalmology) 
Nurse / Technician 
visit 58.53 (42;71) 
Gamma 
(34.3; 0.59) 
NHS Reference Costs (Non-
Consultant Led: Follow-up 
Attendance Non-Admitted 
Face-to-face. 130: 
Ophthalmology)70 
Fundus fluorescein 
angiography 117.26  
Gamma 
 (25; 0.21) 
NHS Reference Costs (HRG 
BZ23Z Minor Vitreous 
Retinal Procedures)70 
Optical coherence 
tomography 51.27 (32;62) 
Gamma 
(48.8; 0.95) 
NHS Reference Costs 2011-
12. (HRG RA23Z 
Ultrasound Scan, less than 
20 minutes)70 
Treatment     
Medication 
ranibizumab 
(Lucentis®) 742.17  
Gamma 
 (4; 0.01) 
BNF71  
 
Gamma probability distributions were defined for unit cost data for probabilistic sensitivity 
analysis as these are defined non negative and provide a possibility of a right tail that could 
account for few very high unit cost cases. Ranges for Reference cost based data are also reported 
in Table 27; these are Lower and upper quartiles. These were used to tailor cost probability 
distributions.   
 
The cost of profound visual loss/blindness from the NHS and Personal Social Services 
perspective was calculated following Colquitt et al.60 The authors used proportion for service 
utilisation developed by Meads et al. (Table 28).72 The unit costs reported by Colquitt et al.60 
were updated using Hospital and Community Health Service (HCHS) specific price inflation 
index (base 2005=100) for March 2012 (e.g. £121.85).  Using alternative weekly cost figure of 
£497 for residential care (the item in the list with higher unit cost) reported by Curtis,73 results 
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in an annual cost of £556 and £537 for the first and subsequent years, respectively, and were 
used as the basis for deterministic sensitivity analysis.  
 
Table 28 Cost of profound visual loss/blindness 
  
Requiring 
(%) 
Cost (£, 
2005) 
Cost (£, 
2012) 
Annual 
Cost (£) 
Monthly 
Cost (£) 
Severe sight impairment 
registration 95% 115 140 £133 £11.09 
Low-vision aids 33% 150 183 £60 £5.03 
Low-vision 
rehabilitation 11% 259 316 £35 £2.89 
Community care 6% 6,552 7,984 £479 £39.92 
Residential care 30% 13,577 16,544 £4,963 £413.59 
Depression 39% 431 525 £205 £17.07 
Hip replacement 5% 5,379 6,554 £328 £27.31 
Total year 1    £6,203 £517 
Total year 2+       £5,975 £498 
 
7.2.5 Utility weights 
Guidelines for economic evaluation of health care technologies in the UK advocate the use of 
a preference-based measure of utility.74 We conducted a focused search for these data for AMD 
individuals. It was confirmed that one group had the majority of studies in this area75,76 and data 
from Brown et al.75 were included in the economic model. The study by Brown et al. used the 
time trade-off approach on 72 consecutive patients seen at the Retina Vascular Unit at Wills 
Eye Hospital, Philadelphia, USA, to obtain utility weights for alternative visual acuity scores76. 
Table 29 presents utility weights used in the economic model according to the Markov model 
health state. Confidence intervals were also obtained from Brown et al.75 Mean utility weights 
and confidence intervals were used to define beta distributions (Table 29) for probabilistic 
sensitivity analysis.  
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Table 29 Utility weights 
Health State Mean 95% CI 
Probability 
Distribution Source 
>6/12 0.89 
(0.82 to 
0.96) Beta(12.7; 1.6) 
Colquitt et al60 based on 
Brown et al75 
≤ 6/12 to > 6/24 state 0.81 
(0.73 to 
0.89) Beta(18.7; 4.4)  
≤ 6/24 to > 6/60 state 0.57 0.47 to 0.67) Beta(42.4; 32)  
≤ 6/60 to > 3/60  state 0.52 
(0.38 to 
0.66) 
Beta(51.4; 
47.4)  
≤ 3/60 0.4 
(0.29 to 
0.50) 
Beta(59.6; 
89.4)  
Utility decrements (monthly) due to adverse events Brown et al 76 
Cataract 0.012    
Endophthalmitis 0.025    
Retinal detachment 0.023    
Uveitis 0.025    
assumed equal to 
Endophthalmitis 
 
Utility decrements due to adverse events were retrieved from Brown et al.76 The authors derived 
utility values from 233 patients with AMD and decrement values were obtained from 
individuals who experienced alternative adverse events. Table 29 shows the (monthly) utility 
decrements used within the model. These were applied to the proportion of individuals who 
experienced an adverse event from within those that were under treatment (Table 26).  Searches 
were conducted to retrieve information on the effect of treatment injections on the quality of 
life of patients with nAMD; however no evidence was found.  Moreover, from discussions 
within the Project Advisory Group and clinical experts, anxiety seemed to be associated with 
the uncertainty of the disease condition (i.e. active or inactive) rather than the treatment itself.  
Adding a utility decrement for each monthly monitoring visit for all strategies would have had 
no effect on the final results.  As such, no utility adjustments were conducted due to treatment 
injections.  
 
7.2.6 Base case and sensitivity analyses 
The UK NICE guidelines of methods for technology appraisals were followed.74 The model 
base case analysis was run for a cohort of 65 year old men for a time horizon of 35 years 
87 
 
(lifetime). A one month cycle length was defined. The analysis was conducted from the NHS 
and Personal Social Services perspective.  Costs were expressed in 2011-2012 pounds sterling 
and effectiveness in quality-adjusted life years (QALYs). Costs and QALYs were discounted 
at 3.5%.74 Cost-effectiveness analysis results are reported using incremental cost-effectiveness 
ratios (ICERs).54 ICERs are calculated as the ratio between the difference in average cost 
between two alternative strategies and the difference in average QALYs. This ratio measures 
the additional cost that would have to be paid in order to obtain an extra unit of effectiveness 
(i.e. an extra QALY). Probabilistic analysis results are reported using cost-effectiveness 
acceptability curves (CEACs).77,78  CEACs show the probability of a particular strategy to be 
cost-effective at alternative values of willingness to pay for an extra QALY.  
 
Sensitivity analysis 
Uncertainty in the economic model was explored conducting one-way sensitivity analysis, 
scenario analysis and probabilistic sensitivity analysis.  As mentioned above, the base case 
analysis was run for a male cohort. Gender specific data were not available and the only 
different data for men and women were mortality rates. Female mortality data show longer life 
expectancy. These could result in longer time for benefits, but also costs. A further analysis was 
conducted using mortality data for women to observe the effect of longer life expectancy in the 
model results. 
 
One-way sensitivity analyses were conducted on test diagnosis sensitivity and specificity, the 
probability of ophthalmologist diagnosis or monitoring results being unclear, tests and 
assessment monitoring sensitivity and specificity, probability of the nurse or technician 
assessment being unclear, and unit costs for OCT, FFA and ranibizumab. 
 
Further deterministic sensitivity analyses were conducted using alternative discount rates for 
costs and QALYs, as well as prevalence rates for nAMD. In addition, population utility weights 
were retrieved from Czoski-Murray et al.79 The authors elicited time trade-off based utility 
values from 108 healthy individuals for AMD states simulated using contact lenses. 
 
Given base case and sensitivity analyses results, three scenario analyses were tested. All of 
these incorporated data that favoured OCT (Table 30). Scenario 1 used the upper limit for the 
95% CI for OCT sensitivity and specificity for diagnosis and monitoring obtained from the 
systematic review of diagnostic and monitoring studies, together with £20.90 and £139 unit 
costs for OCT and FFA, respectively.  Scenario 2 used the same data as for scenario 1 but 
assuming a cost per treatment injection of £50 instead of £742.  Finally, scenario 3 assumed the 
same input data as for scenario 1 but monitoring pathways that based their decisions on OCT 
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only considered the unit cost of the OCT test for the monitoring visit as that of the OCT test for 
an optometry community service (£20.90).80 The cost of an ophthalmologist visit was not 
considered in every monitoring visit but added only if the patient needed to be treated. This 
scenario explores the effect of monitoring patients within the community and only refers them 
to secondary care for treatment.  
 
Table 30 Input data for scenario analyses 
Variable Diagnosis Monitoring Source 
    
FFA    
Sensitivity 0.99 0.99 Assumption 
Specificity 0.99 0.99 Assumption 
OCT    
Sensitivity 0.98 0.93 
Systematic review of diagnostic and 
monitoring studies 
Specificity 0.88 0.67 
Systematic review of diagnostic and 
monitoring studies 
Unit costs 
(2011-2012 
£)   
FFA 139  
NHS Reference Costs 2011-12. 
(HRG BZ23Z Minor Vitreous 
Retinal Procedures)70 
OCT 20.9  
General Ophthalmic Services: 
Increases to NHS Sight Test Fee.81  
 
Base case and selected sensitivity analyses are presented in the next section. Full sensitivity 
analysis results are reported in Appendix 9.  
 
7.2.7 Results 
Table 31 reports base case analysis results for men for the nine compared strategies. Model 
strategies are ordered in terms of average cost in an ascending order. Diagnosis with FFA 
combined with the nurse or technician-led monitoring strategy (e.g. nurse or technician as first 
monitoring contact conducting a VA examination and interpreting OCT test results; if negative 
discharge, if positive or unclear, refer to an ophthalmologist for further assessment) was the 
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strategy with the lowest average total cost. The next non-dominated strategy (i.e. dominated 
strategy meaning a strategy with higher expected costs and lower expected QALYs) is  
diagnosis based on FFA only, followed by ophthalmologist-led monitoring. This strategy has  
higher total expected cost but also produces higher total expected QALYs. However, the 
incremental cost for an extra QALY (i.e. ICER) to adopt this strategy is above the often 
accepted cost-effectiveness threshold (i.e. £30,000).74 All other strategies are dominated by 
either of the strategies that based diagnosis in FFA only followed by nurse led or 
ophthalmologist led monitoring.  Diagnosis based only on OCT appears in third place combined 
with nurse-led monitoring. In terms of costs, the strategies’ order is driven mainly by the 
monitoring pathway, with the lowest average total costs coming from the nurse-led monitoring 
pathway (1st to 3rd places), then the ophthalmologist-led (4th to 6th) and OCT only-based (7th to 
9th) monitoring pathways, respectively. It should be noted, then, that the three model strategies 
that used OCT only as the basis for monitoring criteria were the strategies with higher average 
costs (Table 31). This is due to the cost of treatment, that represents 76% of the total average 
cost within these strategies, the highest proportion for all compared strategies (e.g. average 65% 
and minimum 55%). 
 
Table 31 Base case cost-effectiveness results - men 
Strategy Cost (£) 
Incremental 
Cost (£) QALYs 
Incremental 
QALYs ICER (£) 
3) FFA & Nurse  39,769   -     10.473  0.000 0 
9) Ophthalmologist & Nurse  39,790   21   10.472  -0.001 -33,237 
6) OCT & Nurse  41,607   1,838   10.465  -0.008 -224,403 
2) FFA & Ophthalmologist  44,649   4,880   10.575  0.102 47,768 
8) Ophthalmologist & 
Ophthalmologist 
 44,669   20   10.574  -0.001 -31,094 
5) OCT & Ophthalmologist  47,131   2,482   10.567  -0.008 -293,938 
1) FFA & OCT  62,759   18,110   10.449  -0.126 -144,229 
7) Ophthalmologist & OCT  62,778   18,129   10.449  -0.126 -143,662 
4) OCT & OCT  67,421   22,772   10.442  -0.133 -170,859 
Notes: 
1. The ICERS are calculated against the next cheapest non-dominated strategy. 
 
Figure 15 shows the cost-effectiveness plane for the base case analysis and the nine diagnosis-
monitoring combination strategies. For easier interpretation, data marker shapes relate to the 
diagnosis strategy, while marker filling/colour relates to the monitoring strategy.  Namely, 
square, circle and triangle shapes are used for FFA only, OCT only, and ophthalmologist 
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stepwise diagnosis, respectively. In addition, black, grey and none marker fillings correspond 
to ophthalmologist led, nurse or technician-led and OCT only based monitoring, respectively. 
 
Three clusters can be seen in Figure 15 according to the monitoring strategy. As such, the 
ophthalmologist-led monitoring strategy cluster seems to produce higher expected QALYs and 
slightly higher expected costs compared with the nurse or technician-led monitoring strategy.  
The OCT only monitoring strategy cluster results in a higher expected cost and lower expected 
QALYs compared with the other two monitoring strategies. 
 
Within each of these clusters, the FFA diagnosis strategy dominates OCT only as well as the 
ophthalmologist stepwise diagnosis strategy (e.g. VA, OCT and SLB in all, followed by FFA 
if positive or unclear results). Also, to note is that the ophthalmologist diagnostic and FFA 
diagnostic pathways have very similar expected cost and QALYs within each cluster and, as 
such, data markers seem to overlap. This is due to the close values assumed for diagnosis 
sensitivity and specificity in these two diagnostic pathways.   
 
Figure 15  Base case cost-effectiveness results - men 
 
 
Table 32 and Figure 16 show probabilistic sensitivity analysis for the base case. Diagnosing 
with FFA only followed by nurse or technician-led monitoring has the highest probability of 
being cost-effective for up to £40,000 willingness to pay for an extra QALY. At higher 
threshold values (e.g. £50,000) diagnosing with FFA only followed by ophthalmologist-based 
monitoring has a higher probability of being cost-effective. Overall, diagnosis with FFA with 
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either nurse-led or ophthalmologist-led monitoring has more than a 70% chance of being cost 
effective at willingness to pay values for an extra QALY of between £10,000 and £50,000. 
These strategies lose some ground against ophthalmologist-based diagnosis (e.g. 
‘Ophthalmologist & Ophthalmologist’ and ‘Ophthalmologist & Nurse’) at high levels of 
willingness to pay for extra QALY threshold values (Table 32 and Figure 16). At £30,000 
willingness to pay for a QALY threshold value and regardless of the diagnosis pathways (e.g. 
FFA only, OCT only or ophthalmologist), nurse or technician-led monitoring has a 61% 
probability of being cost-effective. 
 
Table 32 Probabilistic sensitivity analysis. Base case - men 
Strategy 
Probability of strategy being cost-effective at alternative 
threshold values for society’s willingness to pay for a QALY 
(%) 
 £10,000 £20,000 £30,000 £40,000 £50,000 
1) FFA & OCT 0.6 0.9 1.2 1.2 1.7 
2) FFA & 
Ophthalmologist 
12.2 21.8 31.3 36.7 42.6 
3) FFA & Nurse 67.7 57.4 46.4 39.0 29.9 
4) OCT & OCT 0.0 0.0 0.0 0.0 0.0 
5) OCT & 
Ophthalmologist 
0.0 0.0 0.0 0.0 0.0 
6) OCT & Nurse 0.0 0.0 0.0 0.0 0.0 
7) Ophthalmologist & 
OCT 
0.0 0.1 0.1 0.3 0.5 
8) Ophthalmologist & 
Ophthalmologist 
1.5 3.3 7.2 10.3 13.8 
9) Ophthalmologist & 
Nurse 
18.0 16.5 13.8 12.5 11.5 
 
Figure 16 shows that when expanding this range up to £100,000, diagnosing with FFA only 
followed by the ophthalmologist-based monitoring strategy will have more than a 50% chance 
of being cost-effective. In addition, FFA only based diagnosis strategies lose some ground 
against ophthalmologist-based diagnosis strategies (i.e. ‘Ophthalmologist & Ophthalmologist’ 
and ‘Ophthalmologist & Nurse’) at high levels of willingness to pay threshold values (Table 32 
and Figure 16). 
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Figure 16 Cost-effectiveness acceptability curves. Base case – men 
 
 
Sensitivity analysis 
Using mortality rate data for women 
Table 33 and Figure 17 present cost-effectiveness results for women. As expected, all strategies 
produce more QALYs, incurring higher average costs. This is because of the longer life 
expectancy for women. This affects all of the model strategies in a similar manner. As such, 
there are no differences in the (average cost) order of the strategies or the general results 
compared with those for the base case analysis for men (Table 31). Diagnosing with FFA 
followed by nurse or technician-led monitoring is still the strategy with the lowest average cost 
and dominates all other compared strategies, apart from diagnosis with FFA followed by 
ophthalmologist-led monitoring. However, the ICER for moving to the latter strategy is above 
the usually accepted cost-effectiveness threshold (i.e. £30,000).74 
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Table 33 Cost-effectiveness results - women 
Strategy Cost (£) Incremental 
Cost (£) 
QALYs Incremental 
QALYs 
ICER (£) 
3) FFA & Nurse 44,099 0 11.604 0.000 0 
9) Ophthalmologist & 
Nurse 
44,119 21 11.603 -0.001 -30,521 
6) OCT & Nurse 46,125 2,026 11.595 -0.009 -226,433 
2) FFA & Ophthalmologist 49,527 5,428 11.725 0.121 44,959 
8) Ophthalmologist & 
Ophthalmologist 
49,547 20 11.724 -0.001 -28,491 
5) OCT & Ophthalmologist 52,262 2,735 11.715 -0.009 -296,276 
1) FFA & OCT 69,712 20,185 11.576 -0.148 -136,016 
7) Ophthalmologist & OCT 69,731 20,204 11.576 -0.149 -135,517 
4) OCT & OCT 74,847 25,321 11.568 -0.157 -161,433 
 
Similar clusters can be observed in the cost-effectiveness results for men (Figure 15) and 
women (Figure 17), with the three clusters depending on the monitoring care pathway (i.e. OCT 
only, nurse or technician-led, or ophthalmologist-led monitoring).  As was the case with Figure 
15, the ophthalmologist diagnostic and FFA diagnostic pathways have very similar expected 
cost and QALYs within each cluster and, as such, data markers seem to overlap.  The Table 33 
and Figure 17 results indicate that no dramatic differences can be expected for the women and 
men model run results. Therefore, further sensitivity analyses were conducted only for the male 
cohort. 
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Figure 17 Cost-effectiveness results - women 
 
 
7.2.8 One-way sensitivity analyses 
Extensive one-way sensitivity analyses were undertaken. This section reports a selected number 
of these, while full results are presented in Appendix 9. All one-way sensitivity analyses show 
results moving in the expected direction (i.e. lower sensitivity or specificity for OCT would 
result in OCT-based strategies being less cost-effective). Tables 34 to 38 show one-way 
sensitivity analysis for OCT diagnostic sensitivity and specificity, OCT monitoring sensitivity 
and specificity and OCT unit cost, respectively. The base case analysis results seem robust.  In 
all reported sensitivity analyses, diagnosis with FFA combined with nurse or technician-led 
monitoring (based on VA and OCT with a referral to the ophthalmologist if positive or unclear) 
has the lowest total expected costs and dominates all others, apart from FFA for diagnosis with 
ophthalmologist-led monitoring.  In a limited number of model runs alternative strategies stop 
being dominated by diagnosis with FFA followed by nurse or technician-led monitoring. 
However, in many of these cases the variable values used to run the analysis were extreme (see 
Table 34 and 36 for OCT diagnostic and monitoring sensitivities equal to 1, respectively). 
Results are sensitive to the value of monitoring specificity for OCT. Table 37 suggests that 
OCT monitoring specificity above 80% could make diagnosis with FFA combined with 
monitoring with OCT only, a cost-effective strategy. However, this is to almost double the 
specificity values reported for monitoring in chapter 6.  
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Table 34 One-way sensitivity analysis – OCT diagnostic sensitivity 
OCT 
diagnostic 
sensitivity 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
0.8 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,594 10.459 1,824 -0.014 -133,258 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,114 10.561 2,465 -0.014 -173,407 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
 4) OCT & OCT 67,394 10.436 22,745 -0.139 -163,795 
0.9 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,611 10.466 1,841 -0.007 -270,172 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,135 10.568 2,486 -0.007 -355,119 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
 4) OCT & OCT 67,428 10.443 22,779 -0.132 -172,719 
1 3) FFA & Nurse 39,769 10.473    
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OCT 
diagnostic 
sensitivity 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,628 10.473 1,859 0.000 31,635,704 
 2) FFA & Ophthalmologist 44,649 10.575 3,021 0.102 29,593 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,157 10.575 2,507 0.000 11,797,675 
 1) FFA & OCT 62,759 10.449 15,602 -0.126 -124,050 
 7) Ophthalmologist & OCT 62,778 10.449 15,621 -0.126 -123,584 
 4) OCT & OCT 67,462 10.450 20,306 -0.125 -162,290 
 
 
Table 35 One-way sensitivity analysis – OCT diagnostic specificity 
OCT 
diagnostic 
specificity 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
0.55 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 43,619 10.465 3,850 -0.008 -473,564 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 49,821 10.567 5,172 -0.008 -629,095 
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OCT 
diagnostic 
specificity 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
 4) OCT & OCT 72,407 10.442 27,758 -0.133 -209,343 
0.6 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 43,182 10.465 3,412 -0.008 -419,079 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 49,236 10.567 4,587 -0.008 -554,702 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
 4) OCT & OCT 71,324 10.442 26,674 -0.133 -200,943 
0.65 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 42,744 10.465 2,975 -0.008 -364,772 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 48,651 10.567 4,002 -0.008 -481,174 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
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OCT 
diagnostic 
specificity 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
 4) OCT & OCT 70,240 10.442 25,590 -0.133 -192,562 
0.7 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 42,307 10.465 2,538 -0.008 -310,643 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 48,067 10.567 3,418 -0.008 -408,495 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
 4) OCT & OCT 69,156 10.442 24,507 -0.133 -184,200 
0.75 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,870 10.465 2,100 -0.008 -256,690 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,482 10.567 2,833 -0.008 -336,651 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
 4) OCT & OCT 68,072 10.442 23,423 -0.133 -175,856 
0.8 3) FFA & Nurse 39,769 10.473    
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OCT 
diagnostic 
specificity 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,432 10.465 1,663 -0.008 -202,914 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 46,897 10.567 2,248 -0.008 -265,626 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
 4) OCT & OCT 66,988 10.442 22,339 -0.133 -167,531 
0.85 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 40,995 10.465 1,226 -0.008 -149,312 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 46,312 10.567 1,663 -0.009 -195,408 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
 4) OCT & OCT 65,904 10.442 21,255 -0.133 -159,225 
0.9 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 40,558 10.465 788 -0.008 -95,884 
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OCT 
diagnostic 
specificity 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 45,727 10.566 1,078 -0.009 -125,982 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
 4) OCT & OCT 64,820 10.441 20,171 -0.134 -150,937 
0.95 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 40,120 10.465 351 -0.008 -42,629 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 45,143 10.566 494 -0.009 -57,335 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
 4) OCT & OCT 63,736 10.441 19,087 -0.134 -142,667 
1 6) OCT & Nurse 39,683 10.465    
 3) FFA & Nurse 39,769 10.473 86 0.008 10,453 
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 5) OCT & Ophthalmologist 44,558 10.566 4,789 0.094 51,214 
 2) FFA & Ophthalmologist 44,649 10.575 91 0.009 10,545 
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OCT 
diagnostic 
specificity 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 4) OCT & OCT 62,652 10.441 18,003 -0.134 -134,416 
 1) FFA & OCT 62,759 10.449 18,110 -0.126 -144,229 
 7) Ophthalmologist & OCT 62,778 10.449 18,129 -0.126 -143,662 
 
 
Table 36 One-way sensitivity analysis – OCT monitoring sensitivity 
Monitoring 
sensitivity 
OCT 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
0.9 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,607 10.465 1,838 -0.008 -224,403 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,131 10.567 2,482 -0.008 -293,938 
 1) FFA & OCT 63,312 10.503 18,663 -0.072 -260,619 
 7) Ophthalmologist & OCT 63,331 10.503 18,682 -0.072 -258,561 
 4) OCT & OCT 67,974 10.495 23,325 -0.080 -293,337 
1 3) FFA & Nurse 39,769 10.473    
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 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,607 10.465 1,838 -0.008 -224,403 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,131 10.567 2,482 -0.008 -293,938 
 1) FFA & OCT 64,277 10.600 19,628 0.025 788,482 
 7) Ophthalmologist & OCT 64,296 10.599 19 -0.001 -28,229 
 4) OCT & OCT 68,939 10.592 4,662 -0.008 -565,643 
 
 
Table 37 One-way sensitivity analysis – OCT monitoring specificity 
Monitoring 
specificity 
OCT 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
Effectiveness 
ICER 
0.3 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,607 10.465 1,838 -0.008 -224,403 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,131 10.567 2,482 -0.008 -293,938 
 1) FFA & OCT 74,212 10.459 29,563 -0.116 -255,643 
 7) Ophthalmologist & OCT 74,230 10.459 29,581 -0.116 -254,397 
 4) OCT & OCT 80,083 10.452 35,434 -0.123 -287,514 
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Monitoring 
specificity 
OCT 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
Effectiveness 
ICER 
0.4 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,607 10.465 1,838 -0.008 -224,403 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,131 10.567 2,482 -0.008 -293,938 
 1) FFA & OCT 67,780 10.454 23,130 -0.121 -190,790 
 7) Ophthalmologist & OCT 67,798 10.453 23,149 -0.122 -189,953 
 4) OCT & OCT 72,979 10.446 28,330 -0.129 -219,784 
0.5 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,607 10.465 1,838 -0.008 -224,403 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,131 10.567 2,482 -0.008 -293,938 
 1) FFA & OCT 61,521 10.448 16,872 -0.127 -133,240 
 7) Ophthalmologist & OCT 61,540 10.448 16,891 -0.127 -132,734 
 4) OCT & OCT 66,049 10.441 21,400 -0.134 -159,275 
0.6 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
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Monitoring 
specificity 
OCT 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
Effectiveness 
ICER 
 6) OCT & Nurse 41,607 10.465 1,838 -0.008 -224,403 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,131 10.567 2,482 -0.008 -293,938 
 1) FFA & OCT 55,429 10.443 10,780 -0.132 -81,774 
 7) Ophthalmologist & OCT 55,449 10.443 10,800 -0.132 -81,537 
 4) OCT & OCT 59,286 10.435 14,636 -0.140 -104,824 
0.7 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,607 10.465 1,838 -0.008 -224,403 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,131 10.567 2,482 -0.008 -293,938 
 1) FFA & OCT 49,498 10.438 4,849 -0.137 -35,432 
 7) Ophthalmologist & OCT 49,518 10.438 4,869 -0.137 -35,418 
 4) OCT & OCT 52,683 10.430 8,033 -0.145 -55,508 
0.8 3) FFA & Nurse 39,769 10.473    
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,607 10.465 1,838 -0.008 -224,403 
 1) FFA & OCT 43,721 10.433 3,952 -0.040 -99,944 
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Monitoring 
specificity 
OCT 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
Effectiveness 
ICER 
 7) Ophthalmologist & OCT 43,742 10.433 3,973 -0.040 -98,928 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 4) OCT & OCT 46,234 10.425 1,585 -0.150 -10,589 
 5) OCT & Ophthalmologist 47,131 10.567 2,482 -0.008 -293,938 
0.9 1) FFA & OCT 38,093 10.429    
 7) Ophthalmologist & OCT 38,114 10.428 21 -0.001 -34,221 
 3) FFA & Nurse 39,769 10.473 1,676 0.044 37,884 
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 4) OCT & OCT 39,934 10.421 164 -0.052 -3,146 
 6) OCT & Nurse 41,607 10.465 1,838 -0.008 -224,403 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,131 10.567 2,482 -0.008 -293,938 
1 1) FFA & OCT 32,608 10.424    
 7) Ophthalmologist & OCT 32,629 10.423 21 -0.001 -35,125 
 4) OCT & OCT 33,776 10.416 1,168 -0.008 -144,031 
 3) FFA & Nurse 39,769 10.473 7,161 0.049 146,783 
 9) Ophthalmologist & Nurse 39,790 10.472 21 -0.001 -33,237 
 6) OCT & Nurse 41,607 10.465 1,838 -0.008 -224,403 
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Monitoring 
specificity 
OCT 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
Effectiveness 
ICER 
 2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768 
 8) Ophthalmologist & Ophthalmologist 44,669 10.574 20 -0.001 -31,094 
 5) OCT & Ophthalmologist 47,131 10.567 2,482 -0.008 -293,938 
 
 
Table 38 One-way sensitivity analysis – OCT unit cost 
Unit cost 
OCT 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
30 9) Ophthalmologist & Nurse 37,446 10.472    
 3) FFA & Nurse 37,446 10.473 1 0.001 835 
 6) OCT & Nurse 39,071 10.465 1,625 -0.008 -198,353 
 8) Ophthalmologist & Ophthalmologist 42,317 10.574 4,870 0.102 47,980 
 2) FFA & Ophthalmologist 42,318 10.575 1 0.001 1,398 
 5) OCT & Ophthalmologist 44,586 10.567 2,268 -0.008 -268,648 
 7) Ophthalmologist & OCT 60,434 10.449 18,116 -0.126 -143,560 
 1) FFA & OCT 60,436 10.449 18,118 -0.126 -144,295 
 4) OCT & OCT 64,885 10.442 22,567 -0.133 -169,320 
40 3) FFA & Nurse 38,538 10.473    
 9) Ophthalmologist & Nurse 38,548 10.472 9 -0.001 -15,184 
 6) OCT & Nurse 40,263 10.465 1,725 -0.008 -210,601 
107 
 
Unit cost 
OCT 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
 2) FFA & Ophthalmologist 43,414 10.575 4,875 0.102 47,723 
 8) Ophthalmologist & Ophthalmologist 43,423 10.574 9 -0.001 -13,878 
 5) OCT & Ophthalmologist 45,783 10.567 2,369 -0.008 -280,538 
 1) FFA & OCT 61,528 10.449 18,114 -0.126 -144,264 
 7) Ophthalmologist & OCT 61,536 10.449 18,122 -0.126 -143,608 
 4) OCT & OCT 66,078 10.442 22,664 -0.133 -170,044 
50 3) FFA & Nurse 39,630 10.473    
 9) Ophthalmologist & Nurse 39,650 10.472 19 -0.001 -31,202 
 6) OCT & Nurse 41,456 10.465 1,825 -0.008 -222,848 
 2) FFA & Ophthalmologist 44,510 10.575 4,879 0.102 47,763 
 8) Ophthalmologist & Ophthalmologist 44,529 10.574 19 -0.001 -29,154 
 5) OCT & Ophthalmologist 46,979 10.567 2,469 -0.008 -292,428 
 1) FFA & OCT 62,620 10.449 18,110 -0.126 -144,233 
 7) Ophthalmologist & OCT 62,638 10.449 18,128 -0.126 -143,656 
 4) OCT & OCT 67,270 10.442 22,760 -0.133 -170,767 
60 3) FFA & Nurse 40,722 10.473    
 9) Ophthalmologist & Nurse 40,752 10.472 29 -0.001 -47,221 
 6) OCT & Nurse 42,648 10.465 1,926 -0.008 -235,095 
 2) FFA & Ophthalmologist 45,606 10.575 4,884 0.102 47,803 
 8) Ophthalmologist & Ophthalmologist 45,635 10.574 29 -0.001 -44,429 
 5) OCT & Ophthalmologist 48,176 10.567 2,569 -0.008 -304,319 
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Unit cost 
OCT 
Strategy Cost QALYs Incremental 
Cost 
Incremental 
QALYs 
ICER 
 1) FFA & OCT 63,712 10.449 18,106 -0.126 -144,201 
 7) Ophthalmologist & OCT 63,740 10.449 18,134 -0.126 -143,703 
 4) OCT & OCT 68,462 10.442 22,856 -0.133 -171,491 
70 3) FFA & Nurse 41,814 10.473    
 9) Ophthalmologist & Nurse 41,854 10.472 39 -0.001 -63,240 
 6) OCT & Nurse 43,840 10.465 2,026 -0.008 -247,342 
 2) FFA & Ophthalmologist 46,702 10.575 4,888 0.102 47,842 
 8) Ophthalmologist & Ophthalmologist 46,741 10.574 39 -0.001 -59,705 
 5) OCT & Ophthalmologist 49,372 10.567 2,670 -0.008 -316,209 
 1) FFA & OCT 64,805 10.449 18,102 -0.126 -144,170 
 7) Ophthalmologist & OCT 64,842 10.449 18,140 -0.126 -143,751 
 4) OCT & OCT 69,655 10.442 22,953 -0.133 -172,214 
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Scenario analysis 
Scenario analysis favouring the OCT test was conducted to explore conditions under which 
OCT only based strategies could become cost-effective. The scenarios are described in section 
7.2.6 and the input data used reported in Table 30. Best possible OCT test sensitivity and 
specificity were incorporated into the model. In addition, the lowest possible unit cost for OCT 
and a higher assumed unit cost value for FFA were used. Scenario 2 differs in the unit cost 
assumed for each treatment injection (£50) and scenario 3 explores community monitoring (e.g. 
unit cost for OCT as for community optometrist and an ophthalmologist visit cost added only 
when treatment was needed).  Tables 39 to 41 show the scenario analysis results.  For scenario 
1 (Table 39) and scenario 3 (Table 41) strategies that based their diagnosis or monitoring 
decisions on OCT test results only are dominated  (i.e. have higher expected costs and lower 
expected QALYs). It should be noted that, due to the lower unit cost for the OCT test, the 
strategy with the lower expected cost is diagnosis by an ophthalmologist combined with nurse 
or technician-led monitoring.   
 
Table 39 Scenario analysis 1 
Strategy Cost (£) Incremental 
Cost (£) 
QALYs Incremental 
QALYs 
ICER (£) 
9) Ophthalmologist & 
Nurse 
 36,320   -    10.478   
3) FFA & Nurse  36,707   387  10.471 -0.007 -54,280 
6) OCT & Nurse  37,417   1,097  10.470 -0.008 -140,873 
8) Ophthalmologist & 
Ophthalmologist 
 41,284   4,964  10.579 0.101 49,012 
2) FFA & 
Ophthalmologist 
 41,740   456  10.573 -0.006 -73,232 
5) OCT & 
Ophthalmologist 
 42,781   1,497  10.573 -0.007 -218,869 
7) Ophthalmologist & 
OCT 
 48,241   6,957  10.536 -0.043 -161,687 
1) FFA & OCT  48,791   7,507  10.530 -0.050 -151,253 
4) OCT & OCT  50,273   8,989  10.529 -0.050 -179,277 
 
Table 40 shows results for scenario 2 (i.e. the same input data as for scenario 1 but assuming 
cost of treatment of £50 per injection). The pathway strategy with the lowest cost is the 
ophthalmologist stepwise diagnosis followed by monitoring decisions based on OCT only. The 
next costly strategy is the one that based the diagnosis decision on FFA only and the monitoring 
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treatment decision on OCT test results only.  However, this strategy is dominated by the former. 
The next non-dominated strategy was diagnosis by an ophthalmologist followed by an 
ophthalmologist led monitoring (e.g. ‘Ophthalmologist & Ophthalmologist’) with an ICERs of 
£19,917. This is within the usual £30,00074   threshold and potentially worthwhile to adopt. The 
Table 40 results indicate that OCT strategies could become cost-effective if the cost of treatment 
was lower. In terms of the economic model, this would be a lower penalisation for those 
strategies that treat individuals who do not need to be treated (i.e. those tests or strategies that 
result in lower specificity and therefore a higher number of false positive results). 
  
Table 40 Scenario analysis 2 
Strategy Cost (£) Incremental 
Cost (£) 
QALYs Incremental 
QALYs 
ICER (£) 
7) Ophthalmologist & 
OCT 
 13,983   -    10.536   
1) FFA & OCT  14,158   175  10.530 -0.007 -26,423 
4) OCT & OCT  14,583   600  10.529 -0.007 -84,256 
8) Ophthalmologist & 
Ophthalmologist 
 14,840   857  10.579 0.043 19,917 
2) FFA & 
Ophthalmologist 
 15,024   184  10.573 -0.006 -29,567 
5) OCT & 
Ophthalmologist 
 15,477   636  10.573 -0.007 -93,000 
9) Ophthalmologist & 
Nurse 
 15,601   761  10.478 -0.101 -7,511 
3) FFA & Nurse  15,790   949  10.471 -0.108 -8,757 
6) OCT & Nurse  16,218   1,377  10.470 -0.109 -12,627 
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Table 41 Scenario analysis 3 
Strategy Cost (£) Incremental 
Cost (£) 
QALYs Incremental 
QALYs 
ICER (£) 
9) Ophthalmologist & 
Nurse 
 36,320   -    10.478 0.000 0 
3) FFA & Nurse  36,707   387  10.471 -0.007 -54,280 
6) OCT & Nurse  37,417   1,097  10.470 -0.008 -140,873 
8) Ophthalmologist & 
Ophthalmologist 
 41,284   4,964  10.579 0.101 49,012 
2) FFA & 
Ophthalmologist 
 41,740   456  10.573 -0.006 -73,232 
5) OCT & 
Ophthalmologist 
 42,781   1,497  10.573 -0.007 -218,869 
7) Ophthalmologist & 
OCT 
 43,527   2,243  10.536 -0.043 -52,132 
1) FFA & OCT  44,018   2,734  10.530 -0.050 -55,084 
4) OCT & OCT  45,257   3,974  10.529 -0.050 -79,247 
 
7.2.9 Summary and discussion 
This chapter reported on a systematic review of economic evaluations and a model-based 
economic evaluation of alternative strategies for the diagnosis and monitoring of individuals 
with nAMD.  No studies identified in the literature met the inclusion criteria for the systematic 
review. 
 
Nine strategies (combinations of three different diagnostic and monitoring pathways) were 
considered within the economic model. The strategies used to a different extent OCT for 
diagnosis and/or monitoring of nAMD individuals. Extensive deterministic and probabilistic 
sensitivity analyses were conducted. The strategy that based its diagnosis decision on the results 
of FFA only, combined with VA and OCT interpreted together by a nurse or technician as the 
first monitoring step, with a referral to an ophthalmologist if the first monitoring assessment 
was positive or unclear (‘FFA & Nurse’), had the lowest expected total cost. This strategy 
dominated (i.e. lower expected costs and higher expected QALYs) all others apart from one: 
diagnosis with FFA only, combined with monitoring by an ophthalmologist (‘FFA & 
Ophthalmologist’). The ‘FFA & Nurse’ and ‘FFA & Ophthalmologist’ strategies had, 
respectively, a 46.5% and 29.8% probability of being cost-effective at the £30,000 threshold 
value of willingness to pay for an extra QALY. In addition, the ‘FFA & Nurse’ strategy 
dominated all others in the great majority of sensitivity analyses. 
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The strategies that used OCT only for their monitoring decisions were in almost every model 
run ordered last in terms of total expected cost and were often dominated by others. The strategy 
that used OCT only for both diagnosis and monitoring decisions was in almost every model run 
the most costly strategy. 
 
Scenario analysis was conducted in order to explore the conditions under which an OCT only 
strategy would become cost-effective. Three scenarios were developed using the best test 
performance data for OCT combined with a lower cost for OCT (£20.90) and a higher cost for 
FFA (£137).  Scenario 2 added to this a lower unit cost for treatment (e.g. equivalent to the cost 
of bevacizumab, £50, instead of the £742 cost of ranibizumab considered for the base case 
analysis). This scenario showed the ophthalmologist stepwise pathway for diagnosis combined 
with OCT only for monitoring, to be, on average, the least costly strategy. Alternative strategies 
were either dominated (i.e. more costly and produced fewer QALYs) or the resulted ICER was 
well above the usual threshold accepted for policy decisions.74 This was an expected result. The 
low OCT specificity for monitoring in these scenarios and in the base case (0.61 and 0.44, 
respectively) meant that a high number of positive results would actually be false positives. The 
lower cost of treating individuals who do not need to be treated reduced the model penalisation 
for the OCT only based strategies and therefore improved their cost-effectiveness. 
 
Best practice guidelines were followed for this model-based economic evaluation exercise.74,82  
In spite of this, these results should be interpreted with caution. A considerable effort was made 
to retrieve the best available test or assessment performance data by conducting a systematic 
review of the literature. Other data were obtained from focused but reproducible searches. 
Nevertheless, there is an inherent problem with model-based economic evaluations that 
incorporate evidence from several sources, even when these data have been obtained 
systematically. The limitations of the SD-OCT performance data incorporated into the 
economic model have been mentioned in chapter 6, with only two and three studies, 
respectively, contributing to the diagnosis and monitoring performance data. Moreover, while 
OCT diagnosis and monitoring performance data were retrieved from a systematic review of 
the literature, no such data were available for the strategies involving diagnosis or monitoring 
assessment by an ophthalmologist or monitoring assessment by a nurse or technician. 
Therefore, these data for the model were obtained from expert opinion. This constitutes a major 
caveat of the analysis and further research in this area is needed. 
 
This economic model needed to consider individuals’ disease status (i.e. active or inactive 
nAMD) as well as test results on a monthly basis. In addition, these had to be combined with 
alternative visual acuity states in order to incorporate to utility weights into the model. It was 
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felt that considering the effect of a fellow eye status (VA and nAMD status) would add major 
complexity to the model without a great deal of benefit from such incorporation. This is the 
most common approach used among economic models in this health area but constitutes a 
limitation of the current study. Utility weights used were obtained from nAMD individuals and 
grouped according to visual acuity in the better-seeing eye. It is believed that this would better 
reflect individuals’ health status. However, the clear limitation of ‘one eye models’ is the 
underestimation of resources used. A proportion of monitored nAMD individuals will have this 
condition in both eyes instead of one, and, had the disease been active, would be receiving 
treatment injections in each eye.  Intuitively, this would increase the treatment cost for those 
strategies with a higher number of (true and false) positive results (i.e. higher sensitivity and 
lower specificity) and hence would be unlikely to modify the overall conclusions of this 
economic evaluation. 
 
The model did not consider effects on utility due to treatment injections. Anxiety in nAMD 
individuals was believed to occur at each monitoring visit mainly due to the uncertainty of the 
underlying condition (i.e. whether or not nAMD was active) and not the effects of the treatment 
injections.  No evidence was obtained on this issue in spite of focused searches. Further research 
in this area is needed. Utility weight decrements from treatment adverse effects were included 
and this might partially overcome the above-mentioned potential limitation.  
 
Limited evidence was available on the probability of nAMD active individuals becoming 
inactive when under treatment or inactive nAMD individuals becoming active. Data were 
retrieved from the literature and also from a UK-based RCT.9  Survival data were received from 
the IVAN study [personal communication - Dr Chris Rogers, 12th June 2013] on first re-
treatment failure criteria (i.e. inactive individuals who needed to be re-treated). These were used 
to develop model parameter values for the first year of the model run. There were no such data 
available for further failures and we had to rely on the available limited data from the literature69 
or on expert opinion for year 2 onwards. In addition, progression data on visual acuity were 
based on the two year follow-up MARINA study.68  All of these were relatively short term 
follow-up studies (around two years) but used to inform model parameters for a lifetime time 
horizon. These are clear limitations of the model and therefore its results should be interpreted 
with caution.  Further research investigating individuals’ nAMD active/inactive status (e.g., 
probability of disease changing from inactive to active) would be desirable.  
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7.2.10 Conclusions 
A strategy that based its diagnostic decision on the results of FFA only, combined with VA and 
OCT interpreted together by a nurse or technician as a first monitoring step, with a referral to 
an ophthalmologist if this first monitoring assessment was positive or unclear, had the lowest 
expected total cost. This strategy had a 46.5% probability of being cost-effective at a £30,000 
threshold value of willingness to pay for an extra QALY. In addition, this strategy dominated 
all others apart from one (i.e. diagnosis with FFA combined with ophthalmologist-led 
monitoring) in the great majority of sensitivity analyses. Strategies that used OCT test results 
alone to make diagnosis or monitoring treatment decisions were unlikely to be a cost-effective 
use of resources. This result seemed to be driven by the OCT low specificity that resulted in a 
high number of false positive results. The present analysis indicated that a further refinement 
of monitoring (i.e. a further monitoring step other than OCT alone) seemed desirable.  
 
These results should be interpreted with caution. The economic model would benefit from 
further research to better inform a number of model parameter values. Studies that investigate 
the likelihood of nAMD individuals becoming active or inactive after subsequent treatments 
are desirable.  In addition, a preference-based health status and process of care valuation study 
to explore the effects of treatment injections on individuals’ utility weights is needed. Finally, 
a comparative study to establish the performance of the ophthalmologist-based strategy 
compared with the nurse or technician-based strategy for monitoring individuals with nAMD 
is required to inform future economic models in this area. 
 
115 
 
8  ASSESSMENT OF FACTORS RELEVANT TO THE NHS AND OTHER  
  PARTIES 
 
The introduction of OCT and other diagnostic technologies for diagnosis and monitoring of 
patients with nAMD has a range of implications for the NHS, patients and other parties. There 
has already been a shift in the diagnostic pathway for this group of patients caused by the 
adoption of OCT, rather than the previously used FFA, as a method of establishing the diagnosis 
and of evaluating disease activity.  There are consequential effects not only on patient outcomes 
but also on service delivery, health care professionals and wider society of this change in 
preferred diagnostic technologies used.   
 
8.1 Factors relevant to the NHS 
8.1.1 Estimating the numbers of patients with nAMD 
A summary of the epidemiology of nAMD has been described in this study.   In brief, the 
prevalence and incidence of nAMD and the consequent burden to the NHS will increase over 
the next few decades because of the ageing population.  By 2060, mean life expectancy will 
grow by 8.5 years for men (to 84.5 years) and 6.9 years for women (to 89.0 years).83    
 
8.1.2 Implications for service provision 
The clinical workload associated with the frequent follow-up required for patients with nAMD 
is substantial.  As more new patients are diagnosed and the population continues to age, the 
patient population will continue to increase. It is thus vital that clinical services continue to 
adapt so that they can provide a fast and efficient service for patients with nAMD.    
 
There are still challenges and questions about whether ophthalmology departments have 
sufficient capacity and the means to offer relevant testing and treatments within adequate 
timescales.  Local diagnostic pathways require updating and assessment to ensure compliance 
with national guidelines e.g., to detect recurrence of active disease in these subjects.  Occasional 
local disruptions may occur if OCT equipment suffers technical failures.  
 
In 2012 Amoaku et al. published a document entitled “Action on AMD” that was developed by 
eye healthcare professionals and patient representatives with the intention of highlighting the 
urgent and continuing need for change within wet AMD services.55 This document also 
provided examples of good practice and service development, including the possibility of 
involving other health care professionals and using OCT in the community.   
  
116 
 
8.1.3 Considerations regarding the performance of OCT for diagnosis and monitoring 
At the diagnostic stage OCT is currently used in addition to FFA to provide a baseline that will 
be used for comparisons during the monitoring stage.   
 
For monitoring, OCT has virtually replaced FFA in most NHS units.84  During follow-up, 
monitoring also includes visual acuity testing.  There is larger variability in the adoption of 
other tests and perceived need for FFA during follow-up.  The replacement of FFA is probably 
due to the convenience of OCT (e.g. non-invasive, user friendly, quick, efficient).  However, 
expert clinicians recognise the difficulty of interpreting FFA and OCT in patients with 
previously treated nAMD who often develop atrophic changes.  The low specificity of OCT 
observed in this study would suggest that OCT alone should not be used for monitoring.     
 
Another consideration is the evolving technology.  For example, theoretically an increased 
sensitivity and specificity of new versions or novel technologies (SD-OCT) would lead to more 
patients being correctly diagnosed with active nAMD, and fewer wrongly diagnosed as having 
no active disease.  This review did not find sufficient evidence on the performance of SD-OCT 
and it is unclear if it is superior than TD-OCT.    
 
Regarding cost implications, there will be little cost implications for procuring and maintaining 
OCT equipment because most centres already use this technology.  While many units will 
already have access to the new SD-OCT equipment, other centres may have to upgrade the 
current TD-OCT (e.g., purchase or lease new SD-OCT equipment).   
 
There may be a need for training ophthalmology staff to ensure adequate technical skills to 
interpret the OCT scans. There is a learning curve to interpreting OCT images, especially in 
relation to those patients who are being monitored after treatment.  Adequate quality control 
and quality assurance programmes would be needed in order to maintain high standards of 
interpretation.  
 
8.2 Factors relevant to patients and other parties 
A highly specific test may reduce the number of patients undergoing unnecessarily treatment 
with anti-VEGF injections, avoiding the associated discomfort, side effects and possible 
complications.  Using OCT alone for diagnosis or monitoring would be associated with a 
number of false positives and unnecessary treatments.  From the efficiency point of view, a 
specificity of at least 80% would be required for a monitoring strategy using OCT alone to be 
cost-effective.  
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From a patient preference point of view, if the diagnostic performance were adequate, it is likely 
that patients would prefer OCT when compared with FFA because of the unpleasantness of the 
latter procedure.  
 
Monitoring in the community would be a positive development for patients and carers, who 
would have less distance to travel to access OCT testing.  This may be possible as OCT is 
becoming increasingly used by community optometrists but would need to be associated with 
another test (e.g. visual acuity).  Local arrangements and financial support would need to be 
put in place as community optometrists would need to be trained and reimbursed for their 
services.  Community optometrists should also be able to communicate their findings in a timely 
and efficient way to clinicians in secondary care.  However, inequalities in access may arise as 
people from disadvantaged socio-economic backgrounds may be reluctant to attend private 
community optometrists.  
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9  DISCUSSION 
 
9.1 Diagnostic accuracy 
9.1.1 Statement of principal findings 
Diagnostic studies 
Twenty-two diagnostic studies were included (20 full-text papers, two abstracts) involving over 
2000 participants.  The studies reported the performance of OCT (13 studies;), ICGA (eight 
studies), PHP (three studies), colour fundus photography, Amsler grid and FAF (one study 
each) in the detection of nAMD.  Studies that reported true and false positive and negative 
results or provided information that allowed these data to be calculated were considered for 
inclusion in pooled estimates (meta-analyses), which were performed with eye as the unit of 
analysis.  
 
Full-text papers were assessed for risk of bias using the QUADAS-2 tool.  The domains with 
the greatest number of studies judged to be at high risk of bias were the patient selection domain 
(55%, 11/20), for reasons such as inappropriate exclusions and pre-selection of participants, 
and the flow and timing domain (40%, 8/20), for reasons such as the length of time between 
the index test and the reference standard being longer than one week, and not all participants 
being included in the analysis.  In the index/comparator test domain and reference standard 
domain the risk of bias was judged to be unclear in around half of the studies [50% (10/20) and 
60% (12/20) respectively].  However, all of the studies were judged to be of low concern in 
terms of their applicability to the review question. 
 
Only four OCT diagnostic studies (all TD-OCT) provided sufficient data for inclusion in a 
meta-analysis.  The pooled sensitivity and specificity (95% CI) for all OCT was moderately 
high at 88% (46% to 98%) and 78% (64% to 88%) respectively.   
 
Of the other tests of interest, median sensitivity [range] was similarly high for ICGA (93.2% 
[84.6% to 100%]; four studies) and FAF (93.3%; one study), followed by PHP (81.5% [50.0% 
to 84.8%]; three studies) and colour fundus photography (70.0%; one study) and was lowest for 
Amsler Grid (41.7%; one study).  Specificity was highest for colour fundus photography (95%; 
one study), followed by PHP (84.6% and 87.7%; two studies), and was similarly low for FAF 
(37.1%; one study) and ICGA (36.8%; one study).   
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Two studies reported test combinations.  For OCT plus colour fundus photography, sensitivity 
was moderate at 74.1%, with specificity high at 92.0%.  For colour fundus photography plus 
visual acuity sensitivity was low at 53.0% but again specificity was high at 94.0%. 
 
Monitoring studies 
Eight monitoring studies were included (all full-text) involving over 400 participants.  Seven 
reported the performance of OCT (three TD-OCT, three SD-OCT, one both types) and one the 
performance of ICGA in the detection of nAMD activity.  As with the diagnostic studies, the 
QUADAS-2 domains with the greatest number of monitoring studies judged to be at high risk 
of bias were the patient selection domain (25%, 2/8) and flow and timing domain (25%, 2/8), 
for similar reasons to those reported above.  In the index/comparator test domain and reference 
standard domain the risk of bias was judged to be unclear in 50% (4/8) and 37.5% (3/8) of 
studies respectively.  Similar to the diagnostic studies, all of the monitoring studies were judged 
to be of low concern in terms of their applicability to the review question.     
 
Four of the OCT studies provided sufficient data for inclusion in a meta-analysis.  The pooled 
sensitivity (95% CI) for all OCT was moderately high at 85% (72% to 93%) but with low 
specificity at 48% (30% to 67%).  For TD-OCT, the pooled sensitivity and specificity was 
moderate at 70% (56% to 80%) and 65% (48% to 79%) respectively.  It was not possible to 
calculate pooled estimates for the two SD-OCT studies using hierarchical summary receiver 
operating characteristic (HSROC) methodology due to insufficient data.  These studies reported 
sensitivities of 94%29 and 90%15 and specificities of 27% 29 and 47%.15 These results broadly 
reflect those of the diagnostic studies in terms of SD-OCT having higher sensitivity but lower 
specificity than TD-OCT.  In particular the specificity of the SD-OCT monitoring studies was 
quite low.      
 
Other than OCT, one study reported ICGA, with sensitivity of 75.9% and specificity of 88.0% 
for the detection of active nAMD.   
 
9.1.2 Strengths and limitations of the assessment 
In terms of strengths, a comprehensive literature search was undertaken and non-English 
language studies were included.  Risk of bias was assessed using a modified QUADAS-2 
questionnaire, tailored to the needs of this review.  A HSROC model was used for the analysis, 
which takes account of the trade-off between true/false positives and models between-study 
heterogeneity.85  The evidence for diagnosis and monitoring was considered separately.  In 
addition to the pooled estimates for all OCT, separate pooled estimates were undertaken for 
TD-OCT and SD-OCT, but for SD-OCT it was not possible to use HSROC methods. 
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 There was a very limited amount of evidence available for evaluating the diagnostic and 
monitoring performance of SD-OCT ( and limited evidence for the performance of TD-OCT  
with regard to its role in surveillance monitoring of those previously diagnosed with nAMD.  
Although this review considered a number of alternative tests, only a few of these were reported 
by studies that met our inclusion criteria.  There was insufficient information to address the 
questions of (1) the clinical effectiveness of OCT compared with FFA, (2) the acceptability of 
the tests and (3) the performance of other health professionals compared with ophthalmologists 
in interpreting OCT findings.    
 
9.1.3 Uncertainties 
Reference standard   
FFA interpreted by an ophthalmologist was our reference standard test and as such was assumed 
to have perfect sensitivity and specificity for the detection of active nAMD.  Therefore it was 
not possible to address the question of whether OCT might actually have better sensitivity or 
specificity than FFA; the optimal judgement that could have been made about OCT was that it 
had equally high sensitivity and specificity as FFA.  In fact although OCT did have very high 
sensitivity the specificity for diagnosis and monitoring was suboptimal. 
 
Glasziou et al.86 considered the question of when a new test should replace the existing 
reference standard.  They suggested that this might be determined by a ‘fair umpire’ test applied 
to the cases where the new test and reference standard differed.  This third test, although 
potentially less accurate than either the new test or reference standard, could be considered a 
fair umpire, if its errors were considered to be independent of the other tests, although it was 
acknowledged that this would usually be difficult to demonstrate.  Possible umpires suggested 
included causal exposures, concurrent testing, prognosis, or response to treatment.  Glasziou et 
al.86 argued that using this approach, the umpire test might be able to distinguish which test was 
the better reference standard.  An example given was that of a new test for tuberculosis, with 
the tuberculin skin test as the reference standard, interferon-γ enzyme-linked immunospot 
(ELISpot) assays as the new test and tuberculosis exposure as the fair umpire.86  However none 
of the studies included in our review provided a sufficient level of information to allow such a 
‘fair umpire’ approach to be applied.   
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False positives 
Excluding studies where information was only available for detection of phenotypes,33,36,37,51 
specificity for OCT was reported by six15,27,29,31,44,52 of seven monitoring studies but only 
four26,39,45,48 of ten diagnostic studies.   
 
As already reported, specificity for OCT for diagnosis was only moderate and for monitoring 
was lower, with a large number of false positive results.  A few studies provided some additional 
information on their false positive results, with suggested reasons for these including the 
presence of a disciform scar with persistent cystic cavities,44 an increase in the central subfield 
measurement,26 drusen/atrophy ,45,48 cystoid abnormalities ,15 subretinal fluid being detected 
before FFA leakage was observed,39 and the detection of remnants of intraretinal fluid that had 
not yet been resorbed even though the underlying CNV was no longer actively leaking fluid .31  
Do et al.26 suggested that SD-OCT may have lower specificity for the detection of CNV 
compared with TD-OCT because it is more likely to detect structural changes in the retina, 
which may be a normal anatomic variant and not necessarily representative of secondary 
changes in the retina owing to CNV. 
 
Sandhu et al.45 noted that the OCT false positive rate was reduced with the addition of stereo 
colour images (separate test).  In current practice OCT is typically associated with visual acuity 
data which may improve the specificity of the test. 
 
In two of the monitoring studies15,29 participants had been treated with anti-VEGF therapy while 
in five27,31,44,52 they had been treated with PDT.  For all OCT, median sensitivity was similar 
across the anti-vascular endothelial growth factor (anti-VEGF) (90%) and photodynamic 
therapy (PDT) (88%) groups of studies, while median specificity was slightly higher across the 
PDT studies (51%) compared with the anti-VEGF studies (43%)  It is possible that following 
treatment with PDT there is less likelihood of having fluid in the retina than following therapy 
with anti-VEGF, as fluid is a common feature in eyes treated with anti-VEGF, even after many 
sessions of treatment.  Currently PDT is rarely used for nAMD, but the reviewed literature 
reflects this older modality of treatment.  OCT (especially the newer version with the highest 
resolution, SD-OCT) may detect fluid, even when only a small amount is present and it does 
not necessarily relate to CNV activity (e.g. fluid may be present if there is RPE 
dysfunction/damage as a result of the disease or its treatment, as in normal circumstances RPE 
pumps fluid out of the retina).  Therefore it is possible that there might be more OCT false 
positives resulting in lower specificity for detecting active nAMD following anti-VEGF 
compared with PDT treatment.   
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In two diagnostic studies, by Kozak et al.35 and Reichel et al.43 some patients were classed as 
having nAMD who were negative on FFA but positive on one of the other tests being assessed 
(13/541 eyes by TD-OCT in the Kozak study35  and 4/20 participants by ICGA in the Reichel 
study).43  For the purposes of this review these cases were considered to be test false positives 
(as the reference standard of FFA was considered to have perfect sensitivity and specificity).  
However, in some cases (e.g., with retinal haemorrhage) it is possible that ICGA may be better 
than FFA in detecting nAMD.   
 
Heterogeneity across the studies 
Other than the fact that one group of studies was concerned with initial diagnosis of nAMD and 
another with monitoring of those previously diagnosed, there were a number of other 
differences across the studies.  In terms of differences across the participant groups, the 
prevalence of nAMD in the diagnostic studies ranged from 17.2% to 100% (median 80.0%) 
and of active nAMD in the monitoring studies from 49.2% to 83.3% (median 57.9%).  The 
proportion of participants classed as having specific nAMD phenotpyes (e.g. classic CNV, 
occult CNV) varied across the studies.  In eight diagnostic studies and one monitoring study 
participants were judged to have been pre-selected.     
 
Detection of phenotypes 
Twelve studies (eight diagnostic,24,32,33,36,37,40,45,48 four monitoring15,29,31,51) reported the 
sensitivity of OCT in the detection of nAMD phenotypes (predominantly classic, minimally 
classic, occult or retinal angiomatous proliferation (RAP)).  None of the studies reported 
detection of idiopathic polypoidal choroidal vsculopathy (IPCV).  Results were mixed, and 
overall there was insufficient evidence to understand whether the performance of OCT differs 
among the different phenotypes.  The monitoring study by Giani et al29 (SD-OCT) reported 
high sensitivity for the detection of both classic and occult CNV activity (90.9% and 100% 
respectively). 
 
Across four (TD-OCT) diagnostic studies24,33,36,37 reporting detection of RAP the median 
(range) sensitivity was 65% (50% to 100%).  Of the monitoring studies, Khurana et al.15 
reported higher sensitivity for SD-OCT (59%) compared with TD-OCT (35%) for detecting 
retinal cystoid abnormalities, while van de Moere et al.51  reported poor sensitivity for SD-OCT 
for detecting cystoid macular oedema (23%) and pigment epithelial detachment (6%).     
 
Unit of analysis issues 
Twelve OCT studies used one eye per patient in the analysis.24,26,32-37,39,44,45,48  In three of these 
studies24,26,39 the inclusion criteria stipulation for the fellow eye meant that only one (study) eye 
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per subject was eligible for analysis.  In the remaining studies the inclusion criteria were such 
that both eyes of some subjects might have been potentially eligible.15,35,36,40,44,45  Of these, 
however, only the study by van de Moere et al.51 reported the method used for selecting the 
study eye in the event of such a situation, stating that if both eyes were eligible one eye was 
randomly chosen for analysis.  It was unclear from the other studies whether only one eye per 
subject had met the inclusion criteria or whether for some subjects both eyes were eligible but 
only one was selected.    
 
In six OCT studies both eyes of some participants met the inclusion criteria and were included 
in the analysis;15,35,36,40,44,45 however none of these studies mentioned the issue of the possible 
influence that the non-independence of the fellow eye might have on the analysis.   
 
All studies included in the meta-analyses used one eye per subject, apart from the study by 
Sandhu et al.45 (meta-analysis of diagnostic studies) and the study by Khurana et al.15 (meta-
analysis of monitoring studies).  In the study by Sandhu et al45 131 eyes of 118 patients were 
included in the analysis, as 13 patients had bilateral activity.  In the study by Khurana et al.15 
59 eyes of 56 patients were included in the analysis, as three patients had received anti-VEGF 
treatment for nAMD in both eyes.  These studies did not report whether any adjustment had 
been made to take account of the non-independence of the fellow eye and contained an 
insufficient level of detail to allow for an exploration of this issue.  However the potential 
impact of fellow eye non-independence would probably be minor, at most, given the small 
number of subjects in the two studies for whom both eyes were included in the analysis. 
 
9.1.4 Other relevant factors 
Ongoing studies 
No ongoing studies were identified of OCT or alternative tests of interest compared with a 
reference standard of FFA for the diagnosis, monitoring and guiding of treatment for nAMD. 
 
Comparison of our results with other systematic reviews/HTAs 
Our searches identified four HTA reports that included an assessment of OCT in the detection 
of nAMD.12,87-89  The German HTA report by Sturzlinger et al,88 (report summary in English, 
full-text in German) published in 2007, considered head-to-head comparisons between OCT 
and FFA for newly presenting patients.  Eight studies were included, of which three were 
included in our review.32,34,45  The other five studies did not meet our inclusion criteria 
(assessment of retinal pigment epithelial tear,90 retinal pigment epithelial detachment,91 
drusen,92 geographic atrophy,93 and no diagnostic outcomes reported).94  The report’s 
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conclusions were that although OCT yielded diagnostic findings in addition to FFA results, 
OCT could not replace FFA during the primary diagnostic procedure.    
 
The Belgian Health Care Knowledge Centre report by van den Bruel et al,889 published in 2008, 
considered five ophthalmic tests in clinical practice, including OCT.  The assessment identified 
the German HTA report and included an additional three studies,27,36,44 all three of which were 
included in our review.  The review considered FFA as the reference standard for neovascular 
AMD, and, similar to our review, reported high sensitivity (96-97%) and moderate specificity 
(66%) of OCT in detecting choroidal neovascularisation.   
 
In the Australian MSAC report,87 published in 2009, OCT was compared a) with FFA or clinical 
observation in the diagnosis of macular diseases; b) in addition to FFA and clinical examination 
in the monitoring of patients with macular diseases; c) in addition to computerised perimetry 
and clinical examination in the diagnosis of glaucoma; and d) in addition to computerised 
perimetry and clinical examination in the monitoring of patients with glaucoma.  Regarding the 
diagnostic accuracy of OCT for AMD, the MSAC report concluded that due to the absence of 
a valid reference standard, the diagnostic accuracy of OCT for the detection of macular 
abnormalities could not be assessed. This approach contradicted our study, the German and 
Belgian HTA reports and also current practice in the UK where FFA is considered the reference 
standard for the diagnosis of nAMD.  
 
In the evidence-based analysis by the Medical Advisory Secretariat, Ontario, Canada,12 
published in 2009, OCT was compared with the reference standard of FFA for AMD and 
diabetic macular oedema.  The evaluation summarised the German HTA report and the study 
by Sandhu et al45 that was also included in our review.  This report also questioned the validity 
of FFA as a reference standard and presented conclusions that were based on expert 
consultations.    
 
Aflibercept 
In May 2013 NICE published final draft guidance recommending aflibercept solution for 
injection as an option for treating nAMD.  Full guidance is expected to be published in July 
2013.  The treatment and monitoring schedule for this drug differs from that of ranibizumab.  
According to the summary of product characteristics for aflibercept, treatment should be given 
monthly for three consecutive 2 mg doses, followed by one injection every two months, with 
no need for monitoring between injections.  After the first 12 months of treatment, the treatment 
interval may be extended based on visual and anatomic outcomes, with the schedule for 
monitoring determined by the treating doctor. It terms of the economic model, extending the 
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length of time between monitoring visits would reduce the cost associated with monitoring as 
well as the number of treatment courses needed. However, this would be expected to affect all 
model strategies in a similar manner and therefore would be unlikely to modify the general 
conclusions from the economic analysis. This might nevertheless reduce the cost associated 
with treatment and monitoring of nAMD patients for the NHS. 
 
Future technological developments 
It is likely that future technological developments in OCT will be introduced.  Most OCT 
devices create cross-sectional images of the retina.  En-face OCT technology is an emerging 
imaging technique derived from SD-OCT that creates images of frontal sections of retinal layers 
that are compatible with conventional fundus images.  
 
Another emerging technique is OCT angiography, which uses high-speed Fourier-domain OCT 
for non-invasive three-dimensional imaging of the vasculature and blood flow at the posterior 
part of the eye. 
 
9.2 Cost-effectiveness 
9.2.1 Statement of principal findings 
No studies met the inclusion criteria for the systematic review of economic evaluations as none 
compared diagnostic or monitoring strategies for individuals with nAMD. 
 
Nine strategies that used to a different extent OCT for diagnosis and/or monitoring of nAMD 
individuals were considered within the Markov cohort economic evaluation model.  The 
strategy that based its diagnosis decision on the results of FFA only, combined with VA and 
OCT interpreted together by a nurse or technician as the first monitoring step, with a referral to 
an ophthalmologist if the first monitoring assessment was positive or unclear (‘FFA & Nurse’), 
had the lowest expected total cost. This strategy dominated (i.e. lower expected costs and higher 
expected QALYs) all others apart from one: diagnosis with FFA only, combined with 
monitoring by an ophthalmologist (‘FFA & Ophthalmologist’). The ‘FFA & Nurse’ and ‘FFA 
& Ophthalmologist’ strategies had, respectively, a 46.5% and 29.8% probability of being cost-
effective at the £30,000 threshold value of willingness to pay for an extra QALY. In addition, 
the ‘FFA & Nurse’ strategy dominated all others in the great majority of sensitivity analyses. 
 
The strategies that used OCT only for their monitoring decisions were in almost every model 
run ordered last in terms of ascending total expected cost and were often dominated by others. 
126 
 
The strategy that used OCT as its only criteria for diagnosis and monitoring decisions was in 
almost every model run the most costly strategy. 
 
Results were sensitive to the unit cost of treatment injections. A scenario with a lower unit 
cost for treatment (e.g. £50, equivalent to the cost of bevacizumab, instead of £742 
considered for the base case analysis) resulted in the FFA only for diagnosis combined 
with OCT only for monitoring strategy having the lowest total expected cost. 
Alternative strategies were either dominated or had an ICER well above the usual 
threshold stated for cost-effectiveness (i.e. £30,000). 
 
9.2.2 Strengths and limitations of the economic assessment 
The major strength of the economic evaluation is that it attempted to use the best available 
evidence with the compared strategies developed from extensive discussions within the project 
team and advisory group. Best practice guidelines were followed for this economic evaluation 
exercise.74 For instance, test performance data were obtained from the systematic review of the 
literature with other data retrieved from focused but reproducible searches. There is, however, 
an inherent problem with model-based economic evaluations that incorporate evidence from 
several sources, even when these data have been retrieved systematically.  
 
The economic model needed to consider individuals’ disease status (i.e. active or inactive 
nAMD) as well as test results on a monthly basis. In addition, these had to be combined with 
alternative visual acuity states in order to incorporate utility weights into the model. It was felt 
that considering the effect of fellow eye status (VA and nAMD status) would add major 
complexity to the model without much benefit from this incorporation. A clear limitation of the 
so-called ‘one eye models’ is the underestimation of resources used. A proportion of nAMD 
individuals will have this condition in both eyes instead of one eye and would need treatment 
injections in each eye should the disease be active.  In the current model this would increase 
the cost for those strategies with higher numbers of false positives (i.e. lower specificity) and 
therefore would be unlikely to modify the general conclusions of this study.  A ‘one eye model’ 
has also been adopted by other teams involved in economic evaluations in this health area.60 
 
The model did not consider effects on utility due to treatment injections. Anxiety in nAMD 
individuals was believed to occur at each monitoring visit mainly due to the uncertainty of the 
underlying condition (i.e. active or inactive nAMD) and not the effects of the treatment 
injections.  No evidence was obtained on this from the utility weight searches. However, utility 
weight decrements from adverse effects as a result of the treatment were included and this might 
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partially overcome the above-mentioned potential limitation. The model did not consider 
factors relating to patient experience of alternative monitoring schemes. As such, there was no 
consideration of the process of care on patient preferences and only the effect of visual acuity 
and the adverse effects of treatment on individual utility were incorporated into the model.  
 
Limited evidence was available on the probability of nAMD active individuals becoming 
inactive when under treatment or inactive nAMD individuals becoming active. Data were 
retrieved from the literature, from a UK-based RCT [personal communication - Dr Chris 
Rogers, 12th June 2013] and expert opinion. In addition, progression data on visual acuity were 
based on the two year follow-up MARINA study.68  All these data were based on short follow-
up but in a number of cases extrapolated to a lifetime time horizon. These clear limitations of 
the analysis indicate that its results should be interpreted with caution.  Further research looking 
at the individual’s nAMD active/inactive status is desirable.  A conditional or a retrospective 
analysis of existing datasets would be helpful in order to obtain data to inform future economic 
models. 
 
The analysis was conducted from the NHS and Personal Social Services perspective, 
incorporating cost of visual impairment that considered, for instance, cost for community care 
and residential care. The model, however, did not take into account the cost for patients or their 
carers. For instance, as this is likely to be an elderly population, someone might accompany the 
patient for their monitoring visits. These costs have not been considered in the model. 
 
9.2.3 Uncertainties of the economic analysis 
Undoubtedly, the limitations of the data together with the assembly of key data of varied quality 
are of most concern.  Only two and three SD-OCT studies, respectively, contributed to the 
diagnosis and monitoring performance data in the economic model.  Moreover, while OCT 
diagnosis and monitoring sensitivity and specificity data were retrieved from a systematic 
review of the literature, no such data were available for other tests proposed in alternative 
diagnosis or monitoring pathways, e.g. examination by the ophthalmologist or the monitoring 
assessment by a nurse or technician. Therefore, data for the model were obtained from expert 
opinion. These constitute major limitations of the analysis and further research in these areas is 
needed. 
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10 CONCLUSIONS 
 
10.1 Implications for service provision 
In terms of OCT test performance, the evidence, which was limited in quantity, especially for 
monitoring studies, and variable in quality, suggests that: 
• For diagnosis of newly suspected nAMD, OCT has high sensitivity (median 94.5%) and 
moderate specificity (median 73.5).  
• For monitoring of those previously diagnosed with nAMD, OCT has relatively high 
sensitivity (median 95%) but low specificity (median 48%)  
 
The strategy that based its diagnostic decision on the results of FFA only, combined with a 
nurse or technician-led stepwise approach for monitoring, had the lowest expected total cost 
and a 47% probability of being cost-effective at a £30,000 threshold value of willingness to pay 
for an extra QALY.  In addition, this strategy dominated all others apart from one (i.e. diagnosis 
with FFA combined with stepwise ophthalmologist-led monitoring) in the great majority of 
sensitivity analyses.  The economic evaluation results suggest that strategies that used OCT test 
results alone to make diagnosis or monitoring treatment decisions were unlikely to be a cost-
effective use of resources. This seems to be driven by the OCT low specificity inducing a high 
number of individuals with false positive test results being treated.  
 
There has already been a shift in the diagnostic and monitoring pathways for nAMD caused by 
the adoption of OCT.  At the diagnostic stage OCT is currently used in addition to FFA 
(reference standard), while for monitoring it has largely replaced FFA, which is only used in 
selected circumstances.  The evidence suggests that using OCT as the only test for monitoring 
patients with nAMD and detecting activity would, potentially, result in a substantial proportion 
of patients receiving treatment unnecessarily with intraocular injections of anti-VEGF. 
 
The continuing rise in the ageing population, with increasing numbers of people being 
diagnosed with nAMD and moving on to monitoring for renewed disease activity, will continue 
to present challenges for ophthalmology departments to have sufficient capacity to provide 
timely testing, and treatment. 
 
10.2 Suggested research priorities 
• Regarding monitoring of nAMD, in current practice OCT is routinely used, while FFA is 
used only in particular scenarios.  There is a substantial disagreement between OCT and 
FFA.  There is a need to research that OCT (without FFA) is an acceptable way of detecting 
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active nAMD and guiding treatment.  As there is the theoretical possibility of OCT being 
better in some cases than the current reference standard, such studies might be designed to 
include a ‘fair umpire’ test, if available, to examine differences between OCT and FFA, or 
should be designed to incorporate a period of follow-up to assess the consequences of the 
tests in terms of clinical effectiveness outcomes (for example visual acuity).  Currently used 
SD-OCT models should be evaluated, rather than TD-OCT.  
• Regarding diagnosis of nAMD, current practice consists of FFA (as reference standard) 
associated with OCT.  Further research should be considered to establish the added value 
of OCT, and whether OCT (associated with slit-lamp biomicroscopy and visual acuity) can 
fully replace FFA.  As above, such studies might be designed to include a ‘fair umpire’ test, 
or the evaluation of the consequences of the diagnostic intervention.  Currently used SD-
OCT models should be evaluated, rather than TD-OCT.   
• Regarding the different phenotypes of nAMD, further evidence on the natural history, 
efficacy of treatment and diagnostic performance of OCT according to phenotype of nAMD 
is required. 
• For both diagnosis and monitoring of nAMD, prospective studies are required to assess the 
diagnostic accuracy and clinical effectiveness of strategies involving possible different 
combinations and sequences of tests (e.g. visual acuity, slit-lamp biomicroscopy, fundus 
autofluorescence imaging, OCT), including a comparison of their interpretation by 
ophthalmologists compared with other health professionals.  
• To strengthen the evidence base used to develop the economic model, it would be important 
to explore the likelihood of active and inactive nAMD individuals becoming inactive or 
active, respectively.  In addition, a preference based study to assess utility weights (e.g. 
decrements) associated with treatment and frequent monitoring is needed. 
• Further research is needed to evaluate health status (utilities) in patients with nAMD, taking 
into consideration the visual function and spectrum of disease in both eyes and exploring 
the value added by inclusion of fellow eye information. 
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